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ABSTRACT 
IDENTIFICATION AND CHARACTERIZATION OF PDE8 INHIBITORS USING A 
FISSION YEAST BASED HIGH-THROUGHPUT SCREENING PLATFORM 
By Didem Demirbas Cakici 
Advisor: Charles S. Hoffman, PhD 
 
 
In this thesis, I describe the development of a screening platform for detecting PDE8A 
inhibitors using the cAMP-dependent glucose sensing pathway of the fission yeast 
Schizosaccharomyces pombe, which led us to discover several PDE8A selective 
inhibitors. In this system, the only PDE of the fission yeast is replaced with mammalian 
PDE8A1 in strains that have been engineered such that PDE inhibition is required to 
allow cell growth. Using this system, I screened 56 compounds obtained from PDE4 and 
PDE7 high throughput screens (HTSs) and identified a PDE4-PDE8 dual specificity 
inhibitor. Using this as a positive control, I developed a robust high-throughput screen 
(HTS) for PDE8A inhibitors and screened 240,267 compounds at the Harvard Medical 
School ICCB Screening Facility. Approximately 0.2 % of the screened compounds were 
potential PDE8A inhibitors with 0.03% displaying significant potency. Secondary assays 
of 367 of the most effective compounds against strains expressing PDE8A (both full 
length and catalytic domain), PDE4A and PDE7A or PDE7B led to the selection of 
structurally diverse compounds for further testing. To profile the selectivity of twenty-
eight of these compounds, dose response assays were conducted using 16 yeast strains 
that express different PDE isoforms (representing all PDE families with the exception of 
the PDE6 family). These assays identified compounds with different patterns of 
inhibition, including structurally-distinct PDE8A-specific inhibitors. By evaluating the 
effects of these compounds for steroid production in mouse Leydig cells, biologically 
active compounds that can elevate steroid production were identified. 
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CHAPTER ONE 
1 INTRODUCTION 
Cells have evolved extensive and precise ways of elucidating specific cellular responses 
to external stimuli via the mechanisms referred to as signal transduction pathways. In 
these systems, the first messengers or extracellular cues are detected by the cell and the 
signal is amplified by production of intracellular second messengers to regulate 
downstream biological processes. The first second messenger cyclic adenosine 
monophosphate (cAMP) was discovered by Sutherland and colleagues during their 
investigations on the hormonal control of glycogen breakdown (Rall and Sutherland. 
1958). Since the discovery of cAMP in 1950s, the signaling pathways via cyclic 
nucleotides (cAMP and cGMP) have been extensively studied.  
1.1 CYCLIC AMP SIGNALING 
Cyclic AMP signaling mediates a diverse range of cellular responses including metabolic 
events, neurotransmitter release, muscle contraction, hormone secretion, ion channel 
conductance, learning and memory, apoptosis, inflammation, cell growth and 
differentiation (Beavo and Brunton. 2002).  
Upon binding of ligands –hormones, neurotransmitters, growth factors- to their specific 
receptors that are located on the plasma membrane of the target cell, receptor coupled 
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GTP binding proteins (G-proteins) are activated. The stimulatory G protein (Gs) triggers 
the activation of the enzyme adenylyl cyclase, which converts ATP to cAMP (Daniel et 
al. 1998). The targets of cAMP include cAMP-dependent protein kinase A (PKA), cyclic 
nucleotide gated ion channels, and the guanine nucleotide exchange factors Epac1 and 
Epac2 (Figure 1.1). The spatial and temporal control of cAMP signaling is controlled not 
only by the presence of various forms of adenylyl cyclase and target proteins but also by 
its degradation with various isoforms of phosphodiesterases (Houslay and Milligan. 
1997). This control is further orchestrated by organization of members of the cAMP 
signaling pathway by A-kinase anchoring proteins (AKAPs). These proteins 
compartmentalize cellular responses to cAMP by assembling PKA, phosphoprotein 
phosphatases, phosphodiesterases and other signaling effectors into localized complexes 
(Logue and Scott. 2010).  
1.1.1 Cyclic AMP Production 
Cyclic AMP is produced by adenylyl cylase from ATP (Figure 1.2). Adenylyl cyclase 
(AC) is an enzyme that can be activated or inhibited by various subunits of heterotrimeric 
guanine nucleotide binding proteins (G proteins). There are 10 different forms of AC in 
mammalian systems, 9 of which are transmembrane proteins.  
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Figure 1.1 Targets of cyclic AMP 
Known targets of cyclic AMP include cAMP-dependent protein kinase A (PKA), cyclic 
nucleotide gated ion channels, and the guanine exchange factors Epac1 and Epac2. 
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Figure 1.1 Targets of cyclic AMP 
 
TARGETS OF CYCLIC AMP 
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 Figure 1.2 Synthesis and hydrolysis of cAMP 
Cyclic AMP is synthesized from ATP by the action of adenylyl cyclase and hydrolyzed 
by phosphodiesterase enzyme. 
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Figure 1.2 Synthesis and hydrolysis of cAMP 
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1.1.2 Targets of Cyclic AMP 
1.1.2.1 PKA 
The first identified effector of cAMP is cAMP-dependent protein kinase A (PKA). It is 
composed of two regulatory (R) and two catalytic subunits (C). When bound to 
regulatory subunits, catalytic subunits are inactive. The binding of cAMP to regulatory 
subunits induces a conformational change that disrupts the interaction between catalytic 
and regulatory subunits to activate PKA. As a kinase, PKA phosphorylates other proteins 
to alter their activity, cellular location or stability. Besides phosphorylating enzymes 
involved in nutrient metabolism, PKA can also activate cAMP-responsive transcription 
factors (CREB -cAMP response element-binding) by phosphorylation and in this way 
regulates expression of target genes (Daniel et al. 1998). Transcription factors CREM 
(cAMP response element modulator) and ATF-1 (activating transcription factor-1) are 
also controlled by PKA.  
1.1.2.2 Cyclic Nucleotide-Gated Channels 
Cyclic nucleotide-gated (CNG) channels are non-selective cation channels which are 
activated by cGMP or cAMP binding. They were first identified in retinal photoreceptors 
and olfactory sensory neurons and play an important role in signal transduction pathways 
of vision and olfaction. CNG channels form heterotetrameric complexes consisting of 
two or three different types of subunits. CNG channel activity is modulated by 
Ca
2+
/calmodulin and by phosphorylation. In olfactory sensory neurons, the prototypical 
cAMP signaling cascade starts with binding of an odorant molecule to its receptor, which 
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activates a G protein (Golf). This is followed by activation of adenylyl cyclase (ACIII) 
and cAMP production. cAMP opens calcium permeable CNG channels and causes the 
depolarization of the membrane (Kaupp and Seifert. 2002).  
1.1.2.3 Exchange Protein Directly Activated by cAMP 
In addition to PKA and CNG channels, cAMP also affects another target called exchange 
protein directly activated by cAMP (Epac, also known as cAMP-GEF). Epac proteins 
function as guanine nucleotide exchange factors (GEFs) for Ras-like small GTPases 
Rap1 and Rap2. They are directly activated upon cAMP binding. In the inactive state, the 
Epac regulatory domain blocks its catalytic domain to sterically prevent binding of Rap. 
Upon cAMP binding, the regulatory region undergoes a conformational change to 
activate Epac. Utilization of Epac selective cAMP analogs showed that cardiac 
contraction, insulin secretion and vascular permeability are some of the cAMP regulated 
processes that are mediated by the action of Epac. For most of these processes, Epac 
functions in cooperation with PKA. The coordination of both cAMP effectors for 
obtaining a specific response is structured by AKAPs. (Gloerich and Bos. 2010; 
Grandoch et al. 2010).  
1.2 MAMMALIAN PHOSPHODIESTERASES: PDE SUPERFAMILY 
The specific control of the cyclic nucleotide signal is tailored in part by the presence of 
different phosphodiesterases in mammalian tissues. There are three different classes of 
phosphodiesterase enzymes. Class I enzymes are specifically involved in breaking the 
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phosphodiester bond in the cyclic nucleotides to produce 5’AMP or 5’GMP (Figure 1.2). 
The phosphodiesterase superfamily consists of 11 families, which are classified 
according to their structure, regulation, biochemical and pharmacological characteristics. 
Among these, PDE4, PDE7 and PDE8 are cAMP-specific PDEs; PDE5, PDE6 and PDE9 
are cGMP-specific PDEs and PDE1, PDE2, PDE3, PDE10, PDE11 can act on both 
cAMP and cGMP (Figure 1.3) (Bender and Beavo. 2006; Conti and Beavo. 2007). 
1.2.1 PDE1 
There are three genes in the PDE1 family; PDE1A, PDE1B and PDE1C. The members of 
this family are uniquely sensitive to calcium and calcium calmodulin (CaM). They have 
relatively high affinity for cGMP and show different affinities toward cAMP (Kakkar et 
al. 1999)(Bender and Beavo. 2006; Lugnier. 2006). PDE1A is highly expressed in the 
brain, PDE1B found in the brain, heart and skeletal muscle (Yu et al. 1997; Loughney et 
al. 1996), while PDE1C is mostly found in the olfactory epithelium and present in the 
testis (Yan et al. 1995; Yan et al. 1996).  
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Figure 1.3 PDE superfamily 
There are 11 families in the PDE superfamily. PDE4, PDE7 and PDE8 are cAMP-
specific PDEs; PDE5, PDE6 and PDE9 are cGMP-specific PDEs and others can 
hydrolyze both cAMP and cGMP. 
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Figure 1.3 PDE superfamily 
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1.2.2 PDE2 
PDE2 hydrolyzes both cAMP and cGMP and is allosterically regulated by both cyclic 
nucleotides with positive cooperative kinetics, with cGMP being the major regulator 
(Martins et al. 1982). The only gene in this family, PDE2A, has two GAF domains, 
which are important in dimerization and cGMP binding (Martinez et al. 2002). Upon 
cGMP binding, the Km for cAMP binding decreases and the rate of hydrolysis increases 
dramatically. Thus, this enzyme is also referred to as the cGMP-stimulated PDE and 
considered to be important for stimuli that elevate cGMP to reduce cAMP signaling 
(Lerner and Epstein. 2006). PDE2A is present in the adrenal medulla, heart, rat ventricle, 
brown adipose tissue, liver and brain (Coudray et al. 1999; Yanaka et al. 2003).  
1.2.3 PDE3 
The PDE3 family consists of two genes: PDE3A and PDE3B. PDE3 can hydrolyze both 
cAMP and cGMP with a higher rate of hydrolysis for cAMP but higher affinity for 
cGMP that behaves as a competitive inhibitor of cAMP; thus PDE3 enzymes are 
considered as cGMP inhibited cAMP phosphodiesterases (Lugnier. 2006). PDE3A is 
present in the heart, platelets, vascular smooth muscle and oocytes and PDE3B is mainly 
found in pancreatic beta cells, adipocytes, hepatocytes and spermatocytes. Functionally, it 
was shown that PDE3A knock-out mice are infertile as the oocytes do not complete 
meiosis (Masciarelli et al. 2004). On the other hand, PDE3B overexpression was found to 
cause impaired insulin secretion and glucose intolerance (Harndahl et al. 2004).  
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1.2.4 PDE4 
The PDE4 family is the largest PDE family with four genes; PDE4A, PDE4B, PDE4C 
and PDE4D that produce various isoforms due to differences in transcriptional start sites 
and splicing. These enzymes are cAMP-specific; hydrolyzing cAMP with Km values 
ranging between 1 to 4 µM (Houslay and Adams. 2003). The PDE4 family is specifically 
inhibited by rolipram (Ki =0.8 µM). The long forms of PDE4 isoforms contain two 
upstream conserved regions (UCR), UCR1 and UCR2 in the N termini of the enzymes. 
There are shorter isoforms that lack one or both of the UCRs. PDE4 activity is increased 
by PKA mediated phosphorylation in the UCR1 region and demonstrated to be important 
as a short-term feedback mechanism. ERK phosphorylation within the C terminus of the 
catalytic domain has also been shown to regulate PDE4 activity. PDE4 enzymes are 
mainly present in the brain, inflammatory cells, cardiovascular tissues and smooth 
muscles. Differential expression and various intracellular compartmentalization of the 
isoforms make the PDE4 family a critical component of cAMP signaling. Functionally, 
PDE4D knock-out mice showed delayed growth, female infertility and an antidepressant-
like profile (Jin et al. 1999; Zhang et al. 2002). PDE4B deficiency causes the inability to 
induce TNF alpha secretion upon lipopolysaccahride stimulation in mice (Jin and Conti. 
2002).  
1.2.5 PDE5 
The PDE5 family is a cGMP-specific PDE family consisting of a single gene: PDE5A. 
The enzyme has two GAF domains that allow cGMP levels to control PDE5 activity 
14 
 
(Lugnier. 2006). PDE5 enzyme was first purified and characterized from human, bovine 
and rat vascular smooth muscle. PDE5 is mainly expressed in lung, heart and cerebellum 
in mouse (Giordano et al. 2001), in pulmonary arteri in rat (Pauvert et al. 2002), and in 
isolated cardiomyctes in dogs (Senzaki et al. 2001). PDE5 was first demonstrated to be 
involved in vasorelaxation and mediate the nitric oxide/cGMP relaxing effect (Schoeffter 
et al. 1987). The PDE5 inhibitor sildenafil was found to be very effective in treating 
erectile dysfunction during clinical trials and led to the emergence of other FDA 
approved PDE5 inhibitors (vardenafil and tadalafil). Recent studies suggest that these 
compounds are effective in the treatment of other conditions beyond erectile dysfunction 
such as pulmonary hypertension (Wilkins et al. 2008) and Duchenne muscular dystrophy 
(Adamo et al. 2010).   
1.2.6 PDE6 
PDE6 is the main PDE in retinal photoreceptors and critical for rhodopsin signal 
transduction. It is composed of two large catalytic subunits (alpha, beta or alpha-alpha), 
two inhibitory small subunits (gamma) and a delta subunit; all of which are expressed 
from separate genes and have different compositions in rods and cons. There are two 
GAF domains in PDE6. Phototransduction starts with activation of rhodopsin by 
absorption of a photon, which in turn activates G protein transducin. GTP bound 
transducin Tα subunit activates catalytic PDE6αβ subunits by changing the conformation 
of the γ subunit to expose the active site and hence allow cGMP hydrolysis. The decrease 
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in cGMP concentrations upon light stimulus is transmitted by retinal neurons to optic 
nerve and brain (Lugnier. 2006).  
1.2.7 PDE7 
The PDE7 family contains two genes PDE7A and PDE7B, which encode for cAMP-
specific enzymes devoid of GAF domains and other regulatory domains. They have high 
affinity for cAMP (Km = 0.2 µM) and low Vmax values (Michaeli et al. 1993; Bloom and 
Beavo. 1996). PDE7A is widely distributed in human proinflammatory cells, immune 
cells and epithelial cells (Smith et al. 2003; Miro et al. 2000).  The development of PDE7 
specific inhibitors BRL50481 and BC30 and demonstration of their effect in decreasing 
TNFα secretion from U937 cells have shown the importance of PDE7 family in 
inflammation (Alaamery et al. 2010).  
1.2.8 PDE8 
The PDE8 family is composed of two genes; PDE8A and PDE8B. They encode for 
enzymes with high affinity and specificity for cAMP. They are unusually insensitive to 
the general PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) (Vasta. 2006). There are 
PAS and REC domains in the N termini of the PDE8 proteins that are unique to this 
family (Soderling et al. 1998b; Wang et al. 2001a). PDE8A mRNA is expressed in the 
testis, eye, liver, skeletal muscle, heart, kidney, ovary and brain (Soderling et al. 1998b). 
PDE8B protein is mainly found in the thyroid gland and brain (Hayashi et al. 1998b). 
Studies of knock-out mice show that PDE8A is important in steroid production in testis, 
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and that PDE8B is important in steroidogenesis in the adrenal gland (Tsai et al. 2010; 
Vasta et al. 2006).  
1.2.9 PDE9 
The PDE9 family contains the single gene PDE9A, which encodes for a high affinity 
cGMP-specific PDE. Like the PDE8 enzymes, PDE9A is insensitive to IBMX. PDE9 is 
mainly found in the spleen, small intestine and brain in humans (Soderling et al. 
1998c;Fisher et al. 1998b). More than 20 splice variants of PDE9A have been observed 
(Rentero et al. 2003).  
1.2.10 PDE10  
The single member of this family, PDE10A is a dual substrate PDE with a lower Km for 
cAMP and a higher Vmax value for cGMP. Thus, it is suggested to be a cAMP-inhibited 
cGMP PDE. PDE10A contains two GAF domains. It is mainly found in brain, heart, 
placenta, thyroid and testis (Lugnier. 2006). Recent studies using a transgenic 
Huntington’s disease mice model suggest that PDE10A might be associated with 
neuropathology of this disease (Hebb et al. 2004). 
1.2.11 PDE11 
This family contains a dual substrate PDE11A, which can hydrolyze both cAMP and 
cGMP with similar Vmax values and with Km values of 0.5 and 1 µM, respectively 
(Fawcett et al. 2000). It is found in skeletal muscle, prostate, kidney, liver, pituitary and 
salivary glands and testis. Similar to PDE2, 5, 6 and 10 families, PDE11A contains two 
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GAF domains, one of which is absent in certain splice variants (Yuasa et al. 2000). 
Knock-out mice studies suggest that PDE11 is important in spermatogenesis (Wayman et 
al. 2005).   
1.2.12 Phosphodiesterases as Drug Targets 
Attributable to the functional diversity of cAMP signaling pathways in various cellular 
responses, impairment of cAMP signaling contributes to the development and 
pathophysiology of many neurological, endocrine, cardiovascular and inflammatory 
disorders. By virtue of the presence of more than 100 isoforms of PDEs with different 
profiles in tissue specific distribution, regulation, and compartmentalization in the cell, 
specific PDE isoforms are also linked to certain physiological conditions and disease 
states. As a result, the development of isoform selective inhibitors can target specific 
functions or pathological conditions without causing many side effects. 
As explained by Bender and Beavo previously (2006), in controlling the concentration of 
a ligand or second messenger, more rapid changes can be attained by regulation of its 
degradation rather than the rate of its synthesis. This basic pharmacological principle 
holds also true for the regulation of cAMP levels since the Vmax values of 
phosphodiesterase enzymes for cyclic nucleotide hydrolysis are much higher than that of 
cyclases for cAMP or cGMP production. Apart from this, although certain compartments 
have higher cyclic nucleotide concentrations, the endogenous levels of cyclic nucleotides 
are not unmanageably high for a competitive inhibitor to be effective. This had been a 
problem for development of kinase inhibitors since ATP levels are intrinsically high in 
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the cell. Thus, pharmacological intervention of PDEs can result in rapid changes in 
cAMP levels and make them attractive drug targets.  
The goal of this thesis project is to develop a fission yeast based platform for detection of 
inhibitors of PDE8 enzymes and use it to identify such compounds from chemical 
libraries. Therefore, a more in-depth introduction to the PDE8 family is presented in the 
following section.  
1.3 PDE8 FAMILY 
PDE8A is the first PDE to be discovered by means of bioinformatics due to the 
consensus sequence in its catalytic domain. The initial discovery of the PDE8 family was 
described by two separate groups who described human and mouse PDE8A, respectively 
(Fisher et al. 1998a; Soderling et al. 1998a). The presence of unique domains in the N 
terminus suggested that PDE8A is part of a new PDE family (Soderling et al. 1998a). 
The PDE8 family has a very high affinity toward cAMP and contains two genes: PDE8A 
and PDE8B. Orthologs of PDE8 are found in fruit flies, nematodes, sea squirts, zebrafish 
and pufferfish (Vasta. 2006). 
1.3.1 Features of PDE8A and PDE8B 
PDE8 is unique among PDE families in containing a PAS (Per, ARNT, Sim) domain in 
its N terminus (Soderling and Beavo. 2000; Wang et al. 2001b; Hayashi et al. 2002). The 
PAS domain is abbreviated from PER, ARNT, SIM proteins which are the first proteins 
identified to contain this domain. Proteins with PAS domains are signaling proteins and 
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function as a sensory module for oxygen tension, redox potential or light intensity, 
mediating protein-protein interactions (Vasta. 2006) (Figure 1.4). 
The Beavo lab (Soderling et al. 1998a) showed that human and mouse PDE8A sequences 
share only 85% sequence identity within the catalytic domain (while other PDEs have 
more than 93% identity in this region). Wang et al. (2001) cloned cDNAs representing 
five full length human PDE8A splice variants from testis and T cells. They showed that 
human PDE8A1 encodes a hydrophilic protein of 829 amino acids and has 79% 
similarity to mouse counterpart at the amino acid level. Besides the PAS domain existing 
in mouse PDE8A1, the human PDE8A1 contains a unique REC domain which acts as a 
signal receiver or response regulator domain in other proteins.  
Soderling et al. (1998) has also reported a consensus sequence for nuclear localization of 
the type typified by simian virus 40 large T antigen in the mouse PDE8A sequence. 
Unlike the mouse enzyme, human PDE8A1 does not contain a nuclear localization 
consensus sequence, but there are myristoylation sites in the protein. Recently, it was 
shown to be localized to mitochondria. It was also reported that in the human PDE8A1 
promoter, there is a binding site for c-Ets-1, a transcription factor involved in expression 
of several immunologically important genes such as T cell receptor, CD4 etc. in T cells 
(Soderling and Beavo. 2000).  
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Figure 1.4 Domains of PDE8A and predicted structure of the PAS domain 
(A) PDE8 enzymes are unique in the PDE superfamily with regard to the presence of a 
PAS domain. Human PDE8A also contains a REC domain. The locations of the indicated 
domains are drawn based on the data obtained from Conserved Domain Database of 
NCBI website. (B) The PAS domain structure is drawn according to the crystal structure 
of the oxygen detecting domain of FixL protein from Bradyrizobium japonicum. The 
crystal structure was retrieved from PDB website (PDB ID: 1DRM) and illustrated using 
Pymol. 
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Figure 1.4 Domains of PDE8A and predicted structure of the PAS domain 
A 
 
 
B 
 
  
22 
 
Splice variants 
cDNAs representing five full-length human phosphodiesterase (PDE) 8A splice variants 
(PDE8As 1-5) were cloned  from testis and T cells. PDE8A1 encodes a hydrophilic 
protein of 829 amino acids, containing an N-terminal REC domain, a PAS domain, and a 
C-terminal catalytic domain. Compared to PDE8A1, PDE8As 2-5 appear to be expressed 
in much lower abundance. Among various tissues and organs, PDE8A1 and PDE8A2 are 
expressed at various levels (Wang et al. 2001b). 
1.3.2 Enzymatic characteristics  
PDE8 enzymes have high affinities for cAMP with reported Km values in the range of 40-
150 nM (Fisher et al. 1998a; Gamanuma et al. 2003; Soderling et al. 1998a). Neither of 
the PDE8A and PDE8B enzymes hydrolyze cGMP, nor is their cAMP hydrolytic activity 
affected by cGMP (unlike PDE2 or PDE3 families for which cAMP hydrolytic activity is 
modulated by cGMP). The activity of PDE8A was reported to be dependent on divalent 
cations Mg
2+
 and Mn
2+ 
(Fisher et al. 1998a).  
The initial kinetic analysis on PDE8A were performed by Fisher et al. (1998) using 
baculovirus expressed human enzyme (truncated form of PDE8A1), which has very high 
affinity toward cAMP with a Km of 55 nM for cAMP and 124 microM for cGMP. In the 
same study, the Vmax (150 pmol/min/microgram recombinant enzyme) was reported to be 
about 10 times slower than that of PDE4. Full length PDE8A human enzyme showed a 
slightly lower Km value (40 nM) when expressed from Cos-7 cells; while mouse PDE8A 
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enzyme displayed a Km value of 150 nM for cAMP when expressed in Sf9 cells 
(Soderling et al. 1998a). Similar to PDE8A, human PDE8B1 is also a high-affinity 
cAMP-PDE with Km value of 101 nM for cAMP, which is greater than that of PDE8A1 
(40 nM) (Gamanuma et al. 2003).  
Yan et al. (2009) reported a detailed protocol for refolding and purification of a large 
quantity of the PDE8A1 catalytic domain. They observed that the Km of their PDE8A1 
catalytic domain is significantly higher (1-1.8 µM) than those for the full length PDE8, 
which is uncommon when compared to the full length and catalytic domain versions of 
other PDE families. This may reflect the allosteric behavior of PDE8 and the regulation 
of the catalytic activity by its PAS domain. 
PAS Domain/ IkappaB 
The overexpression of recombinant human PDE8A1 was shown to physically associate 
with endogenous IkappaB in a PAS domain dependent manner and competes with NF-kB 
for IkappaB binding (Wu and Wang. 2004). In the same study, IkappaB association 
stimulates PDE8A enzymatic activity 6-fold.  
1.3.3 Structure  
Refolding of the PDE8A1 catalytic domain and its kinetic characterization by H. Ke’s 
group (Wang et al. 2008) provided an important starting point for them to determine the 
crystal structure of PDE8A1 in the unliganded and IBMX-bound forms (Figure 1.5). The 
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structures indicate Tyr748 as an important residue for inhibitor binding and its mutation 
to phenylalanine alleviated the insensitivity of PDE8A to non-selective PDE inhibitors.  
1.3.4 Tissue Distribution and Function 
Tissue distribution 
PDE8A expression was initially assessed by Northern blot analysis. In humans, the 4.5 kb 
mRNA transcript is expressed widely in many tissues with highest levels in testis, ovary, 
small intestine, and colon (Fisher et al. 1998a). Tissue distribution analysis of PDE8A 
mRNA in mouse indicated highest expression in testis, followed by eye, liver, skeletal 
muscle, heart, 7-day embryo, kidney, ovary, and brain in decreasing order (Soderling et 
al. 1998a). In situ hybridizations in testis, the tissue of highest expression, shows that 
PDE8 is expressed in the seminiferous epithelium in a stage-specific manner. Rat PDE8A 
transcripts are high in the liver and testis (Kobayashi et al. 2003).  
In contrast to the wide expression of PDE8A mRNA in various tissues, Northern blot 
analysis indicated that the mRNA encoding human PDE8B is expressed specifically and 
abundantly in thyroid gland as an approximately 4.2 kb mRNA (Hayashi et al. 1998a). It 
is also expressed in lower levels in human brain, kidney, pancreas, spinal cord, placenta,  
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Figure 1.5 Structure of PDE8A with IBMX 
Crystal structure of PDE8A catalytic domain in complex with IBMX shows the cyclic 
AMP binding pocket (where IBMX is located). IBMX (shown in purple in Part b) cannot 
inhibit PDE8A but its binding in the crystal structure identifies Tyrosine 748 as an 
important residue in inhibitor sensitivity (indicated by red arrow). The figures are based 
on the structures retrieved from PDB website (PDB ID is 3ECM) and illustrated as 
solvent excluded surface model (A) and ribbon representation (B) using UCSF 
CHIMERA.  
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Figure 1.5 Structure of PDE8A with IBMX 
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prostate and uterus. Rat PDE8B is particularly abundant in the brain and is not expressed 
in the thyroid gland (Kobayashi et al. 2003). 
In a different study, the expression pattern of PDE7 and PDE8 in the brain was examined 
using in situ hybridization (Perez-Torres et al. 2003). Hybridization levels of PDE8A 
were low, whereas high levels of PDE7B and PDE8B expression was observed in 
hippocampal formation. When compared to control brains, PDE8B was found to be the 
only enzyme that shows a significant increase in cortical areas and parts of the 
hippocampal formation in Alzheimer’s disease brains while its dependence on the disease 
rather than age should be addressed.  
Finally, the expression profiles of ESTs listed under the human PDE8A Unigene Hs.9333 
and PDE8B Unigene Hs.78106 demonstrate that these PDEs are present in most human 
tissues (Vasta. 2006).  
Function 
Studies for deciphering functions of PDE8 enzymes have been mostly limited by the 
unavailability of PDE8 selective inhibitors and knock-out animal models. One of the 
related studies suggested that PDE8A might play a role in activated lymphocytes or in T 
cell activation (Glavas et al. 2001). The Beavo lab previously had shown that PDE7A1 is 
up-regulated in human CD4
+
 T cells and in a follow-up study they showed induction of  
PDE8A1 and PDE7A3 in human T lymphocytes when stiumulated with antibodies 
against CD3 and CD28. It has also been shown that PDE8A1 is constitutively expressed 
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in the human T-cell line Hut78 (Lerner and Epstein. 2006). In addition, PDE8 was 
identified as a new target for inhibition of chemotaxis of activated murine lymphocytes 
(Dong et al. 2006). The non-selective weak PDE8 inhibitor dipyridamole strongly 
inhibited migration of both concanavalin A stimulated and unstimulated splenocytes and 
PDE8A1 was upregulated following ConA stimulation.   
The importance of PDE8 enzymes in steroid production was discovered upon the 
examination of PDE8 knock-out animals. Vasta et al. (2006) showed that Leydig cell 
function is altered by the loss of PDE8A. Leydig cells produce testosterone in the testis in 
response to lutenizing hormone (LH). They reported that PDE8A is expressed in Leydig 
cells and showed a 4 fold increase in the sensitivity of LH for testosterone production in 
the PDE8A knock-out mice. In another study, they observed that under fasting conditions 
triglyceride levels are increased in the liver of wild type mice while no increase is 
observed with PDE knock-out mice (Shimizu-Albergine et al. 2008).  
In a recent study, analysis of ventricular myocytes from PDE8A knock-out mice suggests 
that PDE8A is a key modulator of cAMP signaling in this tissue since absence of this 
enzyme increases L-type Ca
2+
 channel currents and calcium transients (Patrucco et al. 
2010).  
PDE8B expression, as described above, is abundant and almost exclusively expressed in 
the thyroid with some additional expression in the brain (Hayashi et al. 1998a). Relevant 
to that, increased cAMP degradation has also been detected in autonomous thyroid 
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adenomas and PDE8B upregulation was noted in pituitary adenomas. Also, PDE8B gene 
variants are associated with alterations in serum TSH levels. PDE8B may thus provide a 
candidate target for the treatment of thyroid dysfunction (Arnaud-Lopez et al. 2008). 
Recently, some of the genetic abnormalities that predispose individuals to various 
adrenocortical tumors were found to be in the PDE family (Horvath et al. 2008b; Horvath 
et al. 2008a; Horvath and Stratakis. 2008). Mutations in PDE11A and PDE8B were 
detected in patients with isolated adrenal hyperplasia and Cushing syndrome (Stratakis. 
2009). In another study related to insulin response, depletion of PDE8B levels in rat islets 
by siPDE8B increased insulin response to glucose by 70% and the potentiation is of 
similar magnitude during the first and second phase of insulin release (Dov et al. 2008). 
Most recently, an analysis of a PDE8B knock-out mouse model has demonstrated that 
PDE8B is a major regulator of steroidogenesis in the adrenal gland. The effect was also 
confirmed with cell lines treated with a newly published PDE8 inhibitor or an anti 
PDE8B shRNA construct (Tsai et al. 2010). 
1.4 PDE INHIBITORS 
As described in the previous section, PDEs are considered as good drug targets. Some 
compounds with PDE inhibitory activity have been therapeutically used for years. For 
instance, since the 19
th
 century, caffeine has been known to be effective in asthma. We 
now know that caffeine also affects targets other than phosphodiesterases but being a 
weak inhibitor of PDEs it might exert some of its effects through cyclic AMP signaling. 
Likewise, natural compounds theophylline and papaverine have been used in the 
30 
 
treatment of several diseases. The success of these non-selective weak PDE inhibitors 
encouraged the development of more potent and selective PDE inhibitors.   
1.4.1 Non-selective PDE Inhibitors 
The early work by Earl Sutherland studying glucagon and epinephrine hormone action on 
phosphorylase activity in liver homogenates led to the discovery of a heat-stable 
nucleotide, cAMP as a second messenger (Rall and Sutherland. 1958). During these 
studies, it was discovered that caffeine, at high concentrations, increased the activity of 
phosphorylase enzyme and elevated the sensitivity to glucagon or epinephrine. This 
observation pointed out the presence of an enzyme that degrades cAMP and elevation of 
hormone sensitivity by caffeine could be explained by its inhibitory effect on this enzyme 
(Berthet et al. 1957). In 1962, Butcher and Sutherland clearly showed that 
methylxanthines such as caffeine, theobromine and theophylline inhibit cAMP hydrolysis 
(Butcher and Sutherland. 1962). These are the first identified non-selective PDE 
inhibitors, with IC50 values ranging from 100 to 1000 µM (Francis et al. 2011).  
These methylxanthines provided an important starting point for the development of other 
alkylxanthines as PDE inhibitors such as 3-isobutyl-1-methylxanthine (IBMX). IBMX is 
considered as a general PDE inhibitor with IC50 values varying between 2-50 µM 
(Bender and Beavo. 2006) for multiple PDEs. Although it does not inhibit PDE8 and 
PDE9 families, it serves as an important pharmacological tool to implicate cyclic 
nucleotide signaling as playing a role in various biological processes.  
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Among the non-selective PDE inhibitors, papaverine and theophylline have been used 
therapeutically for years (Boswell-Smith et al. 2006). Like other non-selective inhibitors, 
they do not discriminate between different families and mostly have additional non-PDE 
targets. For instance, theophylline, caffeine and IBMX are also non-selective antagonists 
of adenosine receptors (Beavo and Reifsnyder. 1990). 
Early studies of PDE-regulated processes used whole tissue homogenates and extracts, 
which were not suitable for finding isozyme specific inhibitors. The increased 
understanding and characterization of PDE isoforms along with knowledge acquired by 
their crystal structures has facilitated studies to search for isoform specific PDE 
inhibitors.  
1.4.2 Selective PDE Inhibitors 
Selective PDE inhibitors were initially identified by testing structurally related 
compounds of known non-selective inhibitors. For instance, 8-methoxymethyl IBMX can 
inhibit PDE1 enzymes with a 30-50 fold higher selectivity than other PDE isoforms 
(Wells and Miller. 1988). Similarly, erythro-9-(2-hydroxyl-3-nonyl)-adenine (EHNA) 
was found to be selective for the PDE2 family, although it also inhibits adenosine 
deaminase (Podzuweit et al. 1995).  
Efforts to find isozyme selective inhibitors has also led to the discovery of the PDE3 
inhibitors milrinone and cilostazol, which are used as drugs for acute treatment for 
cardiac failure and claudication respectively (Bender and Beavo. 2006; Lugnier. 2006). 
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On the other hand, the PDE4 specific inhibitor rolipram was first discovered as a 
compound with CNS activity and shown to be a potent cAMP-PDE inhibitor in the brain 
(Schneider et al. 1986; Torphy et al. 1992). Specific inhibition by rolipram was a point of 
reference in categorization of cAMP specific PDE isoforms as PDE4 family. Rolipram 
analogs such as piclamilast, cilomilast and roflumilast as well as benzyladenine 
derivatives have been developed as selective PDE4 inhibitors (George and Jeffrey. 2006). 
Most of the compounds developed as PDE4 inhibitors are associated with severe emetic 
response (Robichaud et al. 2002; Mori et al. 2010). In 2010, roflumilast was approved by 
European Commission for maintenance treatment of severe chronic obstructive 
pulmonary disease (Calverley et al. 2009; Fabbri et al. 2010), but failed to receive FDA 
approval. 
Zaprinast, another alkylxanthine, also shows selectivity toward the PDE1, PDE5 and 
PDE6 families. It was initially designed for treatment of allergic diseases and showed 
vasorelaxant effects. This increased the focus on development of PDE5 inhibitors for 
various diseases relevant to vascular smooth muscle relaxation. Pfizer developed a more 
selective compound for PDE5 inhibition, sildenafil, for treatment of angina pectoris, 
whose side effect in clinical trials showed that it could be used in erectile dysfunction and 
led to the development of PDE5 specific compounds (vardenafil, tadalafil, udenafil) with 
less inhibitory effect on PDE6 as compared to sildenafil. Besides their effect on treatment 
of erectile dysfunction, PDE5 inhibitors are being tested for treatment of pulmonary 
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hypertension and Duchenne muscular dystrophy (Boswell-Smith et al. 2006; Lugnier. 
2006).   
For the PDE7 family, the only commercially-available selective inhibitor was BRL50481 
until the discovery of the novel PDE7 inhibitor BC30 from Hoffman lab (Alaamery et al. 
2010). Selective inhibitors for PDE9 and PDE10 families have been described by Pfizer 
(Verhoest et al. 2009a; Verhoest et al. 2009b). Recently, a PDE8 selective inhibitor –also 
developed by Pfizer- has been reported (Tsai et al. 2010; Vang et al. 2010).  
1.4.3 Pharmacological Characteristics of PDE8 
The PDE8 family is pharmacologically different from most other PDE families in that its 
enzymes are insensitive to IBMX (3-isobutyl-1-methyl-xanthine). IBMX is a broad 
spectrum inhibitor that affects the activity of all PDEs -except PDE8 and PDE9- with 
IC50 values of 2-50 µM. The non-selective PDE inhibitor papaverine weakly inhibits 
PDE8A at very high concentrations (174 µM), while the PDE5 inhibitor vardenafil 
inhibits PDE8A at 57 µM and the PDE3 inhibitor trequinsin inhibits PDE8B with IC50 of 
2 µM. Dipyridamole, a weak selective inhibitor of PDE5 and PDE6, also inhibits PDE8A 
and 8B with 10 fold higher IC50 values (Fisher et al, 1998; Hayashi et al 1998). The 
PDE4 inhibitor cilomilast and L-826141 have been reported to have an inhibitory activity 
on PDE8s with an IC50 of 7 µM (Vasta, 2006).  
Due to the absence of PDE8 inhibitors, dipyridamole has been used to assess PDE8 
activity in various studies. However, besides being a better inhibitor of other PDEs 
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(PDE5 and 6), dipyridamole also inhibits adenosine deaminase and thus the results 
should be viewed skeptically. In late 2010, two reports used a novel PDE8 inhibitor 
developed by Pfizer. This compound, PF-4957325, has a low Ki value for PDE8A (0.7 
nM) while it starts to inhibit other PDEs at higher concentrations (Tsai et al. 2010; Vang 
et al. 2010) (Figure 1.6).  
Pharmacological Potential 
The demonstrated role of PDE8A in the regulation of steroidogenesis in Leydig cells 
suggests that PDE8A inhibitors may be used to increase local production of testosterone 
in conditions associated with a deficit in testosterone production including andropause, 
idiopathic male infertility and metabolic syndrome. Also, in theory, a PDE8A activator 
would decrease Leydig cell sensitivity to LH and local production of testosterone, which 
can be used as male contraceptives or in treatment of prostate cancer (Vasta et al. 2006). 
The pharmacological potential of modulators of PDE8 enzymes was previously explained 
by Vasta (Vasta. 2006) who suggested that PDE8A inhibitors could be utilized for the 
treatment of metabolic bone disease based on the detection of PDE8A in human 
osteosarcoma cell line MG-63 and in mouse osteoblastid cell line MC3T3-E1 as an 
increase in cAMP levels can promote osteoblastic differentiation. Similarly, a common 
pathophysiological mechanism of hyperthyroidism, thyroid and pituitary adenomas is the 
constitutive activation of the cAMP dependent mitogenic pathway. It has been proposed 
that an inhibitor might be beneficial to treat hypothyroidism; while activators of PDE8B 
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might help in pituitary adenomas and have therapeutic value in endocrine disorders. Also, 
expression of PDE8B in endometrial stromal cells, for which an increase in cAMP favors 
the uterine decidualization process and therefore supports egg implantation, might 
suggest it as a target as a therapy for endometrial development and implantation in 
subfertile women. 
1.4.4 Approaches in PDE inhibitor discovery 
As described earlier, the traditional starting point for development of selective inhibitors 
is either previously known PDE inhibitors or compounds that resemble cyclic 
nucleotides. These studies rely on classic medicinal chemistry approaches and use 
rational drug design based on the structure activity relationship to produce selective 
inhibitors (Manallack et al. 2005). The success of this approach is well documented by 
the development of sildenafil, where the structural analogy between cGMP and zaprinast 
was used to increase the selectivity for the PDE5 enzyme (Manallack et al. 2005; Terrett 
et al. 1996). Besides screening for the analogs of known PDE inhibitors, novel 
approaches such as fragment based or scaffold based lead generation are also being 
employed. Fragment based hits can be detected by protein crystallography and NMR 
(Carr et al. 2005), while a scaffold based approach utilizes high-throughput scintillation 
proximity assay followed by co-crystallography (Card et al. 2005). Recently, Naganuma 
et al. (2009) increased the selectivity of their lead compound to the catalytic domain of 
PDE4B over PDE4D using structure-activity relationship and Pfizer reported novel 
PDE10A- and PDE9A-specific inhibitors using structure based drug design (Verhoest et 
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al. 2009a; Verhoest et al. 2009b). All of these PDE inhibitor discovery methodologies 
can only identify the compounds that bind the active site since catalytic domain 
preparations and sequences are used in experimentation and design processes.  
In this thesis, I developed a fission yeast based screening approach using the full length 
PDE8A that will detect compounds without any dependence on conserved PDE catalytic 
domain structure or known non-selective PDE inhibitors. By its nature, the compounds 
obtained from this chemical screen will be permeable to yeast cells and will show low 
toxicity since stimulation of growth is assessed. Compounds that promote growth are 
unlikely to promiscuously bind to other proteins, a lack of toxicity serves as a proxy for 
high specificity. In addition, since the measured phenotype is growth over the course of 
two days, the compounds from this screen should be chemically stable. In short, we 
believe a yeast growth based screen will result in better lead compounds for drug 
development than those selected by traditional approaches. 
1.5 UTILIZATION OF YEAST AS A TOOL FOR STUDYING MAMMALIAN 
PDES 
1.5.1 Use of Yeast to Study Mammalian Proteins 
Besides serving as important model organisms for the study of biological processes in 
eukaryotes, the budding yeast Saccharomyces cerevisiae and the fission yeast 
Schizosaccharomyces pombe have been used as hosts for cloning of human genes by their 
ability to functionally complement a defective gene in the host yeast strain. For instance, 
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the human Cdc2 cyclin-dependent kinase gene was first cloned by its ability to suppress 
the temperature-sensitive growth of an S. pombe cdc2
-
 mutant strain (Lee and Nurse. 
1987). Yeast strains expressing human proteins are also used to study the function of the 
human protein and to identify mutations that alter function, as shown in a study of the 
p53 protein expressed in S. pombe (Bischoff et al. 1992). Use of yeast cells are also 
extended to cell growth based high-throughput screens which were successfully 
employed to find inhibitors of sirtuin NAD-dependent deacetylase (Grozinger et al. 
2001), mammalian K
+
 channel (Zaks-Makhina et al. 2004) and mammalian p38α kinase 
(Friedmann et al. 2006).  
Previous studies with S. cerevisiae demonstrated the feasibility of working with 
mammalian PDE genes in a yeast system. S. cerevisiae expresses two PDE proteins, the 
Pde1 low-affinity enzyme and the Pde2 high-affinity enzyme (Nikawa et al. 1987a; Sass 
et al. 1986). Deletion of these two enzymes causes high cAMP levels, which interferes 
with the normal response to nutrient starvation and result in a heat shock sensitive 
phenotype in stationary phase cells. Complementation of PDE activity to restore heat 
shock resistance served as a basis for library screens to clone novel mammalian PDEs 
and led to the identification of the rat PDE4B and human PDE7A genes (Colicelli et al. 
1989; Colicelli et al. 1991; Michaeli et al. 1993). In addition, the effect of PDE inhibitors 
could be assessed in the yeast by using heat shock sensitivity phenotype as shown by 
sensitivity of normally heat shock resistant PDE4B expressing strain to the PDE4 
inhibitor rolipram (McHale et al. 1991; Pillai et al. 1993; Pillai et al. 1994; Torphy et al. 
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1992). This differential phenotype in heat shock sensitivity in the presence and absence 
of a PDE inhibitor was used by Colicelli lab to identify rolipram resistant PDE4B 
derivatives (Pillai et al. 1993). Thus, the use of yeast cells to study PDE enzymes is 
feasible since the enzymes are functional, show similar pharmacological properties as in 
mammalian cells and it is suitable to isolate compound insensitive PDE mutants. 
However, the utility of this system for large scale studies is limited due to the necessity 
of using significantly high concentrations of compounds to see the heat sensitivity 
phenotype and requirement of working with stationary phase cells. 
In this study, we are using a cAMP-dependent growth phenotype in fission yeast S. 
pombe to study mammalian PDEs. As described in the next section, this growth 
phenotype, which successfully identified genes in the cAMP-dependent glucose sensing 
pathway via genetic screens, is more sensitive for the identification of chemical inhibitors 
of mammalian PDEs and hence it is suitable for high-throughput assays. 
1.5.2 Cyclic AMP Signaling and fbp1 Transcriptional Regulation in the Fission 
Yeast S. pombe 
Both the budding yeast S. cerevisiae and the fission yeast S. pombe utilize G proteins and 
produce cAMP signals in response to glucose detection (D'Souza and Heitman. 2001; 
D'Souza et al. 2001; Hoffman. 2005a; Hoffman. 2005b; Lengeler et al. 2000; Thevelein 
and de Winde. 1999; Thevelein et al. 2000). In both yeasts, activation of adenylyl cyclase 
causes an elevation in cAMP levels, which is partially limited by the PDE enzyme 
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activity as a means of feedback regulation (Ma et al. 1999; Nikawa et al. 1987b; Wang et 
al. 2005). 
Many components of the cAMP dependent glucose sensing pathway of the fission yeast 
have been discovered by studying mutants with defects in glucose repression of the fbp1 
gene, which encodes the gluconeogenetic enzyme fructose-1,6-bisphosphatase (Hoffman 
and Winston. 1990; Hoffman and Winston. 1991). The genetic identification of these 
mutants relied on the use of a reporter construct that expresses the ura4 gene from the 
fbp1 promoter. The ura4 gene codes for the orotidine-5'-phosphate (OMP) decarboxylase 
enzyme that is required for uracil biosynthesis. However Ura4 and the Ura5 orotate 
phosphoribosyltransferase convert the pyrimidine analog 5FOA into a toxic form. Thus, 
in the presence of glucose wild type cells repress the reporter and in turn they cannot 
grow in medium lacking uracil. On the other hand, glucose insensitive transcript (git) 
mutants, which have defects in cAMP signaling, cannot repress the fbp1 promoter even in 
the presence of glucose. Their constitutive expression of the fbp1-ura4 reporter renders 
them able to grow in the absence of uracil while they become sensitive to 5FOA. 
Constitutive mutants include strains with defects in the Git3 G protein coupled receptor 
(GPCR) (Welton and Hoffman. 2000), any of the three subunits of a heterotrimeric G 
protein composed of the Gpa2 Gα (Nocero et al. 1994), the Git5 Gβ (Landry et al. 2000), 
and the Git11 Gγ (Landry et al. 2000; Landry and Hoffman. 2001), the Git2/Cyr1 
adenylate cyclase (Hoffman and Winston. 1991), the Git1 adenylate cyclase binding 
protein (Kao et al. 2006), Hsp90 (Alaamery and Hoffman. 2008), the Git7 HSP90 co-
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chaperone (Schadick et al. 2002), and the Pka1 PKA catalytic subunit (Jin et al. 1995). 
This reporter construct was also successfully used to identify negative regulators of PKA 
such as cgs1
+
 that encodes the regulatory subunit of PKA and cgs2
+
 that encodes the only 
PDE in S. pombe. Using the fbp1 driven reporters, cgs1
-
 mutations were identified in a 
genetic selection for suppressors of an adenylyl cyclase deletion allele (Stiefel et al. 
2004), while cgs2
+
 PDE gene mutations were identified in a genetic selection for 
suppressors of an activation defective form of adenylyl cyclase (Wang et al. 2005). In 
both selections, the cgs1
-
 and cgs2
-
 mutations restored 5FOA-resistant (5FOA
R
) growth 
by increasing the PKA activity. Therefore, the use of fbp1 driven reporters is beneficial in 
identifying mutations that either reduce PKA activity to stimulate growth in medium 
lacking uracil or increase PKA activity to stimulate growth in medium containing 5FOA. 
Since the selection is based on an increase in growth for both decreased and increased 
cAMP conditions, as opposed to ‘no growth’ phenotype, the screens were robust with 
low background. Recently, the successful use of this reporter in genetic screens has been 
extended to expedite high-throughput compound screens for chemical inhibitors of 
heterologously expressed PDEs.  
1.5.3 The Use of fbp1-ura4 Promoter for Screening for PDE Inhibitors 
The cell growth based screen to detect PDE inhibitors was developed using the 
previously described glucose sensing pathway of the fission yeast. In this pathway, 
glucose is sensed by GPCR (Git3); which activates the Gpa2 Gα subunit of the 
heterotrimeric G protein Gαβγ (Gpa2-Git5-Git11). Upon activation of adenylyl cyclase 
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by Gpa2 (Gα), the glucose detection signal is conveyed inside the cell as elevated cAMP 
levels to activate cAMP dependent protein kinase A, which then represses fbp1 
transcription. One component of this pathway is Cgs2, the only PDE of the fission yeast. 
We replaced the S. pombe PDE (Cgs2) with mammalian orthologs by heterologous 
recombination into the cgs2 locus. The two reporters expressed from the fbp1 promoter 
(fbp1-lacZ and fbp1-ura4) allow us to study this pathway as well as the heterologously 
expressed mammalian PDEs (Figure 1.7).  
The key to develop a strain suitable for high-throughput screen of PDE inhibitors lies in 
having a 5FOA sensitive strain as a starting point and in optimizing the growth conditions 
to achieve a differential growth phenotype in the absence and presence of potential 
inhibitors. An engineered 5FOA sensitive strain has sufficiently low levels of cAMP to 
allow expression from fbp1-ura4 reporter. In the presence of a compound that inhibits 
PDE, there will be an increase in cAMP levels, which will cause repression of fbp1-
driven transcription. Hence, in the presence of a PDE inhibitor, ura4 is not expressed and 
the cells will be able to grow in 5FOA medium. 
The Hoffman lab showed that introduction of minimal signaling defects can be sufficient 
to obtain 5FOA sensitivity for PDE4 and PDE7 enzymes, as the nature of the defect to 
yield 5FOA sensitivity rely on the level of cAMP hydrolytic activity of the mammalian 
PDE in the S. pombe system.   
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Figure 1.6 Structures of some PDE inhibitors 
Structures of some PDE inhibitors are shown. (IBMX: 3-isobutyl-1-methylxanthine; 
EHNA: erythro-9-(2-hydroxy-3-nonly)adenine)). 
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Figure 1.6 Structures of some PDE inhibitors 
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Figure 1.7 Glucose sensing pathway of fission yeast 
Glucose is detected through a GPCR and activates PKA as described in the text. Figure is 
drawn using ProteinLounge Pathway Builder Tool. 
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Figure 1.7 Glucose sensing pathway of fission yeast 
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For example, a milder defect of deletion of git11 (encodes for Gγ) is sufficient for a 
PDE4D3-expressing strain while a gpa2 (Gα) deletion is required for PDE4A, PDE4B 
and PDE7A strains to confer 5FOA sensitivity. High-throughput screens with mouse 
PDE4A1, rat PDE4A5, mouse PDE4B3, human PDE7A1, and S. pombe PDE Cgs2 
against 87,000 compounds were previously carried out at the Broad Institute. In these 
screens, the compounds that allowed 5FOA resistant growth with Z scores above 8.53 
(the cutoff used by the Broad Institute’s Chemical Biology Program) were considered as 
hits. Among these, previously known PDE inhibitors which included rolipram and 
zardaverine as PDE4 specific inhibitors were detected. Besides the known inhibitors; 
novel isoform selective PDE inhibitors, such as imperatorin being a PDE4B selective 
inhibitor and BC30 as a PDE7A inhibitor, were also discovered (Alaamery et al. 2010; 
Ivey et al. 2008). 
On the other hand, for yeast strains expressing PDE8A, introduction of the 
aforementioned defects in the glucose sensing pathway are not enough to get a clean 
5FOA sensitive phenotype. In this thesis, I will describe the development of a platform to 
screen inhibitors of PDE8A strain where a more drastic change in the glucose sensing 
pathway was successfully employed. This system worked well for detection of PDE8 
inhibitors from a known collection of PDE inhibitors and optimized to give excellent 
screening conditions in high-throughput format, and eventually led to identification of 
novel PDE8 inhibitors. As with the PDE4 and PDE7 screen, compounds identified in this 
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screen show biological activity in mammalian cell culture assays even prior to further 
development via medicinal chemistry. 
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CHAPTER TWO 
2 MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Yeast Strains and Growth Media 
Yeast strains used in this study are listed in Table 2.1. The majority of the strains possess 
fbp1::ura4
+
 and ura4::fbp1-lacZ reporters, which are translational fusions integrated at 
the fbp1
+
 and ura4
+
 loci, respectively (Hoffman and Winston. 1990) (Figure 2.1). Yeast 
was grown and maintained using yeast extract agar (YEA) and yeast extract liquid (YEL) 
(Gutz et al. 1974) supplemented with 100 mg/L adenine. Defined medium EMM (MP 
Biochemicals) was supplemented with required nutrients at 75 mg/L, except for L-
leucine, which was at 150 mg/L. Sensitivity to 5-fluoro-orotic acid (5FOA) was 
determined on SC solid medium containing 0.4 g/liter 5FOA and 8% glucose as 
previously described (Hoffman and Winston. 1990). Liquid medium for 5FOA growth 
assays is the same as the solid medium, but without agar. Strain matings were performed 
on malt extract agar (MEA). Cells were grown at 30°C.  
2.1.2 Bacterial Strains and Growth Media 
ElectroTen-Blue® electroporation-competent cells (Agilent Technologies - Stratagene 
Products) were used as Escherichia coli host strain for plasmid amplification.  
49 
 
Table 2.1 Strain list 
Strain Genotype 
CHP14 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32   ade6-M210  his7-366  cgs2-2  git3-14 
CHP861 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  ade6-M210  his3-D1  leu1-32  gpa2::his3
+
 
CHP870 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  ade6-M210  his7-366  git3::GFP-kan 
CHP1113    h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his3D-1  pap1Δ::ura4  cgs2::PDE4B3  gpa2::his3
+
 
CHP1148    h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  cgs2::PDE8A1  gpa2∆::his3
+
 
CHP1186 h
+
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  git11∆  pap1∆  cgs2::PDE4D3 
CHP1189 h
+
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  gpa2∆  pap1∆  cgs2::PDE7A1  
CHP1194 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆ git2∆::his7
+
  cgs2::PDE3B[LEU2
+
] 
CHP1200 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  git2∆::his7
+
  cgs2-2 
CHP1202 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  git2∆::his7
+
  cgs2::PDE8A1[LEU2
+
] 
CHP1204 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2::PDE8A1[LEU2
+
] 
CHP1205 h
90
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2::PDE8A1 
CHP1207 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2-2 
CHP1209 h
-
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  git3∆  cgs2::PDE7B1  
CHP1218 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  git2∆::his7
+
  cgs2::PDE9A5 
CHP1220 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2::PDE1C4 
CHP1222 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1D  git2∆::his7
+
 cgs2::PDE1B1 
CHP1223 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2::PDE5A1 
CHP1224 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his7-366  pap1∆  git2∆::his7
+
  cgs2∆::PDE11A4  
CHP1249 h
-
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  git3∆  pap1∆  cgs2::PDE3A 
CHP1262 h
-
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  gpa2∆  pap1∆  cgs2::PDE4A1 
CHP1265 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his3-D1  pap1∆  gpa2∆  cgs2-2  gpa2∆::his3
+
 
CHP1268 h
-
  fbp1-ura4
+
  ura4::fbp1-lacZ  leu1-32  git3∆  pap1∆  cgs2::PDE4B2 
CHP1346 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  cgs2-2 
CHP1403 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  git2∆::his7
+
  gpa2∆  cgs2D::PDE2A2 
DDP13 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  ade6-M210  cgs2::PDE8A[LEU2
+
]  gpa2::his3
+
 
DDP26 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  cgs2::PDE4A1  gpa2::his3
+
 
DDP38 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his3-D1  pap1∆  gpa2∆  cgs2-2  gpa2∆::his3
+
  
ars1(EcoRI)::pNMT1-PDE8Acatalytic 
DDP40 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  cgs2-2 ars1(EcoRI)::pNMT1-PDE8Acatalytic 
DDP42 h
-
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  his3-D1  pap1∆  gpa2∆  cgs2-2 gpa2∆::his3
+
  
ars1(EcoRI)::pNMT41-PDE8Acatalytic 
DDP44 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  pap1∆  cgs2-2 ars1(EcoRI)::pNMT41-PDE8Acatalytic 
DIP72 h
90
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  ade6-M210  cgs2::PDE4B3  gpa2::his3
+
 
JZ666 h
90
    leu1
-
    ade6-M216    cgs2::ura4
+
    ura4-D18 
LWP98 h
+
  fbp1::ura4
+
  ura4::fbp1-lacZ  leu1-32  ade6-M216  his3-D1  cgs2-2  gpa2::his3
+
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Figure 2.1 Translational fusions for monitoring cAMP dependent growth 
(A) Translational fusions fbp1::ura4
+
 and ura4::fbp1-lacZ were used to monitor cAMP 
dependent glucose sensing pathway. (B) The phenotypes associated with wild type, git 
mutants and cgs2 mutants under 8% glucose (repressed) conditions are indicated.  
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Figure 2.1 Translational fusions for monitoring cAMP dependent growth 
A 
 
 
B 
 Phenotype under repressed conditions 
Genotype 5FOA Ura β-galactosidase 
Wild type 5FOA
R
 Ura
-
 Low β-gal 
git mutant 5FOA
S
 Ura
+
 High β-gal 
cgs2 mutant 5FOA
R
 Ura
-
 Low β-gal 
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Cells were grown in Luria Bertani (LB) broth (1% tryptone, 0.5% yeast extract, 1% 
NaCl) and transformants were selected on 100 mg/L ampicillin containing LB media. 
Cells were grown at 37°C. 
2.1.3 Enzymes 
All restriction endonuclease digestion enzymes and buffers were obtained from New 
England Biolabs. AccuPrime™ (Invitrogen), Herculase II Fusion DNA Polymerases 
(Agilent Technologies) and FailSafe™ PCR System (Epicentre Biotechnologies) 
enzymes were used in PCR amplification reactions. 
In vitro phosphodiesterase assays were performed using full length, recombinant human 
PDE8A1 (USBiologicals or BPS Bioscience), partially purified full length human 
recombinant PDE8B (Scottish Biomedical), catalytic domain of human PDE7A (Biomol 
International) and catalytic domain of PDE4A10 (generously provided by Drs. H. Wang 
and H. Ke). 
2.1.4 Compound Libraries 
High throughput screening was performed against chemicals from the Harvard Medical 
School ICCB-Longwood compound collection. As known bioactives collections; NINDS 
Custom Collection 2, Biomol 3- ICCB Known Bioactives and Prestwick 1 Collection 
were screened. Commercial Libraries from Asinex 1, Biomol-TimTec1, Bionet 1, Bionet 
2, CEREP, ChemBridge 3, ChemDiv 1, ChemDiv 2, ChemDiv 3, ChemDiv 4, ChemDiv 
6, Enamine 1, Enamine 2, I.F. Lab 2, Life Chemicals 1, MayBridge 1, MayBridge 2, 
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MayBridge 3, Maybridge 4, Maybridge 5, MixCommercial Plate 1, MixCommercial 
Plate 2, MixCommercial Plate 3, Mix Commercial Plate 5, Peakdale 1 collections were 
screened as well as natural product extracts from the following collections; ICBG 4 
Fungal Extracts, ICBG 5 Fungal extracts, ICBG-12 Fungal Extracts, MMV 1, MMV 2, 
MMV 3, NCDDDG 1, NCDDG 3, NCDDG 5, NCDDG2, STARR Foundation2- 
Extracts, Organic Fractions-NCI Plant and Fungal Extracts (Table 2.2). 
2.1.5 Small Molecules 
Small molecules were purchased from A.G. Scientific, Sigma, Tocris Bioscience, Specs, 
Maybridge, ChemDiv, ChemBridge, Enamine, Asinex, Aldrich Chemistry.  
2.1.6 Assay Kits 
Cyclic AMP levels were determined using an enzyme immunoassay kit from Assay 
Designs. Progesterone levels were quantified by Neogen or Oxford Biomedical Research 
immunoassay kits. Testosterone and pregnenolone detection was performed using 
Neogen and Diagnostics Biochem Canada Inc ELISA kits, respectively. Lastly, IL-2 
assays were performed using an ELISA kit from R&D Systems. 
2.2 METHODS 
2.2.1 Strain Construction 
Murine PDE8A1 was integrated into the chromosome under the cgs2 promoter in two 
steps. First, it was amplified by PCR using oligonucleotides containing approximately 60  
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Table 2.2 Screened compound libraries 
Commercial Known Bioactives 
ActiMolTimTec1 BIOMOL ICCB Known Bioactives 2 
Asinex 1 NINDS Custom Collection 2 
Bionet1 Prestwick1 Collection 
Bionet (Ryan Scientific) 2   
CEREP Natural Products 
ChemBridge3 ICBG Fungal Extracts 12 
ChemDiv1 (Combilab and 
International) ICBG Fungal Extracts 4 
Chemical Diversity 2 ICBG Fungal Extracts 5 
ChemDiv3 Medicines for Malaria Venture 
ChemDiv4 Medicines for Malaria Venture 2 
ChemDiv6 Medicines for Malaria Venture 3 
Enamine 1 NCDDG1 
Enamine 2 NCDDG2 
IFLab2 NCDDG3 
Life Chemicals 1 NCDDG5 
Maybridge1 
Organic NCI Plant and Fungal 
Extracts 
Maybridge2 Starr Foundation Extracts 2 
Maybridge3   
Maybridge4   
Maybridge5   
Mixed Commercial Plate 1   
Mixed Commercial Plate 2   
Mixed Commercial Plate 3   
Mixed Commercial Plate 5   
Peakdale1   
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nucleotides of sequence flanking the S. pombe cgs2 gene and incorporated into the 
pKG3-ura4 plasmid by gap repair transformation. A restriction fragment from this 
plasmid that possesses about 500 bp of cgs2 sequences flanking PDE8A was used to 
insert PDE8A into cgs2 locus by homologous recombination. The homologous 
integration was confirmed by PCR. Standard genetic crosses and tetrad dissection were 
used to introduce fbp1-lacZ and fbp1-ura4 reporter genes, pap1∆ allele and mutant alleles 
of components of cAMP signaling pathway such as git3∆, gpa2∆, git2-2.   
2.2.1.1 Gap Repair Transformation 
An overnight culture of cells were grown to log phase in YEL, refreshed by the addition 
of an equal volume of YEL and and grown 3-4 more hours before harvesting. Pelleted 
cells were washed twice with sterile distilled water and once with 1X LiAC/TE buffer. 
The cells were resuspended in LiAC/TE buffer to a density of ~10
8
 cells/mL. 2 µL of 
denatured salmon sperm DNA, 3 µL of StuI linearized pKG3-ura4 plasmid, 7-10 µL of 
cleaned and concentrated PCR product were added in 100 µL of cell suspension and were 
incubated at room temperature for 10 minutes. After addition of 260 µL of 40 % PEG / 
LiAC-TE buffer, the cell suspension was further incubated for 1 h at 30°C. The cells 
were then treated with 43 µL DMSO and heat shocked at 42°C for 5 minutes. Gently 
pelleted cells were resuspended in 300-1000 µL distilled water and plated out on EMM-
Leu selective medium.  
Cloning of full length PDE8A into pKG3-ura4 plasmid was performed using host strain 
JZ666 that lacks PDE activity. Plasmid pKG3-ura4, which carries cgs2 sequence 
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disrupted with ura4 gene, was linearized within the ura4 sequence and co-transformed 
with the PCR product to facilitate insertion of PDE8A into the cgs2 locus. Transformants 
were selected on EMM-Leu medium. The phenotypic screening for functional PDE 
activity was performed where applicable.  
The strain that expresses the catalytic domain of PDE8A was constructed by amplifying 
and cloning a 1325 bp region of the PDE8A gene into EcoRI-linearized pNMT1 and 
pNMT41 vectors via gap repair transformation. The recipient strain was also JZ666 and 
iodine staining of colonies grown on EMM-Leu plate was used as an assessment of PDE 
activity, which increases mating and thus iodine staining.  
2.2.1.2 Plasmid Rescue from Yeast (Smash and Grab) 
Cells were grown on EMM-Leu medium and collected by resuspending cells in sterile 
distilled water. Cells were collected by microcentrifugation and resuspended in 200 µL 
Smash and Grab buffer, 200 µL phenol-chloroform and 0.3 g glass beads and vortexed 
for 3 minutes as previously described by (Hoffman and Winston. 1987). Upon 
centrifugation for 5 minutes, the supernatant was collected. Prior to electroporation into 
E. coli cells, the plasmid mixture was cleaned by treating with equal volume of 
chloroform followed by isopropanol precipitation.  
2.2.1.3 Transformation into E. coli and plasmid amplification 
Ten microliters of ElectroTen-Blue
®
 electroporation-competent cells were mixed with 1-
2 µL of transforming DNA and volume was completed to 100 µL. Cells were 
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electroporated in 1mm gap electroporation cuvettes (Fisher) under 2250 Volts, 22.5 
kV/cm, 200 ohm, 25 µF. Electroprated cells were immediately mixed with 900 µL of LB 
broth and incubated at 37°C for 90 minutes before being plated out in LB-Ampicillin 
selective media.  
Single E. coli colonies were inoculated into LB medium and cultured overnight for 
plasmid amplification. Plasmids were isolated from E. coli cells using QIAprep Spin 
Miniprep Kit (Qiagen) according to manufacturer’s instructions. 
2.2.1.4 Knock-in Transformation by Integrating into the Chromosome 
The yeast transformation was performed as described for gap repair transformation. As 
the transforming DNA, 10-15 µL of target DNA that has flanking sequences to the 
intended locus of integration was used.  
For full length PDE8A integration, gap repaired plasmid that possess PDE8A was 
digested with restriction enzymes XhoI and PacI and used as the transforming DNA. As 
the recipient strain, JZ666, which carries a ura4
+
-marked disruption of cgs2
+
, was used. 
After transformation, cells were grown overnight in YEL before being plated onto 5FOA 
medium. As a parallel experiment, an enrichment step was incorporated by growing cells 
in PM complete medium with 0.1% glucose and 3% glycerol for 2 days before plating 
onto 5FOA medium in order to render growth advantage to cells expressing functional 
phosphodiesterase. Transformants were then transferred to EMM-his plates by replica 
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plating and screened for sporulation, which is a phenotype associated with regained PDE 
activity, i.e. low cAMP levels, in the recipient host strain lacking Cgs2.  
The catalytic domain of PDE8A was cloned into the S. pombe genome using strains 
CHP1265 and CHP1346 as hosts. The BlpI-linearized plasmid that possesses PDE8A 
catalytic domain under nmt1 and nmt41 promoters was integrated into the ars1 region. 
Stable integrants were selected by picking Leu
+
 colonies after subsequent replica plating 
of transformants onto YEA plates to allow for loss of autonomous plasmids.  
2.2.1.5 Strain Mating and Tetrad Dissection 
Matings were performed by mixing and plating freshly grown parent strains onto MEA 
plates. Followed by 1-2 days of incubation at 30°C, the cells were transferred onto a YEA 
plate and zygotic asci were individually selected and separated from other cells by the aid 
of a needle dissector. The cells were incubated at 37°C for 2-3 hours for ascus wall break 
down. Each spore from a single zygotic ascus was placed apart from each other in an 
orderly fashion and grown for a few days until they formed visible colonies. The tetrads 
were scored for the chosen phenotypes by replica plating onto selective media. Where no 
growth phenotype is available, colony PCR was performed. The presence of fbp1-lacZ 
fusion protein was detected by X-gal filter lift assay. 
2.2.1.6 X-gal Filter Lift 
Colonies freshly grown on YEA plates were replica plated onto nitrocellulose membrane. 
The membrane was submerged in liquid nitrogen for one minute and allowed to thaw. 2.5 
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mL of Z buffer was mixed with 150 µL X-gal substrate (5-bromo-4-chloro-3-indolyl-
beta-D-galactopyranoside, 20 mg/ mL) in a Petri dish and a filter paper was placed inside. 
The thawed membrane was put on the filter paper with cell side up and incubated at 30°C 
for 10-30 minutes until the color development was observed. LacZ expressing colonies 
turn to blue. 
2.2.1.7 Colony PCR 
Colony PCR reactions were carried out using the Failsafe enzyme and buffer system 
according to the manufacturer’s instructions. PCR reaction mixture was prepared without 
the template and enzyme. As template, a pin head size of freshly grown cells were 
transferred into each reaction tube by the aid of a pipette tip and incubated at 98°C for 10 
minutes. The enzyme was added after this incubation step and regular PCR reaction was 
carried out. 
2.2.2 β-Galactosidase Assays of fbp1-LacZ Expression  
Beta galactosidase assays were performed on mid-log phase cultures that were pregrown 
in cAMP containing EMM media prior to compound treatment. After pregrowth, cells 
were washed in EMM and subcultured in EMM with compounds for 24 hours at 30°C 
aiming for mid log phase cultures. Cells were collected and the pellet was washed with 
water before being resuspended in breaking buffer. The cell extracts were prepared by 
vortexing with glass beads as previously described (Nocero et al. 1994). The activity of 
the extracts was determined by the rate of the yellow color development from ONPG 
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(ortho-Nitrophenyl-β-galactoside) substrate at 28°C. The reactions were stopped by 
addition of 1 M sodium carbonate and optical density was measured at 420 nm. The beta 
galactosidase specific activity of the extracts was quantified with respect to the total 
soluble protein concentration, which was determined using BCA protein assay kit 
(Pierce).     
2.2.3 5FOA Growth Assay 
Cyclic nucleotide dependent 5FOA growth response of cells was monitored in 50 µL 
5FOA medium in 384-well microtiter plates (untreated, flat clear bottom). Cells were 
inoculated at an initial cell density of 0.5-2 x 10
5
 cells/ mL. Pregrowth conditions of each 
strain were optimized in order to repress the fbp1-ura4
+
 reporter prior to inoculation into 
5FOA medium. This is most often achieved by subculturing exponential phase cells in 
EMM complete medium containing cAMP. The plates were then incubated at 30ºC for 48 
hours in airtight containers that have moist paper towels. At the end of incubation, plates 
were vortexed in a microtiter dish vortexer and optical densities were measured at 600 
nm using a plate reader (SpectraMax Plus).  
2.2.4 Low-Throughput Screening of Compounds 
Fifty-six compounds identified as inhibitors of PDEs from high-throughput screens 
against PDE4 and PDE7 enzymes were tested against a PDE8A-expressing strain 
(CHP1204). The experiments were performed with 0.5 mM cAMP in pregrowth medium 
and 40 µM cAMP in 5FOA. The compounds were tested at three different concentrations 
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of compounds (100, 50 and 25 µM) using eight different wells per condition (Figure 2.2). 
As a positive control, a PDE4B3-expressing strain (CHP1113) was used. Medium 
containing 1% DMSO was used as a negative control, while medium containing 1% 
DMSO and 5 mM cAMP was used as a positive control. As an internal positive control 
for the growth of a PDE4B3-expressing strain, 20 or 40 µM of rolipram was added to the 
medium. For each strain two independent cultures were used. 
2.2.5 Z Factor Test 
The suitability and quality of the assay conditions for high throughput format was 
evaluated by Z factor test as previously described by Zhang et al (1999). The Z factor 
coefficient ( = 1 −
	



 ; where  and  are standard deviations of positive and 
negative controls,  and  are means of positive and negative controls, respectively) 
was calculated as a function of mean values and standard deviations of both negative and 
positive control values in order to reflect both the assay signal dynamic range and the 
data variation associated with the signal measurements. For PDE8A strains, DMSO 
(0.2%) was used as negative control while 5 mM cAMP or 10 or 20 µM of BC69 was 
used as positive control. 96 or 192 wells were used for both negative and positive control 
conditions for each assay. 
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Figure 2.2 Plate layout for high-throughput screening assays 
Plate layouts for control plate and an experimental plate were indicated using actual data 
plates. The half of the master control plate contains DMSO while second half has 5 mM 
and 10 mM BC69. An experimental plate contains four wells filled with 5FOA with 0.2 
% DMSO and four wells filled with 20 µM BC69, which were added after or before 
pinning process. The location of the in-plate controls varies in some plates depending on 
the empty wells in the chemical library plate.  
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Figure 2.2 Plate layout for high-throughput screening assays 
 
A   Master control plate for pinning 
 
 
B   Experimental plate with in-plate controls 
 
  
10 mM  5 mM  
BC69 
DMSO 
BC69 
DMSO 
64 
 
2.2.6 High-Throughput Screening 
The cultures were pregrown in EMM complete medium containing 0.5 or 1 mM cAMP 
for CHP1204 (full length PDE8A) and DDP40 (catalytic domain of PDE8A), 
respectively. After delivery of 25 µL of SC-based growth medium containing 0.4 g/L 
5FOA into each well of 384-well microtiter dishes (untreated, with flat clear bottoms), 
100 nL compounds were pinned. Cells were then transferred into the microtiter plates at a 
final density of 0.5x10
5
 cells/mL or 1x10
5
 cells/mL for CHP1204 and DDP40, 
respectively. The 5FOA medium used for CHP1204 strain also contains 40 µM final 
concentration of cAMP since the strain is deleted for adenylyl cyclase. As control, a 
master plate containing DMSO and 5 mM and 10 mM BC69 (a compound identified as a 
positive control in the low-throughput screen) was prepared and used for pinning as 
appropriate. Other positive control dishes contained 5mM cAMP in the 5FOA medium. 
In addition, each plate contained four wells containing 0.2 % DMSO in the medium and 
four wells containing 20 µM BC69 in the medium as in-plate negative and positive 
controls (Table 2.3). Cultures were grown for 48 hours at 30ºC, sealed in an airtight 
container with moist paper towels to prevent evaporation. Optical density (OD600) of each 
well was measured using Wallac Envision plate reader (Figure 2.3). 
2.2.7 Dose Response Profiling of Compounds  
Dose response profiling of compounds was performed in 5FOA medium with compound 
concentrations in a range of 4 orders of magnitude starting from 100 µM and performing 
2/3 dilutions in 18 consecutive columns until obtaining 0.101 µM. Cells were added in 25 
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µL volume on top of 25 µL of 2X compound containing medium to achieve 50 µL final 
volume in each well. Plate incubations and OD measurements were performed according 
to standard 5FOA assay procedure as described.  
In order to profile different phosphodiesterases (PDE) against a given compound, 16 
different strains expressing different PDEs were used. The pregrowth condition and 
initial cell density for each strain was previously optimized by Hoffman lab members as 
indicated in Table 2.3.  
2.2.8 In vitro PDE Assay 
In vitro PDE assays were performed as previously described by Wang (Wang et al. 
2005). This technique depends on measurement of the rate of substrate depletion by 
counting the amount of unreacted 
3
H-cAMP after the reaction product (5’-AMP) is 
differentially precipitated with barium hydroxide. For Michaelis-Menten kinetics 
experiments, the reactions were performed in 50 mm Tris·HCl (pH 8.5), 10 mM MgCl2 
or 4 mM MnCl2, 5 mm dithiothreitol, and 10 nM 
3
H-cAMP with varying concentrations 
of cold cAMP in the presence of inhibitors or DMSO for 30 minutes. The reactions were 
stopped with 200 µL 0.2 M ZnSO4 and 5’-AMP was precipitated with 200 µL 0.25 N 
Ba(OH)2 by centrifugation for 15 minutes at 14000 rpm. The remaining radioactivity in 
the supernatant was quantified in 4 mL of scintillation fluid with Perkin Elmer liquid 
scintillation analyzer (Tri-Carb 2900 TR). The half maximal inhibitory concentration 
(IC50) of inhibitors was determined using 5-11 different concentrations of compounds at a 
fixed cAMP concentration.  
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Table 2.3 Optimized growth conditions for 5FOA assays 
 
PDE Pregrowth supplement Cyclic nucleotide in 
5FOA medium 
Cell density 
(x10
5
 cells/mL) 
PDE1B 2.5 mM cAMP 15 µM cAMP 0.5 
PDE1C 2.5 mM cAMP 15 µM cAMP 0.5 
PDE2A 0.25 mM cAMP 15 µM cAMP 2.0 
PDE3A 5.0 mM cAMP NA 1.0 
PDE3B 0.25 mM cAMP 33 µM cGMP 2.0 
PDE4A 5.0 mM cAMP NA 2.0 
PDE4B 5.0  mM cAMP NA 2.0 
PDE4D 200 µM rolipram NA 1.5 
PDE5A 0.25  mM cAMP 200 µM cAMP 2.0 
PDE7A 2.5 mM cAMP NA 1.0 
PDE7B 2.5 mM cAMP NA 1.0 
PDE8A 0.5 mM cAMP 40 µM cAMP 0.5 
PDE8A catalytic 20 µM BC69 NA 1.0 
PDE9A 0.25 mM cAMP 600 µM cGMP 2.0 
PDE10A 0.25 mM cAMP 15 µM cAMP 2.0 
PDE11A 0.25 mM cAMP 50 µM cGMP 0.75 
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Figure 2.3 High-throughput screening process  
High-throughput screening process starts with filling the plates with 25 µL 5FOA 
medium. After the delivery of 100 nL of tested compounds, cells were delivered at the 
optimized density. Optical density was read after 2 days of growth at 30ºC. 
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Figure 2.3 High-throughput screening process  
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2.2.9 Measurement of Steroid Release from Mouse Leydig Tumor Cells 
The mouse Leydig tumor cell line MA-10 was used to test the effect of PDE8A inhibitors 
on steroidogenesis. Since these cells express very low or undetectable amounts of 
P450c17, the enzyme with 17 alpha-hydroxylase and 17,20 lyase activities in the 
synthesis of steroid hormones, the major steroid output of the cells is progesterone. MA-
10 cells were seeded in 24 or 48 well plates to achieve 60-80% confluency after 2-3 days 
in RPMI medium. Cells were washed and incubated with serum free medium for 2 hours 
before compound treatment. The basal progesterone levels were determined by collecting 
the media after 3h of inhibitor treatment in a 5% CO2 incubator at 37°C. In order to 
determine the effect of the compounds in the presence of LH hormone, cells were treated 
with 3 ng/mL recombinant LH for 2 hours following a 2h pre-incubation with 
compounds. The media was collected and progesterone levels were quantified with 
ELISA kit for progesterone detection. 
2.2.10 Measurement of Testosterone Production From Primary Leydig Cells 
Leydig cells were isolated from testes of wild type and PDE8A/B knock out adult mice as 
previously described (Vasta et al., 2006). Immediately upon isolation, Leydig cells were 
resuspended in DMEM/F-12 medium supplemented with 1% BSA and 150 µL aliquots 
were dispensed in 48-well plates. After a few hours of incubation at 37°C to allow cell 
attachment, 30 µL of media with test compounds were added in duplicate wells to obtain 
10 and 40 µM final concentration. The media were collected after 3 hours of incubation. 
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The amount of testosterone released into the media was measured by an ELISA kit from 
Neogen.  
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CHAPTER THREE 
3 DEVELOPMENT OF A FISSION YEAST BASED SCREENING 
PLATFORM FOR IDENTIFICATION OF PDE8 INHIBITORS 
In recent years, several studies began to uncover the functional roles of PDE8A and 
PDE8B enzymes especially in steroid formation in the Leydig cells or adrenal glands. 
However, the absence of commercially available PDE8-specific chemical inhibitors 
limits the ability of scientists to study these enzymes that may eventually serve as 
therapeutic targets. In this study, we aim to develop a fission yeast screening platform in 
order to identify PDE8 inhibitors. 
3.1 CONSTRUCTION OF PDE8A EXPRESSING STRAINS 
Full length mouse PDE8A gene was incorporated into the yeast genome in two steps. 
Firstly, the mouse PDE8A gene was PCR-amplified with PDE8A specific primers that 
contain cgs2 (yeast PDE) complementary flanking regions and inserted into plasmid 
pKG-ura4 by gap repair transformation. Then, a restriction fragment from the gap 
repaired plasmid containing PDE8A with 500 bp cgs2 flanking sequence was used for 
direct homologous recombination into the strain JZ666 (cgs2::ura4
+
) (Figure 3.1.). In 
order to enrich for the desired transformants, transformation was followed by allowing 
cells to grow to stationary growth before cells were plated into the 5FOA medium. The 
cells that contain a functional PDE should be able to sense the starvation cues (i.e. have 
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lower cAMP levels as compared to PDE-lacking cells that have high basal cAMP levels) 
and would have a growth advantage compared to the host strain. This approach helped to 
identify colonies that express PDE8A. Although PDE8 expression did not yield a very 
strong mating competent phenotype, transformants were screened for their ability to 
sporulate in starvation medium and the candidates were confirmed to carry PDE8A by 
PCR. The strain expressing PDE8A from the cgs2 locus was crossed with other strains to 
introduce the fbp1::ura4, ura4::fbp1-lacZ reporter genes and a pap1 deletion to enhance 
drug sensitivity. Strains with different mutations in the glucose sensing pathway (i.e. 
glucose insensitive transcript mutants, git) were constructed in order to vary cAMP 
synthesis and generate different degrees of 5FOA sensitivity. When the strain expressing 
PDE8A in JZ666 background was crossed with CHP14 (fbp1::ura4, ura4::fbp1-lacZ, 
git3-14) and CHP870 (fbp1::ura4, ura4::fbp1-lacZ, git3::GFP-Kan), the PDE8A 
containing progeny turned out to be  5FOA resistant. This shows that in the fission yeast 
system, PDE8A is less active than Cgs2 so that there is a relatively higher level of cAMP 
to repress fbp1-ura4 expression, which confers 5FOA resistance. On the other hand, 
when gpa2 deletion was introduced to the PDE8A strain, partial sensitivity to 5FOA was 
observed in solid medium. 
The strain expressing the catalytic domain of PDE8A was constructed as follows. First, a 
1325 bp region of the PDE8A gene (including codons 443 to 824) was amplified and 
cloned into EcoRI-linearized pNMT1 and pNMT41 vectors via gap repair transformation. 
The PDE activity was assessed by iodine staining on EMM-Leu selective media.  
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Figure 3.1 Construction of a PDE8A-expressing strain 
PDE8A was cloned into the yeast genome in two steps. (A) Mouse PDE8A PCR product 
with complementary cgs2 sequences was cloned into linearized pKG3-ura4 plasmid by 
gap repair transformation. This step resulted in a plasmid that carries the PDE8A gene 
with cgs2 flanking sequences. (B) Restriction digest of PDE8A from the gap-repaired 
plasmid resulted in a DNA fragment containing longer cgs2 complementary sequences, 
which was used for homologous recombination of the PDE8A gene into the cgs2 locus.  
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Figure 3.1 Construction of a PDE8A expressing strain 
A)   Gap repair transformation 
 
 
B)   Integration into the chromosome 
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Figure 3.2 Cells that express catalytic domain of PDE8A were detected by their 
ability to sporulate in starvation medium 
The host strain that lacks PDE cannot sporulate under starvation conditions. On the other 
hand, a functional PDE (in this case catalytic domain of PDE8A) restores sporulation.  
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Figure 3.2 Cells that express catalytic domain of PDE8A were detected by their 
ability to sporulate in starvation medium 
 
Starvation conditions- No glucose 
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Many colonies stained dark brown, which is an indication of presence of zygotes and asci 
as opposed to only vegetative cells. The presence of asci was confirmed by microscopy 
(Figure 3.2). The presence of more visible asci at this stage compared to the strain 
expressing the full-length PDE8A does not indicate that the PDE8A catalytic domain is 
more active than the full-length enzyme as the two forms of the enzyme were expressed 
from promoters of different strengths. The nmt promoters are strong and constitutive and 
thus it is expected to yield more activity compared to the cgs2 promoter.  
After cloning the catalytic domain PDE8A fragment into the plasmid, linearized plasmids 
were integrated into the ars1 region of strains CHP1265 and CHP1346.  
3.2 ASSESSMENT OF INHIBITOR ACTIVITY IN VIVO BY MONITORING β-
GALACTOSIDASE 
The presence of a lacZ reporter gene under the fbp1 promoter provides a tool for the 
assessment of phosphodiesterase activity and the inhibitory effect of candidate 
compounds on the phosphodiesterase enzyme in the cell. Inhibition of phosphodiesterase 
leads to elevated internal cyclic AMP levels that repress the reporter and decrease β-
galactosidase activity (Figure 3.3).  
In order to monitor in vivo PDE8 activity in the absence or presence of PDE inhibitors, I 
tested the β-gal levels of PDE8-expressing strain with dipyridamole, trequinsin, IBMX, 
and rolipram. Dipyridamole is a PDE5 and PDE6 inhibitor with weak inhibitory activity 
on PDE8. The PDE3 inhibitor trequinsin has been reported to inhibit PDE8B with an IC50 
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of 2 µM and there is no data on its effect on PDE8A. 24 h treatment of these compounds 
at up to 200 µM did not change β-gal levels compared to control (data not shown). The 
inability of these compounds to affect β-gal levels could be due to poor solubility in the 
yeast medium or a failure to enter the yeast cells. I also tested the effect of IBMX 
(general PDE inhibitor that does not inhibit PDE8) and rolipram (PDE4 specific 
inhibitor) on a PDE8A expressing strain. As expected, they did not show an effect on β-
gal levels. The experiment with rolipram was done in comparison to PDE4 expressing 
strains and provided some insights about the relative activities of these mammalian 
enzymes in the yeast (Figure 3.3.). Accordingly, PDE4A and PDE4B seem to be more 
active than PDE8A and their activity is lower than S. pombe PDE Cgs2. Although no 
compound was effective in changing PDE8A’s activity in β-galactosidase experiments, 
more than 10 fold decrease in β-gal levels were observed on PDE4A and PDE4B 
expressing strains when treated with 50 µM rolipram. This shows the utility of this 
system to assess compound activity on mammalian phosphodiesterases. 
3.3 BASIS OF SCREENING FOR PHOSPHODIESTERASE INHIBITORS 
In Schizosaccharomyces pombe, cAMP signalling is controlled by the regulation of both 
adenylyl cyclase and phosphodiesterase (Cgs2). It is possible to control cAMP levels by 
modulating the phosphodiesterase activity. A screen for an inhibitor of a mammalian 
phosphodiesterase utilizes the 5FOA growth of a strain in which fission yeast 
phosphodiesterase is replaced with the mammalian ortholog.  
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Figure 3.3 Beta-galactosidase assays are used to assess inhibitor activity 
(A) Beta-galactosidase and 5FOA growth phenotypes of an ideal candidate strain to be 
used for assessment of an inhibitor activity. (B) Beta-galactosidase activity of Cgs2 
(CHP861), Cgs2-2 (LWP98), PDE4A (DDP26), PDE4B (DIP72), and PDE8A-
expressing (DDP13) yeast strains after 24 h incubation with 50 and 100 µM rolipram. 
cgs2-2 gene has a frameshift mutation that leads to a non-functional gene product. 
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Figure 3.3 Beta-galactosidase assays are used to assess inhibitor activity 
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Figure 3.4 Basis of an inhibitor screen  
For detection of inhibitors, the starting strain should confer 5FOA sensitivity in the 
absence of compounds. An effective inhibitor can elevate cAMP levels and result in 
5FOA resistance.  
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Figure 3.4 Basis of an inhibitor screen 
A) Without a PDE inhibitor 
 
B) With a PDE inhibitor 
 
 
 
In the presence of a PDE8A inhibitor, 
cAMP levels increase, the fbp1 
promoter is repressed, and ura4 is 
not expressed. 
 
GROWTH IN 5FOA MEDIUM 
NO GROWTH IN 5FOA MEDIUM 
With a limited amount of cAMP in the 
cell, the fbp1 promoter is derepressed 
and ura4 is expressed. 
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This starting strain should have low enough cyclic AMP levels to allow the expression 
from the fbp1 promoter. In this case, the ura4 gene under the fbp1 promoter is expressed 
and the starting strain cannot grow in 5FOA (5-Fluoroorotic acid) which is converted to a 
toxic product in the presence of ura4 gene product OMP decarboxylase. In this system, 
the presence of a PDE inhibitor would increase the intracellular cAMP levels, which 
causes repression of the fbp1 promoter and cells would become 5FOA resistant (Figure 
3.4). Hence, the first step in creating a tool for screening for PDE inhibitors is to make a 
5FOA sensitive strain with the PDE of interest. This can be achieved by introducing 
mutations in genes required for adenylyl cyclase activation to lower cyclic AMP 
synthesis.  
3.4 DEVELOPMENT OF AN ASSAY TO SCREEN FOR PDE8 INHIBITORS 
3.4.1 Efforts to Optimize PDE8A for Inhibitor Screening 
The requirement for an effective screen to have a clean background becomes of 
paramount importance for high-throughput formats. This is achieved by starting with a 
5FOA sensitive strain. It is also important to obtain dramatic differential growth between 
the positive control (2.5-5 mM cAMP and DMSO in 5FOA) and negative control (only 
DMSO in 5FOA) conditions.  
The following efforts were made to obtain suitable conditions for screening for PDE8A 
inhibitors: 
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i) The introduction of git3-14 (GPCR) mutation or deleting git3 were not 
enough to confer 5FOA sensitive growth in a strain bearing PDE8A (this 
suggests that PDE8A has much less activity than Cgs2). 
 
ii) CHP1148 strain (pap1::ura4 cgs2::PDE8A gpa2::his3+) was tested for 
suitability for screening. The 5FOA sensitive starting strain should be pre-
incubated with cyclic AMP prior to the screening in order to repress 
transcription at the fbp1-ura4 reporter, creating a 5FOA resistant starting 
point, which will be maintained if cAMP levels could be kept high by means 
of inhibiting PDE. As a starting point, different cAMP concentrations in the 
pre-growth medium and different initial cell densities were tested separately 
(Figure 3.5). There was no difference between the negative and positive 
control conditions with different pre-growth media. Although a difference was 
observed between the positive and negative control conditions with 2x10
4
 
cells/mL initial cell density; the difference was not robust. The required 
condition of drastic differential growth between positive control and negative 
control groups could not be achieved with this strain. 
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Figure 3.5 Strain CHP1148 is not suitable for inhibitor screening 
PDE8A expressing strain with gpa2 deletion (CHP1148; pap1::ura4 cgs2::PDE8A 
gpa2::his3
+
) did not show any differential growth between positive and negative control 
conditions under different cAMP concentrations in the pre-growth medium (A) or with 
different initial cell densities (B). 
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Figure 3.5 Strain CHP1148 is not suitable for inhibitor screening 
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iii) More stringent 5FOA medium was tested. 0.6 and 0.8 g/L 5FOA in the 
medium (as opposed to 0.4) prevented the growth even in the positive control 
conditions (the highest optical density was 0.085 and 0.065, respectively). 
0.5g/L 5FOA media seemed more promising since it allowed growth of cells 
with 0.25x10
5
 cells/mL initial density up to 0.33 optical density. Increased cell 
densities were tested with 0.45 g/L 5FOA medium. Only encouraging data 
was obtained with 0.5x10
5
 cells/mL initial cell density and 0.25 mM cAMP in 
the pre-growth medium, which yielded optical density values of 0.17 for 
negative control and 0.83 for positive control conditions. However, it was not 
reproducible under DMSO pinning conditions. 
iv) A PDE8A strain with git3 and gpa2 double deletion was constructed but did 
not give a promising Z factor (data not shown). 
 
In summary, while the gpa2∆ strains displayed 5FOA sensitivity on solid medium, it 
was insufficient sensitivity in liquid medium to allow for screening of candidate 
inhibitors.  
3.4.2 Optimization of PDE8A Strain with Adenylyl Cyclase Deletion 
Since deletion of either git3 (GPCR) or gpa2 (Gα) failed to confer 5FOA sensitive 
growth in liquid medium, a deletion of git2 (adenylyl cyclase) was introduced into a 
PDE8A-expressing strain. A strain that lacks adenylyl cyclase requires external addition 
of cAMP to repress fbp1 transcription. In this system, PDE activity could be detected as 
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judged by an increase of the level of exogenous cAMP needed to confer 5FOA-resistant 
growth. A cgs2-2 strain that has no functional phosphodiesterase was used as a control to 
mimic a fully inhibited phosphodiesterase.  
In order to select for the best strain for this experiment, various strains were subjected to 
5FOA growth under cyclic AMP titration. Two of the strains are PDE8A-expressing 
strains that have the LEU2 marker linked to PDE8A with or without a pap1 deletion. 
Another PDE8A strain without the LEU2 marker was also tested. For the positive control, 
cgs2-2 mutation and git2 deletion strains with and without pap1 deletion were used. The 
cAMP dose response curve depicted in Figure 3.6 explains many aspects of the adenylyl 
cyclase deletion strategy. It shows that pap1
+
 strains grow better than pap1 deletion 
strains in 5FOA. This gene encodes for a zinc finger transcription factor that is required 
for expression of ABC transporters and when deleted it enhances drug sensitivity by 
allowing the drug to stay inside the cell longer. The increased 5FOA sensitivity of pap1 
deletion strains can be explained by higher retention of 5FOA inside the cells. Also, the 
PDE8A strain reaches higher optical densities earlier than the PDE8A(LEU2) strain, 
indicating that it has higher cAMP levels (i.e. lower phosphodiesterase activity). The 
increased sensitivity associated with PDE8A-LEU strain compared to PDE8A strain 
suggests the presence of more than one copy of PDE8A in the former strain. As a follow-
up, lower cAMP concentrations in the pre-growth medium were also tested (Figure 3.7).  
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Figure 3.6 PDE8A strain with adenylyl cyclase deletion requires more exogenous 
cAMP to grow in 5FOA medium than Cgs2-2 strain 
(A) Figure shows the 48 h growth behavior of adenylyl cyclase deletion strains in a 
cAMP titration experiment. Cells were grown in a pre-growth medium that contains 1 
mM cAMP. Cells were inoculated at 0.5x10
5
 cells/mL initial cell density. (B) Strain pair 
that gives the most differential growth is shown at low cAMP concentrations. (CHP1200: 
cgs2-2, pap1
+
; CHP1207: cgs2-2, pap1∆; CHP1202: PDE8A(LEU2), pap1+; CHP1205: 
PDE8A, pap1∆) 
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Figure 3.6 PDE8A strain with adenylyl cyclase deletion requires more exogenous 
cAMP to grow in 5FOA medium than Cgs2-2 strain 
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Figure 3.7 Effect of different cAMP concentrations in the pre-growth medium 
The cAMP titration curve of cultures grown in different concentrations of cAMP shows 
that 0.5 or 1 mM cAMP in the pre-growth medium did not cause any change in the 
growth profile of PDE8A-expressing strain. 
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Figure 3.7 Effect of different cAMP concentrations in the pre-growth medium 
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It was shown that optical density values of cultures pre-grown in media containing 1 mM, 
0.5 mM, or 0.25 mM cAMP are very close to each other at 50 µM cAMP concentration 
in the 5FOA medium. This concentration of cAMP in 5FOA medium confers 5FOA-
resistance to a strain lacking both adenylyl cyclase and PDE activity (cgs2-2, git2) but it 
is still low enough for keeping PDE8A expressing strain in 5FOA sensitive state. This 
suggests that when the activity of PDE8A is totally inhibited, this amount of exogenous 
cAMP would be enough to allow growth in 5FOA. Thus, addition of 40 µM cAMP in 
5FOA growth medium was found to be the optimal condition for the screening assay. 
3.5 LOW-THROUGHPUT SCREENING OF PDE8A INHIBITORS 
Optimization of the PDE8A-expressing adenylyl cyclase deletion strain (CHP1204) for 
detection of PDE inhibitors allowed me to test fifty-six compounds that were identified 
from high-throughput screens against PDE4 and PDE7 enzymes. I tested each compound 
using three different concentrations (100, 50 and 25 µM) against two independent 
cultures. As a control, each compound was also tested against a PDE4B3-expressing 
strain (CHP1113). Positive control condition was 5 mM cAMP (and 1% DMSO) in the 
5FOA medium, while 1% DMSO containing 5FOA medium served as a negative control.  
The 5FOA growth response of the PDE4B3 strain in the presence of the test compounds 
was consistent with the known compound inhibition profile. Also, the strain responded to 
the PDE4 inhibitor rolipram in each experiment. Among the test collection, several 
compounds promoted the 5FOA growth of the PDE8A-expressing strain. An exemplary 
profile is shown from an experiment, where six compounds were tested (Figure 3.8). In 
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this assay, compound BC69 promotes the growth of strain CHP1204 (PDE8A) at each 
concentration. For both strains, one percent DMSO did not have an adverse effect on 
growth.  Among the screened compounds, several compounds were found to be effective 
in promoting 5FOA-resistant growth. Figure 3.9 and 3.10 show the scatter plots of 
average absorbance values obtained at 50 µM compound concentration from culture A 
against culture B for PDE8A and PDE4B strains, respectively. It shows that the 5FOA 
growth profile of PDE8A strain is very reproducible (Figure 3.9A) while that of PDE4B 
strain showed discrepancy between culture A and culture B in some instances (Figure 
3.10A). Figures 3.9B and 3.10B show the scatter plots of absorbance values at 100 µM 
against 25 µM compound concentration. This might show trends where the effect of the 
compound differs significantly at different concentrations. For instance, BC21 and BC24 
showed better response for PDE8A strain at 100 µM and 25 µM, respectively. On the 
other hand, for PDE4B strain a collection of compounds responded better at the lower 
concentration. Finally, we can also examine the data by a scatter plot of average 
absorbance value for PDE8A against PDE4B strains (Figure 3.11). Accordingly, each 
compound that promoted growth of PDE8A strain also promoted growth of PDE4B 
strain. In addition, compound BC69 gave the best response among the test compounds for 
increasing growth of the PDE8A-expressing strain. 
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Figure 3.8 Compound BC69 promotes the growth of a PDE8A-expressing strain 
Average optical density values of strain CHP1204 (PDE8A) (A) and CHP1113 (PDE4B) 
(B) in the presence of compounds BC67, BC69, BC47, BC58-6 and BC58-9 shows that 
BC69 promotes the 5FOA growth of both strains. 
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Figure 3.8 Compound BC69 promotes the growth of a PDE8A-expressing strain 
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Figure 3.9 Compounds that promote 5FOA growth of a PDE8A-expressing strain 
are identified 
(A) Scatter plots of average optical density values of culture A against culture B for 
CHP1204 at 50 µM compound concentration is shown. Experimental wells are shown in 
red, negative control DMSO is shown in blue and 5 mM cAMP control is shown in 
yellow. The collection of test compounds includes fifty-six PDE4 and/or PDE7 inhibitors 
along with other candidate PDE inhibitors from the Hoffman lab. (B) Scatter plot of 
average optical density values of 100 µM compound concentration against 25 µM 
compound concentration is shown. Compounds resulted in optical densities above 0.4 
were labeled. Rolipram control is shown in gray. 
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Figure 3.9 Compounds that promote 5FOA growth of a PDE8A-expressing strain 
are identified 
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Figure 3.10 Compounds that promote 5FOA growth of PDE4B-expressing strain 
CHP1113 are re-confirmed 
(A) Scatter plots of average optical density values of culture A against culture B for 
CHP1113 at 50 µM compound concentration is shown. Experimental wells are shown in 
light blue, negative control DMSO is shown in dark blue, rolipram control is shown in 
gray, and 5 mM cAMP control is shown in yellow. The collection of test compounds 
includes fifty-six PDE4 and/or PDE7 inhibitors along with other candidate PDE 
inhibitors from the Hoffman Lab. (B) Scatter plot of average optical density values of 
100 µM compound concentration against 25 µM compound concentration is shown. 
Compounds resulted in optical density values above 0.6 were labeled. 
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Figure 3.10 Compounds that promote 5FOA growth of PDE4B-expressing strain 
CHP1113 are re-confirmed 
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Figure 3.11 BC69 shows the strongest effect on PDE8A 
(A) Scatter plot of average optical density values of PDE8A strain against PDE4B strain 
at 50 µM compound concentration is shown. Experimental wells are shown in purple, 
negative control DMSO is shown in blue, rolipram is shown in gray, and 5 mM cAMP 
control is shown in yellow. The collection of test compounds includes fifty-six PDE4 
and/or PDE7 inhibitors along with other candidate PDE inhibitors from the Hoffman lab. 
(B) Compounds that resulted in optical density values above 0.4 for PDE8A strain are 
labeled. Compounds with inhibitory potential on PDE8A are from PDE4 collection since 
they also promote growth of PDE4B strain. BC69, which indicated with a red circle, 
gives the strongest growth phenotype for PDE8A. 
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Figure 3.11 BC69 shows the strongest effect on PDE8A 
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3.6 EVALUATION OF IDENTIFIED COMPOUNDS 
3.6.1 Dose Response Profiling 
The compounds that showed some increase in the 5FOA growth of strain CHP1204 were 
retested with increasing compound concentrations ranging from 0.3-80 µM. These dose 
response curves indicated that compounds BC21, BC24, BC39, BC42, BC51, BC55, 
BC60, BC62, BC63, BC66, BC69 and BC76 all increase growth of the PDE8A-
expressing strain to OD>0.5 in the 5FOA medium (Figure 3.12). For BC24, the effect is a 
bell-shaped curve, while a wider plateau is seen with other compounds. Among these 
compounds, compound BC69 produced the highest growth response. 
3.6.2 Cyclic AMP Titration Curves 
The effect of some promising compounds (BC24, BC42, BC51, BC55, and BC69) on the 
growth of PDE8A (CHP1204) and Cgs2-2 (CHP1207) strains was tested in a cAMP 
titration experiment in order to evaluate the possibility that some compounds affect the 
growth response via a non-PDE target. In this experiment, a fixed concentration of the 
compounds was added in the 5FOA medium along with different concentrations of 
cAMP. If the compound is acting through PDE, then it should shift the cAMP titration 
curve of the strain that expresses PDE8A to the left while curve of the strain without a 
functional phosphodiesterase (Cgs2-2) remains unchanged. A leftward shift in the Cgs2-2 
growth curve would suggest that the compound is acting on other components of the 
glucose sensing pathway or uracil biosynthesis pathway.  
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Figure 3.12 Dose response curves of identified compounds 
Dose response curves of selected compounds (BC21, BC24, BC42, BC51, and BC55 on 
panel A; BC60, BC63, BC66, BC69, BC76, and dipyridamole on panel B) after 48 hours 
of growth in 5FOA medium shows that BC69 is the most effective compound in 
elevating growth of the PDE8A-expressing strain (CHP1204). Dipyridamole does not 
affect the cAMP-dependent yeast growth phenotype. 
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Figure 3.12 Dose response curves of identified compounds 
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Figure 3.13 shows that compound BC24 shifts the curve of PDE8A-expressing strain 
furthest to the left but not as much as to reach to Cgs2-2 growth curve. The effect of 
BC42 seems less than BC24 while the effect of BC51 and BC55 are the least and equal to 
each other. Upon closer examination, BC24 barely shifts the curve of the Cgs2-2 strain 
while the other compounds shift the curve more to the left. This indicates that the effect 
of compounds BC42, BC51 and BC55 on the PDE8A strain might result from their effect 
on a non-PDE target (Figure 3.13B). The cAMP titration curve in the presence of BC69 
shifted the curve of PDE8A, while it did not affect the curve of Cgs2-2 expressing strain 
that lacks functional phosphodiesterase activity (Figure 3.14). 
3.7 IN VITRO EVALUATION OF PDE ACTIVITY 
The hydrolysis of cyclic AMP by human PDE8A was monitored using radiolabeled 
cAMP substrate ([
3
H]cAMP) as the tracer. The enzyme activity of recombinant full 
length human PDE8A1 was measured at 50 nM substrate concentration with or without 
inhibitors. The inhibitory effect of some promising compounds on PDE8A was verified 
by this in vitro assay (Figure 3.15). As described in the previous cAMP titration 
experiments with the compounds BC24, BC42, BC51, and BC55, only compound BC24 
did not affect Cgs2-2 strain’s growth in 5FOA, suggesting its ability to act on the PDE 
enzyme itself. This is further confirmed with the in vitro assays where unlike compounds 
BC21, BC42, BC51 and BC55, only BC24 seemed to inhibit PDE8A weakly. The 
inhibitory effect also seems greater at 10 µM compared to 20 µM; this is also consistent 
with the bell-shaped growth curve that is obtained by BC24.  
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Figure 3.13 cAMP titration curves against Cgs2-2 strain points out non-PDE targets 
for compounds BC42, BC51 and BC55 
(A) cAMP titration curves of Cgs2-2 and PDE8A-expressing strains are generated in the 
presence of a fixed concentration (20 µM) of the compounds and compared to no-
compound conditions. The effect of the compounds was shown by their ability to produce 
a leftward shift on PDE8A-expressing strain. (B) The 5FOA growth curve at low cAMP 
concentrations and the fold difference of Cgs2-2 growth in the presence and absence of 
compounds (OD600 with compound/OD600 no compound) are shown. The unchanged 
growth behavior of the Cgs2-2 strain in the presence of BC24 suggests that BC24 acts 
through PDE inhibition.  
 
 
 
 
 
 
 
 
 
 
108 
 
Figure 3.13 cAMP titration curves against Cgs2-2 strain points out non-PDE targets 
for compounds BC42, BC51 and BC55 
 
 
B                                                       
  
0
0.2
0.4
0.6
0.8
1
1.2
0 50 100 150 200
A
v
er
a
g
e 
O
D
6
0
0
cAMP Concentration (µM)
Cgs2-2
Cgs2-2 + BC24
Cgs2-2 + BC42
Cgs2-2 + BC51
Cgs2-2 + BC55
PDE8A
PDE8A + BC24
PDE8A + BC42
PDE8A + BC51
PDE8A + BC55
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 5 10 15 20
O
D
6
0
0
[cAMP] (µM)
Cgs2-2
Cgs2-2 + BC24
Cgs2-2 + BC42
Cgs2-2 + BC51
Cgs2-2 + BC55
PDE8A
PDE8A + BC24
PDE8A + BC42
PDE8A + BC51
PDE8A + BC55
Fold increase in OD600 of Cgs2-2 strain in 
the presence of compounds  
 No cAMP 5 µM 10 µM 
BC24 1.0 1.1 1.2 
BC42 0.9 1.5 1.7 
BC51 1.0 1.7 1.9 
BC55 1.2 1.7 1.8 
109 
 
Figure 3.14 BC69 causes a leftward shift of the PDE8A cAMP titration curve 
(A) Compound BC69 shifts the cAMP titration curve of the PDE8A-expressing strain to 
the left, while it does not have an effect on the curve of Cgs2-2 (no PDE) strain. (B) The 
structure of compound BC69 is shown. 
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Figure 3.14 BC69 causes a leftward shift of the PDE8A cAMP titration curve 
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Figure 3.15 In vitro assays confirm PDE8 inhibition by BC69 
In vitro enzyme assays with human PDE8A were performed at 10 µM and 20 µM 
compound concentrations in the presence of 50 nM cAMP for 20 minutes. Percent 
inhibition data for cAMP hydrolysis show that BC60, BC62, BC63 and BC69 inhibit 
human PDE8A and BC69 displays the highest inhibition.  
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Figure 3.15 In vitro assays confirm PDE8 inhibition by BC69 
Percent inhibition of cAMP hydrolysis 
Compound 10 µM 20 µM 
BC21 12 11 
BC24 22 14 
BC41 -2 -13 
BC42 7 17 
BC51 5 -5 
BC55 5 3 
BC60 38 53 
BC62 N/A 66 
BC63 42 49 
BC66 N/A 35 
BC69 N/A 72 
BC76 18 31 
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On the other hand, compounds BC60, BC62, BC63 and BC69 inhibit human PDE8A1 in 
the in vitro enzyme assays better than other compounds with an estimated IC50 of 20 µM 
or lower. The greatest inhibition was observed with BC69.  
3.8 OPTIMIZATION OF A PDE8A CATALYTIC DOMAIN STRAIN FOR 
INHIBITOR SCREENING 
The PDE8A catalytic domain was cloned into two different plasmids under nmt1 and 
nmt41 promoters (Tommasino and Maundrell. 1991). Two different backgrounds were 
used for stable integration (intact cAMP signaling pathway, git
+
 or gpa2 deleted). The 
candidate strains were grown in different pre-growth conditions with different cell 
densities to attain optimum 5FOA conditions to be used in small molecule screening.  
When the cells were grown at 1x10
5
 cells/ mL initial concentration with 0.5 mM cAMP 
in the pre-growth medium, DDP44 (pNMT41, git
+
) was found to have very high OD 
values for both positive and negative control conditions, indicating that the expression is 
very low such that the strain becomes 5FOA resistant. On the other hand, DDP40 
(pNMT1, git
+
) and DDP42 (pNMT41, gpa2∆) had very low values for 5FOA and did not 
grow in cAMP, a condition that can be considered as 5FOA super sensitivity (Figure 
3.16A). Increasing cAMP concentration to 2.5 mM cAMP in the pre-growth medium did 
not result in a differential growth between positive and negative control conditions when 
different initial cell densities were tested (Figure 3.16B). Since nmt promoters can be 
transcriptionally repressed by thiamine, I used 2.5 µg/mL thiamine in the pre-growth 
medium along with 1 mM cAMP. From the 5FOA response, the expression level seem to 
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be decreased but differential growth was not achieved (Figure 3.17A). Finally, pre-
growth conditions that previously have been shown to work with the highly active 
PDE4D bearing strain were tested. In this case, instead of using cAMP in the pre-growth 
medium, utilization of a PDE inhibitor or cGMP help to achieve differential growth 
conditions. I tested 0.5 mM cGMP or 50 µM BC69 in the pre-growth medium. As a 
result, cGMP pre-growth was found to produce differential growth for strain DDP42; 
however it did not respond to BC69 positive control (Figure 3.17B). On the other hand, 
BC69 pre-growth resulted in a very distinct differential growth for strain DDP40 between 
negative control and BC69 positive control (Figure 3.18). Although this strain under 
these conditions did not respond to high levels of cAMP, since a compound response was 
observed against BC69, the conditions were further refined by testing different 
concentrations of BC69 in the pre-growth medium. As a result, 20 µM BC69 was found 
to be the optimum condition that gives dramatic differential response between positive 
and negative control conditions for the PDE8A-catalytic domain expressing strain.  
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Figure 3.16 Optimization of a PDE8A-catalytic domain expressing strain for small 
molecule screening 
(A) Average optical density values of strains expressing PDE8A-catalytic domain that 
were grown with 0.5 mM cAMP in the pre-growth medium and plated with 1x10
5
 
cells/mL initial cell density are shown. (B) Effect of initial cell density is shown with 2.5 
mM cAMP in the pre-growth medium. Their growth behaviors in the negative control 
condition (5FOA medium with DMSO) and in positive control conditions (20 µM BC69 
or 5 mM cAMP) were monitored. 
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Figure 3.16 Optimization of a PDE8A-catalytic domain expressing strain for small 
molecule screening 
A 
 DMSO cAMP BC69 
DDP46 (pNMT1, gpa2∆)  0.48 0.38 0.44 
DDP40 (pNMT1, git+) 0.1 0.1 0.1 
DDP42 (pNMT41, gpa2∆) 0.09 0.08 0.08 
DDP44 (pNMT41, git+) 1.17 1.12 1.14 
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Figure 3.17 Effect of thiamine and cGMP in the pre-growth medium 
The strains were grown in different pre-growth media: (A) 1 mM cAMP supplemented 
with 2.5 µg/mL thiamine, (B)  0.5 mM cGMP. Different strains were tested at 0.5 x10
5
 or 
1x10
5
 cells/mL initial cell density. Their growth behaviors in negative control condition 
(5FOA medium with DMSO) and in positive control conditions (20 µM BC69 or 5 mM 
cAMP) were monitored. 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
Figure 3.17 Effect of thiamine and cGMP in the pre-growth medium 
A  Effect of thiamine in pre-growth medium 
         
 
B  Effect of cGMP in pre-growth medium 
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Figure 3.18 Effect of BC69 in the pre-growth medium 
(A) The strains were grown in the presence of 50 µM BC69 in the pre-growth medium 
and tested at 0.5 x10
5
 or 1x10
5
 cells/mL initial cell density. Their growth behaviors in 
negative control condition (5FOA medium with DMSO) and in positive control 
conditions (20 µM BC69 or 5 mM cAMP) were monitored. (B) The growth phenotype of 
DDP40 strain is shown when 20, 40 or 50 µM BC69 were supplemented in the pre-
growth medium. Cells were plated at 0.5 x10
5
 or 1x10
5
 cells/mL initial cell density.  
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Figure 3.18. Effect of BC69 in the pre-growth medium 
A   Effect of BC69 in pre-growth 
 
 
 
B  
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3.9 CONCLUSION 
In this chapter, I demonstrated the utilization of the cAMP-dependent glucose sensing 
pathway of S. pombe for identification of inhibitors of PDE8A that has low activity when 
expressed in the yeast cells. The differential growth between the negative and positive 
control conditions was achieved by deleting the adenylyl cyclase gene. The ability of a 
compound to inhibit PDE8A was judged by the decrease in the amount of exogenous 
cAMP required to stimulate saturation growth in the 5FOA medium. This suggests that 
the adenylyl cyclase deletion strategy can be successfully adapted to other mammalian 
phosphodiesterases that have low activity in the fission yeast system. Among the fifty-six 
compounds that were identified from high-throughput screens against PDE4 and PDE7 
families, I identified BC60, BC62, BC63 and BC69 as PDE8 inhibitors. Compound 
BC69 was shown to have the greatest inhibition potential on PDE8A, and was used for 
optimization of a strain that expresses the catalytic domain of PDE8A for small molecule 
screens. Furthermore, the PDE4/PDE8 dual specificity inhibitor BC69 can serve as a 
positive control for high-throughput screens of PDE8 inhibitors.  
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CHAPTER FOUR 
4 DISCOVERY OF NOVEL PDE8 INHIBITORS THROUGH HIGH-
THROUGHPUT SCREENING 
4.1 OPTIMIZATION OF HIGH-THROUGHPUT SCREENING  
In high-throughput screening, one of the prerequisites is to demonstrate that the negative 
and positive control conditions are drastically different from each other and they are 
consistent and reproducible within each group. One way of measuring this suitability is 
described by Zhang et al. (Zhang et al. 1999) as a concept called Z factor (see Material 
and Methods for the formula). The formula of Z factor takes the sum of the standard 
deviations of the negative and positive control conditions as well as the difference 
between the mean values of those conditions into account. If the Z factor is above 0.5, the 
screening conditions are considered to be suitable for HTS such that the positive hit 
values obtained are unlikely to be due to chance events. As the Z factor becomes higher, 
the quality of the HTS increases. For example, a screen with a Z factor of 0.9 is 
considered to have excellent conditions to allow for the detection of true positive hits. 
Thus, it is imperative to demonstrate that the selected conditions are optimized for HTS 
assays.  
During the development of HTS conditions for the PDE8A-expressing strain CHP1204, 
several compounds (namely BC69, BC62 and BC63) that were obtained as PDE8A/PDE4 
123 
 
dual specific inhibitors in the low-throughput screening were tested in order to determine 
the best positive control compound that will result in the highest Z factor. Additionally, 5 
mM cAMP was also included as a positive control. However in this case, the cAMP 
control is not as relevant as a positive control with an inhibitor compound since under 
screening conditions the ability of the strain to grow up to saturation is limited by the 
amount of exogenously provided cAMP in the assay.  
During the HTS, compounds are transferred from the stock plates to the assay plates by 
the aid of 384-well steel pin arrays by a process referred to as pinning. Before starting 
compound pinning experiments, the initial tests with the indicated compounds were done 
by direct addition of the compounds into the 5FOA medium. The negative control 
conditions were set to 0.2 % DMSO, which is the concentration attained when 100 nL of 
compounds are pinned in each well. It was demonstrated that 10 µM BC69 is able to give 
the highest Z factor with a value of 0.77 as opposed to 0.69 and -5.6 obtained by BC62 
and BC63, respectively. In this assay, the cyclic AMP control yields a Z factor value of 
0.85 (Figure 4.1). 
4.2 Z FACTOR TEST 
Before starting actual screening of the compounds, a master plate with DMSO and 5 and 
10 mM BC69, which gives 10 and 20 µM final compound concentration when 100 nL is 
pinned, was prepared (Figure 2.2A). The lower concentration was included as a reference  
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Figure 4.1 Z factor test identifies conditions with BC69 as excellent for HTS 
Z factor test with DMSO as negative control conditions and 5 mM cAMP or 10 µM of 
BC69, BC62 or BC63 as positive control conditions indicates that BC69 is the best 
compound control. The plate pictures represent real growth data in a color scale that 
ranges from blue to red (blue-green-yellow-orange-red) with increasing OD values. 
Green indicates low OD, orange indicates high OD.   
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Figure 4.1 Z factor test identifies conditions with BC69 as excellent for HTS 
(A) 
 
  
(B) 
 
 
 
(C) 
  
 Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.12 0.012 
0.85 5 mM cAMP 0.816 0.023 
 Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.129 0.012 
0.77 10 µM BC69 0.760 0.035 
5 µM BC69 0.141 0.014 -5.6 
 Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.136 0.013 
0.69 10 µM BC62 0.67 0.042 
10 µM BC63 0.363 0.050 -5.6 
10 µM  
5 mM cAMP DMSO 
DMSO 5 µM 
BC69 
BC63 DMSO    BC62 
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point since some of the compounds in the available libraries are prepared in 5 mg/ml 
concentration. In addition, compounds with higher molecular weight this might result in 
lower initial concentrations.  
Two independent Z factor tests were done under actual pinning conditions in order to 
ensure the reproducibility using both full length and catalytic domain PDE8A-expressing 
yeast strains CHP1204 and DDP40, respectively. The results of the control pinnings are 
summarized in Table 4.1. Both strains demonstrated screenable conditions with either 10 
or 20 µM BC69 as the positive control. 
4.3 SCREENING ASSAY WITH KNOWN BIOACTIVE COMPOUNDS 
The first assay was performed against the known bioactives collection at the ICCB 
Screening facility, which includes BIOMOL ICCB Known Bioactives2- High Conc 
(number of compounds: 480), Prestwick1 Collection (number of compounds: 1,120) and 
NINDS Custom Collection 2 (number of compounds: 1,040). These compound libraries 
have 2,640 compounds from different classes of ion channel blockers, GPCR ligands, 
second messenger modulators, nuclear receptor ligands, actin and tubulin ligands, kinase 
inhibitors, protease inhibitors, gene regulation agents, lipid biosynthesis inhibitors, as 
well as other well-characterized compounds that perturb cell pathways and influence 
brain activity. 1,120 of these compounds are off-patent compounds with known safety 
and bioavailability in humans and 602 of them are FDA approved  
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Table 4.1 Independent control pinnings with BC69 against CHP1204 (full length 
PDE8A) and DDP40 (catalytic domain PDE8A)  
(A)  
 
 
 
 
 
(B) 
 
 
 
 
 
  
Full-length 
PDE8A 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.12 0.01 
0.54 10 µM BC69 0.52 0.05 
20 µM BC69 0.61 0.05 0.64 
    
PDE8A-catalytic 
domain 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.24 0.03  
10 µM BC69 0.75 0.06 0.47 
20 µM BC69 0.75 0.05 0.5 
Full-length 
PDE8A 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.16 0.03 
0.6 10 µM BC69 0.80 0.06 
20 µM BC69 0.83 0.06 0.61 
    
PDE8A-catalytic 
domain 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.19 0.03  
10 µM BC69 0.78 0.07 0.49 
20 µM BC69 0.78 0.04 0.65 
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(http://iccb.med.harvard.edu/screening/compound_libraries/#known; access date 
12/29/2010).  
The screening against known bioactive compounds was performed against full length 
(CHP1204) and catalytic domain PDE8A-expressing strains (DDP40) with the goal of 
prioritizing one strain to be used in the rest of the screening experiments. As shown in 
Table 4.2, Z factor values obtained from the master plate were excellent for full length 
PDE8A-expressing strain (CHP1204), while a very high background growth was 
observed for catalytic domain strain DDP40 that resulted in negative Z factor values for 
this particular experiment. Thus, CHP1204 was used in subsequent experiments for 
screening.  
The overview of the results of this assay can be seen in Figure 4.2, where plate grids 
drawn with respect to optical density values are shown. In the known bioactives 
collection, only two compounds were found to promote growth of the PDE8A-expressing 
strain in 5FOA medium. The most effective compound from these collections is the 
steroid epiandrosterone, which is a natural metabolite of steroid hormone 
dehydroepiandrosterone (Plate/well no: 1569 G22). The average optical density values of 
some of the known phosphodiesterase inhibitors and cyclic nucleotide analogs that are 
present in the bioactives collection are shown in Table 4.3. None of these compounds 
promoted growth of the PDE8A-expressing strain. Obtaining a low number of hits in this 
collection is expected since there have been no previously developed inhibitors against 
PDE8A.  
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Table 4.2 Z factor values of the screen against known bioactives collection 
 
Full-length 
PDE8A 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.094 0.015 
0.8 10 µM BC69 0.607 0.019 
20 µM BC69 0.728 0.02 0.83 
    
PDE8A-catalytic 
domain 
Average 
OD600 
Standard 
Deviation 
Z factor 
value 
DMSO 0.637 0.029  
10 µM BC69 0.817 0.067 -0.637 
20 µM BC69 0.801 0.035 -0.178 
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Figure 4.2 Plate grids with respect to optical density 
Screening against known bioactives collection is illustrated as plate grids based on optical 
density values for CHP1204 (A) and DDP40 (B). Color scale is from red (low OD) to 
blue (high OD). Plate CP-01 is the master plate that has controls DMSO in the left half 
and 5 or 10 mM BC69 in the second half. Plate CP-02 is the 5 mM cAMP control but the 
top half of the plate is empty due to cell delivery problems during the experiment. Gray 
color indicates empty wells. The compound that responds best is indicated with a circle 
(Plate 1569, well G22). A high background for DDP40 interferes with the interpretation 
of the results.  
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Figure 4.2 Plate grids with respect to optical density 
(A)  CHP1204 (Full-length PDE8A) 
 
(B)  DDP40 (Catalytic domain of PDE8A) 
 
  
Low OD High OD 
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Table 4.3 Growth response of CHP1204 in the presence of known PDE inhibitors or 
cyclic nucleotide analogs 
 
Plate/Well no Compound name Average Optical Density 
1791 J04 8-methoxymethyl-IBMX 0.079 
1791 L08 Bromo-cGMP [8-Bromo-cGMP] 0.068 
1792 A19 dibutyrylcyclic AMP 0.0995 
1792 A21 dibutyrylcyclic GMP 0.107 
1568 M06 Dipyridamole 0.0635 
1791 N16 Dipyridamole 0.066 
1920 I10 Dipyridamole 0.076 
1792 E03 EHNA 0.0815 
1792 I15 IBMX 0.0955 
1571 E12 Milrinone 0.0935 
1791 H06 Milrinone 0.0735 
1569 F08 Papaverine hydrochloride 0.0955 
1920 F06 Papaverine hydrochloride 0.0805 
1570 J10 Rolipram 0.0705 
1791 D18 Rolipram 0.0835 
1922 B19 Sildenafil 0.086 
1791 D14 Trequinsin 0.085 
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All of the screening experiments were carried out in duplicate. This leads to the 
identification of hits in a more consistent way. Figure 4.3 shows scatter plots of 
absorbance values from two different replicates. For CHP1204 data, we can dissect the 
major characteristics of the screen by comparing the distribution of control and 
experimental wells in the chart. The clustering of negative control wells (dark blue 
circles) near the origin -located away from the positive control wells (yellow circles)- 
indicates the significant difference between those two conditions, which is also 
demonstrated by a high Z factor. Most data points are aligned diagonally. This shows the 
reproducibility of the assay. 
4.4 DETERMINATION OF HITS 
The screen for identification of PDE8A inhibitors was performed against 222,711 
compounds from commercial libraries and known bioactives collections and 18,980 
compounds from natural product libraries. In total, 241,691 small molecules from 700 
different compound plates were screened at 23 separate pinning appointments. These 
compounds correspond to 40 different small molecule libraries (listed in Material and 
Methods). 
For the interpretation of the screening data, besides the raw OD600 values, the Z scores for 
plate A (Zscore_A) and plate B (Zscore_B) were also calculated using the Standardize 
function of Microsoft Excel. The composite Z score values were calculated by scaling the 
vector [Zscore_A, Zscore_B] by the cosine correlation with a vector corresponding to  
134 
 
Figure 4.3 Screening against known bioactives collection typifies the quality of HTS 
Scatter plot of absorbance values from plate A against plate B is shown. (A) Only control 
wells are demonstrated. Blue indicates negative control DMSO, yellow indicates 10 µM 
or 20 µM compound BC69. (B) Experimental wells are shown in red. The data set has a 
correlation value of 0.996. 
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Figure 4.3 Screening against known bioactives collection typifies the quality of HTS 
(A) 
 
(B) 
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‘perfect reproducibility’ (i.e. equal Z-scores in both replicates). Compounds that produce 
composite Z scores above 8.53 are considered as hits. This cutoff value is determined 
according to previous work (Ivey et al. 2008; Seiler et al. 2007). 
Once the compounds meet the composite Z score criterion, I categorized them according 
to their average absorbance values. We consider the compounds promoting growth with 
OD≥0.6 as strong hits. OD values between 0.2 and 0.4 are considered as weak hits and 
values between 0.4 and 0.6 are considered as moderate hits. For instance, the composite Z 
score value for epiandrosterone is 12.1, suggesting that this is a statistically significant hit 
but it is considered as a weak hit since the average optical density is 0.23. All screened 
compounds with their annotation as strong, moderate and weak positives are given in 
Figure 4.4. 
According to these criteria, among 241,691 compounds 2,447 total hits (1.01%) were 
identified. They were classified as follows: 
• Strong Positives : 63 (0.03%) 
• Moderate Positives : 390 (0.16%) 
• Weak Positives : 1,994 (0.83%) 
4.5 SCREENING AGAINST NATURAL PRODUCTS 
PDE8A-expressing strain was tested against several natural product libraries (for list see 
Material and Methods). These libraries contain partially purified extracts from  
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Figure 4.4 Compounds that give positive response are categorized as strong, 
moderate or weak ‘hits’ 
The data is annotated according to composite Z score and average absorbance values. The 
compounds that have composite Z score values below 8.53 are not considered as hits. The 
compounds that met this criterion are categorized according to their OD values as 
follows: OD ≥ 0.6 strong hit (indicated in red), 0.4≤OD<0.6 moderate hit (indicated in 
dark blue), 0.2≤OD<0.4 weak hit (indicated in light blue). The scatter plot shows all of 
the compounds screened from commercial libraries. 
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Figure 4.4 Compounds that give positive response are categorized as strong, 
moderate or weak ‘hits’. 
 
 
 
 
 
 
 
STRONG 
MODERATE 
WEAK 
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endophytic fungi (fungi that live in higher plants) or from diverse organisms that grow in 
Costa Rica, including lichens, cyanobacteria, and sponges. Crude extracts from the fungi 
were obtained and further fractionated to eliminate nuisance compounds, especially those 
of high molecular weight or high polarity (http://iccb.med.harvard.edu/screening/ 
compound_libraries/ncddg1.htm; access date 2/19/2011). The Starr Foundation collection 
contains dried extracts from traditional Chinese medicinal plants. The dried extracts were 
all resuspended at ~15 mg/mL in DMSO (except for Organic fractions--NCI Plant and 
Fungal Extract library, which was prepared at 5 mg/mL). From these collections, no 
strong hits were detected (Table 4.4, Figure 4.5). Among the 18,980 compounds, 176 are 
annotated as weak hits and 2 are identified as moderate hits, which yielded average 
absorbance values of 0.49 (Plate/well no: 2031-F03; composite Z score: 27.8) and 0.41 
(Plate/well no: 2028-D08; composite Z score: 23.5). The former compound was included 
in the secondary assays and resulted in a similar response (average OD: 0.45; Z score: 
20).  
4.6 SCREENING AGAINST COMMERCIAL LIBRARIES 
I screened a total of 220,071 compounds from the commercial libraries (excluding known 
bioactives) against a full-length PDE8A-expressing strain (CHP1204). From these 
libraries 2,260 compounds were annotated as hits (63 strong hit, 388 moderate hit, 1815 
weak hit; Figure 4.6). According to the result distribution from each library, the majority 
of hits are obtained from Asinex, Chembridge3, ChemDiv4, Enamine2, and Maybridge5 
libraries. They all yielded at least 1% hit ratio (Table 4.5, Figure 4.7).  
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 Table 4.4 Result distribution with respect to known bioactives and natural products 
Known Bioactives 
No. 
compounds 
 S 
hits 
 M 
hits 
 W 
hits 
 
Total 
hits 
Frequency 
of hits (%) 
       
BIOMOL ICCB Known Bioactives 2 480    0 0 
NINDS Custom Collection 2 1,040   1 1 0.1 
Prestwick1 Collection 1,120   1 1 0.1 
       
Natural Products 
No. 
compounds 
 S 
hits 
 M 
hits 
 W 
hits 
 
Total 
hits 
Frequency 
of hits (%) 
       
ICBG Fungal Extracts 12 2,816   48 48 1.7 
ICBG Fungal Extracts 4 704    0 0.0 
ICBG Fungal Extracts 5 2,112   10 10 0.5 
Medicines for Malaria Venture 2,464   17 17 0.7 
Medicines for Malaria Venture 2 2,464   16 16 0.6 
Medicines for Malaria Venture 3 704  1 6 7 1.0 
NCDDG1 380   14 14 3.7 
NCDDG2 2,816   11 11 0.4 
NCDDG3 1,056   5 5 0.5 
NCDDG5 1,056  1 29 30 2.8 
Organic NCI Plant and Fungal 
Extracts 
1,408   1 1 0.1 
Starr Foundation Extracts 2 1,000     20 20 2.0 
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Figure 4.5 No strong hits are identified from natural products collection 
Scatter plots of average absorbance (A) or Z score (B) values of plate A against plate B 
are shown. In-plate controls are demonstrated; negative control DMSO wells are in blue, 
wells containing positive control BC69 are yellow. Experimental wells are shown in 
orange for average absorbance and in purple for Z score values. The data shows all 
natural compounds that were screened against CHP1204 except one set. 
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Figure 4.5 No strong hits are identified from natural products collection 
 
A 
 
 
 
B 
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Figure 4.6 Strong hits are identified from commercial libraries 
Scatter plots of average absorbance (A) or Z score (B) values of plate A against plate B 
are shown. In-plate controls are demonstrated; negative control DMSO wells are in blue, 
wells containing positive control BC69 are yellow. Experimental wells are shown in 
orange for average absorbance and in purple for Z score values. The data represents 
compounds from the entire commercial libraries that were screened against CHP1204. 
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Figure 4.6 Strong hits are identified from commercial libraries 
 
A 
 
 
B 
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Table 4.5 Result distribution with respect to commercial compound libraries 
Commercial 
No. 
compounds 
S 
hits 
M 
hits 
W 
hits 
Total 
hits 
Frequency 
of hits (%) 
       
ActiMolTimTec1 8,517  4 37 41 0.5 
Asinex 1 12,378 1 24 130 155 1.3 
Bionet1 4,800   2 2 0.0 
Bionet (Ryan Scientific) 2 1,700 1 2 6 9 0.5 
CEREP 4,800  1 2 3 0.1 
ChemBridge3 10,560 15 80 652 747 7.1 
ChemDiv1 (Combilab and 
International) 
28,863  3 11 14 0.0 
Chemical Diversity 2 8,561   1 1 0.0 
ChemDiv3 16,544 8 15 111 134 0.8 
ChemDiv4 14,696 6 57 117 180 1.2 
ChemDiv6 44,000 5 17 40 62 0.1 
Enamine 1 6,004 2 1 7 10 0.2 
Enamine 2 26,576 22 150 580 752 2.8 
IFLab2 292  1  1 0.3 
Life Chemicals 1 3,893  8 20 28 0.7 
Maybridge1 7,744   3 3 0.0 
Maybridge2 704  3 3 6 0.9 
Maybridge3 7,639 3 9 54 66 0.9 
Maybridge4 4,576  1 3 4 0.1 
Maybridge5 3,212  12 33 45 1.4 
Mixed Commercial Plate 1 352    0 0.0 
Mixed Commercial Plate 2 320    0 0.0 
Mixed Commercial Plate 3 255    0 0.0 
Mixed Commercial Plate 5 268    0 0.0 
Peakdale1 2,817   3 3 0.1 
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Figure 4.7 Some commercial libraries yielded higher frequency of hits 
The data represent compounds from Asinex, Chembridge3, ChemDiv4, Enamine2, and 
Maybridge5 libraries. Scatter plots of average absorbance (A) or Z score (B) values of 
plate A against plate B are shown. In-plate controls are shown; negative control DMSO 
wells are in blue, wells containing positive control BC69 are in yellow. Experimental 
wells are shown in light blue for average absorbance and in red for Z score values.  
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Figure 4.7 Some commercial libraries yielded higher number of hits 
A 
 
 
B 
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4.7 OVERALL EVALUATION OF THE SCREEN 
The result distribution histograms with respect to average absorbance and composite Z 
score values are plotted in Figure 4.8. Two peaks can be observed for the results 
distribution of average absorbance data, which indicates that the average of the basal 
growth was different in certain experiments. When this distribution is plotted with respect 
to composite Z score, the data is normalized with respect to the basal growth for that 
assay and produces a single peak. One interesting feature of both of these distribution 
curves is the presence of a right-hand tail. The range of the tails reaches up to composite 
Z score of 129 and average absorbance of 0.89. When the distribution chart is drawn to 
show the standard deviations, we see that 2684 wells displayed positive values greater 
than 3 standard deviations away from the mean. The positive hits are selected from this 
group. 
In order to monitor the response plate by plate in the experiments following known 
bioactives screening, in-plate positive and negative controls of 4 wells were also included 
into each plate. This helped to control plate based problems and was useful in 
determining if prolonged experimentation time (i.e. the time from the start to the finish of 
the cell delivery process) adversely affected the plates processed at a later time than 
previous ones so that preventive measures for obtaining reproducibility and consistency 
for each plate could be implemented.  
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Figure 4.8 Result distribution histograms have a right-hand tail 
Result distribution histograms display a right-hand tail where the positive hits are located. 
(A) Result distribution with respect to average absorbance values is shown (left panel). 
Distribution by standard deviation shows that 2633 compounds have OD values greater 
than 3 standard deviations apart from the mean (right panel). (B) Result distribution with 
respect to composite Z score values is shown (left panel). The right-tail is shown in 
enlarged scale in the right panel. 
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Figure 4.8 Result distribution histograms have a right-hand tail 
 
A 
 
 
 
B 
 
 
  
151 
 
For instance, in the early experiments, I was delivering the cells that were resuspended in 
5FOA medium into the wells that contains 2x cAMP and the compounds. After observing 
that the optical density values for the positive control plates are decreasing in the plates 
that received the cells toward the end of the experiment (i.e. experienced a longer wait 
time in the 5FOA medium), I changed the delivery medium to 5FOA with 2x cAMP (this 
time the plate contains the compounds in 5FOA lacking cAMP) in order to give more 
chance for the cells to stay in the ‘5FOA resistant’ state. During the experiments, where 
approximately 40 compound plates were pinned, the indicated problem was still observed 
such that the optical density values in duplicate plates differ from each other, hence 
affecting the reproducibility. In order to circumvent that, I started to resuspend the cells 
separately for the second duplicates so that the time that cells spend in the 5FOA medium 
prior to delivery and incubation is minimized. This helped to prevent seeing sharp OD 
changes between duplicate plates as monitored by the positive control wells.   
Throughout the screen, although each set of experiments resulted in high Z factors for 
each plate, the basal growth and highest optical density that the cells can reach showed 
some variation from experiment to experiment. For instance, high OD values in negative 
control wells were observed in one experiment such that the data points are located 
further from other data points with negative control wells in the scatter plot (Figure 4.6). 
Depending on these variation, a given optical density value might correspond to different 
composite Z scores. Figure 4.9 shows this variation among different experiments.  
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Figure 4.9 Experimental variations are observed between average absorbance 
values and their corresponding composite Z scores 
Scatter plot of average absorbance values against composite Z scores is shown. Positive 
control wells are shown in yellow, negative control wells are in blue, experimental wells 
are in gray. 
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Figure 4.9 Experimental variations are observed between average absorbance 
values and their corresponding composite Z scores 
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For example, an optical density of 0.5 corresponds to a composite Z score value less than 
20 for some assays, while in other assays it can represent composite Z scores up to 60 –
even more than 80 in one instance. The data from individual pinnings form single lines 
some of which overlap with each other. Regardless of this, each group had a good 
separation between the negative and positive controls and was informative in terms of the 
identification of the hit compounds. 
4.8 SECONDARY SCREENING: CHERRYPICKING 
Secondary screening of the selected compounds was done in two sets. The compounds 
were picked by careful examination of the primary screening data. Strong and moderate 
hits were picked but most weak hits with low OD values were omitted. During the first 
round of cherrypicking 280 compounds were selected, while 87 compounds were 
included in the second set. The volume of compounds that was provided for 
cherrypicking assays was slightly greater than 1 µL. Firstly, I wanted to repeat the 
primary screening conditions and screened CHP1204 (full-length PDE8A-expressing 
strain) against the selected compounds at the same concentration as the primary screen, 
which is achieved by transferring 100 nL of compounds into each well by the aid of 
pocket tips. According to the OD values after 48 h of growth, 56 % of the compounds 
retested as promoting growth if we consider compounds that increased the OD above 0.2 
for the first set. For the second set, I set the cutoff as 0.3 since the average OD of the 
negative values were higher and 73 % of the compounds were confirmed. When the Z 
score values that are above 5.0 were considered, 65 % of the compounds were confirmed 
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to promote growth in the 5FOA medium for both sets (Figure 4.10). One of the reasons 
for failure of some of the compounds to promote growth in 5FOA medium as seen in the 
primary screen could be the inefficiency of the compound transfer by the pocket tips 
compared to the pinning process.  
In addition to testing against full-length PDE8A-expressing strain, I wanted to test these 
compounds against the strain that expresses the catalytic domain of PDE8A (DDP40). In 
this way, we are able to obtain additional data to suggest the ability of the test compounds 
to inhibit PDE8A. At the same time, if a response is not seen this could lead to detection 
of compounds that inhibit PDE8A through interactions with the regulatory domain. The 
compounds were tested against DDP40 at the same concentration as the primary screen 
(Figure 4.11). Unfortunately, only 71 of these compounds promoted growth in 5FOA to 
yield Z score values above 8.0.  
As a way of determining the selectivity of these compounds toward PDE8A, the 
cherrypick plates were also screened against strains expressing PDE4A or PDE7 enzymes 
(Figure 4.12). These families were chosen since they are the other two 
phosphodiesterases that specifically hydrolyze cAMP. For the first set of experiments, 
CHP1262 (PDE4A) and CHP1189 (PDE7A) strains were tested by the transfer of 50 nL 
of the compounds into assay wells. This corresponds to the half of the concentration used 
during the primary screen. For the second set, instead of CHP1189, PDE7B-expressing 
strain CHP1209 was used since more overlap in 5FOA growth was being observed for 
PDE7B relative to PDE7A.   
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Figure 4.10 Comparison of primary and secondary screens 
(A) Scatter plot of absorbance values from cherrypick assay against average absorbance 
values from the primary screen is shown. (B) Scatter plot of Z score values from 
cherrypick assay against Z score value of plate A from primary screen is shown. 
Compounds tested in the first set of cherrypick experiments are shown in red, second set 
are shown in blue. 
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Figure 4.10 Comparison of primary and secondary screens 
A 
 
B 
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Figure 4.11 Comparison of response by strains that express full-length or catalytic 
domain PDE8A in the cherrypick assay 
Scatter plot of absorbance values of CHP1204 strain (full-length) against DDP40 
(catalytic domain) are shown. Thirty eight compounds out of 366 yielded absorbance 
values above 0.5 for CHP1204 and above 0.4 for DDP40. 
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Figure 4.11. Comparison of response by strains that express full-length or catalytic 
domain PDE8A in the cherrypick assay 
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Figure 4.12 Cherrypick results 
Cherrypick results from the second set are shown. The plate pictures represent real 
growth data in a color scale that ranges from blue to red (blue-green-yellow-orange-red) 
with increasing OD values. Green indicates low OD, red indicates high OD. For 
CHP1204 (PDE8A) and DDP40 (PDE8A-catalytic domain) 100 nL of compounds are 
transferred, for CHP1262 (PDE4A) and CHP1209 (PDE7A) half of this concentration 
was tested. Two rows from each side of the plate are kept empty, the plates contain 87 
test compounds. 
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Figure 4.12 Cherrypick results 
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Figure 4.13 Comparison of response by the PDE8A-expressing strain against strains 
that express PDE4A or PDE7A/B in the cherrypick assay 
(A) Scatter plot of Z score values from PDE4A–expressing strain (CHP1262) is shown 
against CHP1204. (B) Scatter plot of Z score values from PDE7A (CHP1189) or PDE7B 
(1209) expressing strains is shown against CHP1204. PDE7A is tested in the first set of 
cherrypicking assay (shown in red), while PDE7B is used in the second one (shown in 
blue).  
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Figure 4.13 Comparison of response by the PDE8A-expressing strain against strains 
that express PDE4A or PDE7A/B in the cherrypick assay 
A 
 
B 
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The compound that resulted in the best growth response for CHP1262 strain (PDE4A) is 
BC69 that resulted in Z score value of 155. There are 20 compounds that yielded Z score 
values above 5.0 (Figure 4.13A). On the other hand, CHP1189 (PDE7A) also yielded Z 
score values above 100 for three compounds (Plate/well no: 1665 A07, 1785 B07, 1728 
H22). There are 20 compounds that have absorbance values above 0.100 (this 
corresponds to Z score value of approximately 16). Testing against CHP1209 (PDE7B) 
helped to eliminate 33 compounds out of 87 (Figure 4.13B). 
Upon examination of the cherrypick data along with the primary screen results, 30 
compounds, 28 of which are structurally-distinct, were purchased to be pursued in further 
analyses. 
4.9 CONCLUSION 
I optimized high-throughput screening conditions for adenylyl cyclase deletion strain 
CHP1204 that expresses full-length PDE8A using BC69 as a positive control. The assay 
conditions yield Z factor values between 0.6 and 0.9 in different experiments, which 
indicates a robust high-throughput screen. A total of 241,691 compounds from known 
bioactives, natural products, and commercial libraries were screened; 2447 total hits were 
identified. The positive hits are mostly from commercial libraries. Secondary assays with 
the selected compounds confirmed the effect of approximately 70% of these compounds 
on the 5FOA growth of strain CHP1204. Some of the non-specific compounds were 
eliminated by determining their effect on PDE4A, PDE7A or PDE7B-expressing strains. 
165 
 
Based on our assessment of the potency and selectivity of the cherry-picked candidates, 
thirty compounds were purchased to be further analyzed. 
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CHAPTER FIVE 
5 EVALUATION OF THE COMPOUNDS IDENTIFIED IN HTS 
Thirty compounds (Table 5.1) selected from the cherrypick collection are confirmed by 
their dose response profile on PDE8A-expressing strains. They are further evaluated in 
terms of their dose dependent effect on the growth of yeast strains that express other 
mammalian PDEs. The inhibitory effect of these compounds on PDE8A is verified by in 
vitro enzyme assays.  
5.1   DOSE REPSONSE PROFILING AGAINST PDE8A 
Thirty compounds that were found to promote growth of the PDE8A-expressing strain 
CHP1204 were tested against the same strain under concentrations increasing from 0.1 
µM to 100 µM. The dose response profiles of the compounds are given in Figure 5.1. as 
separate graphs. Compound BC8-8 and BC8-20 increase the growth of PDE8A-
expressing strain to higher OD values at lower concentrations compared to other 
compounds (Figure 5.1.A). Compound BC8-17 and BC8-1H show a bell-shaped dose 
response profile suggesting growth inhibition at high concentrations. Among the tested 
compounds only BC8-3, BC8-7, BC8-25 and BC8-27 fail to promote growth of PDE8A-
expressing strain (Figure 5.1.E-F). Although BC8-3 was able to increase OD value of 
CHP1204 in the primary and secondary screens, BC8-7, BC8-25 and BC8-27 did not 
confirm in the cherrypick assays either. Inability of the purchased form of the compounds 
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to stimulate growth in the ‘in house’ tests might be due to the presence of different forms 
of active molecules in the compound stocks. Although no significant compound 
degradation has been observed by freeze/thaw cycles during HTS practices (Kozikowski 
et al. 2003), some degradation can be seen over time due to the exposure of the 
compounds to DMSO. In this case, the storage conditions might have led to the active 
form or simply the purchased compound might be impure.  
I also tested these compounds against strain DDP40 that expresses the catalytic domain 
of PDE8A. Only twelve compounds (BC8-1, BC8-1F, BC8-1H, BC8-2, BC8-5, BC8-6, 
BC8-8, BC8-9, BC8-14, BC8-15, BC8-16, and BC69) promote the growth of this strain 
(Figure 5.2). When compared to cherrypick data, all of these compounds -except BC8-
23- showed the same inhibition profile. On the other hand, BC8-23 worked in the 
cherrypick assays against strain DDP40, while it did not promote growth during ‘in 
house’ dose response tests.  
5.2   DOSE RESPONSE PROFILING AGAINST OTHER STRAINS 
After verifying their effect against PDE8A-expressing strains, I tested the compounds 
against other strains that express different phosphodiesterases to determine the PDE 
inhibition profile of these compounds and to identify the ones that are selective to 
PDE8A. 
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Table 5.1 Primary and secondary screening data for selected compounds  
Primary Screen Cherrypick assays (Absorbance) 
Hoffman 
Lab ID 
Average 
Absorbance 
Composite Z 
Score 
PDE8A PDE8Acat PDE4A 
PDE7A or 
PDE7B (in 
bold) 
BC69 0.8685 104.8 0.772 0.883 0.592 0.051 
BC8-1 0.679 57.6 0.524 0.7 0.104 0.046 
BC8-2 0.7395 24.0 0.596 0.406 0.11 0.185 
BC8-3 0.693 22.0 0.441 0.21 0.111 0.092 
BC8-4 0.7555 24.7 0.556 0.132 0.098 0.045 
BC8-5 0.7885 54.3 0.713 0.897 0.172 0.141 
BC8-6 0.8295 57.6 0.125 0.085 0.115 0.047 
BC8-7 0.8265 57.4 0.12 0.077 0.097 0.044 
BC8-8 0.595 68.2 0.869 0.81 0.112 0.04 
BC8-9 0.5145 19.2 0.646 0.569 0.102 0.055 
BC8-10 0.629 19.3 0.568 0.402 0.101 0.041 
BC8-11 0.6255 52.1 0.571 0.098 0.117 0.045 
BC8-12 0.62 51.5 0.715 0.244 0.11 0.079 
BC8-13 0.567 16.7 0.622 0.241 0.102 0.074 
BC8-14 0.634 52.9 0.6 0.289 0.1 0.065 
BC8-15 0.423 35.0 0.59 0.729 0.099 0.043 
BC8-16 0.9165 50.3 0.691 0.787 0.099 0.048 
BC8-17 0.4905 39.6 0.621 0.081 0.118 0.106 
BC8-18 0.5385 45.1 0.604 0.155 0.189 0.112 
BC8-19 0.4200 31.6 0.475 0.108 0.131 0.104 
BC8-20 0.5005 54.7 0.661 0.096 0.208 0.18 
BC8-21 0.34 34.7 0.562 0.146 0.131 0.109 
BC8-22 0.7330 16.5 0.609 0.137 0.157 0.141 
BC8-23 0.6610 69.6 0.55 0.597 0.123 0.151 
BC8-24 0.3610 32.4 0.526 0.125 0.121 0.06 
BC8-25 0.4325 41.3 0.117 0.062 0.109 0.098 
BC8-26 0.6470 14.0 0.433 0.13 0.139 0.154 
BC8-27 0.4775 46.9 0.183 0.114 0.133 0.153 
BC8-28 0.4235 40.2 0.128 0.114 0.116 0.088 
BC8-1F 0.7185 84.7 0.721 0.783 0.089 0.043 
BC8-1H 0.559 57.0 0.565 0.753 0.105 0.126 
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 Figure 5.1 Dose response profiling of identified compounds against CHP1204 
The 5FOA growth phenotype of full-length PDE8A-expressing strain CHP1204 was 
tested in the presence of compounds that were identified from HTS. (A-F) The 
compounds are grouped according to their ED50 values, which is the effective dose to 
exert the half-maximal response. Panel F also includes dose response profile of PDE4/8 
dual specificity inhibitor BC69. 
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Figure 5.1 Dose response profiling of identified compounds against CHP1204 
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Figure 5.2 Dose response profiling of identified compounds against DDP40 
The 5FOA growth phenotype of DDP40 strain that expresses the catalytic domain of 
PDE8A is assessed in the presence of compounds that were identified from HTS. (A) 
Compounds that promote growth are shown. (B) Compounds that fail to promote growth 
are shown.  
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Figure 5.2 Dose response profiling of identified compounds against DDP40 
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The Hoffman lab strain collection contains 15 different strains that express different PDE 
enzymes representing each PDE family except PDE6. The 5FOA growth phenotype of 
different strains identified compounds with different inhibition profiles. When PDE4 
inhibitor rolipram is profiled, consistent with its well-established pharmacological 
characteristics, it promoted the 5FOA growth of only PDE4A, PDE4B and PDE4D-
expressing strains (Figure 5.3).  
5.2.1  Compounds That Promote the 5FOA Growth of Most PDE-Expressing 
Strains 
Compounds BC8-2, BC8-6, BC8-12, BC8-13, BC8-14, BC8-18, BC8-19, BC8-20, BC8-
21, and BC8-26 elevated the 5FOA growth of many strains that express different PDEs 
(Figure 5.4). The observation of a similar effect against different strains may suggest that 
these compounds act via a non-PDE target to promote growth in the 5FOA medium. 
However, the presence of some strains that do not respond to any of these compounds 
was also observed. For instance, the PDE inhibition profile of these compounds is similar 
in their failure to promote the growth of PDE4D-expressing strain (CHP1186). A similar 
phenomenon was observed for PDE4B-expressing strain (CHP1268); it did not respond 
to any of these compounds but only had a slight increase in OD in the presence of BC8-
12. PDE4A-expressing strain (CHP1262) did not respond to any of the compounds from 
this group except BC8-19, BC8-20 and BC8-21. Similarly, a strain that expresses PDE3A 
(CHP1249) did not respond to other compounds except BC8-19 and slightly responded to 
BC8-20 and BC8-21. On the other hand, DDP40 that expresses the PDE8A-catalytic 
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domain did not respond to most of the compounds with the exception of BC8-2, BC8-6, 
and BC8-14. Except for a slight elevation in OD in the presence of BC8-21 or BC8-26; 
PDE5A-expressing strain CHP1223 did not respond to these compounds. Finally, strains 
CHP1189 and CHP1209, which express PDE7A and PDE7B respectively, showed some 
elevation in their OD values in the presence of these compounds except for BC8-18, 
BC8-19 and BC8-21. 
5.2.2 Compounds That Promote the 5FOA Growth of Several Strains 
Compounds BC8-3, BC8-4, and BC8-28 promote the growth of several strains that 
express different phosphodiesterases, but not all of them. As stated previously, BC8-3 did 
not work well on the PDE8A-expressing strain (CHP1204); likewise it slightly promoted 
growth for PDE7A strain (CHP1189). However, a profound effect in growth was 
observed for strains expressing PDE7B (CHP1209), PDE11A (CHP1224), PDE10A 
(CHP1455) and PDE9A (CHP1218). On the other hand, BC8-4 mainly promoted the 
growth of PDE8A (CHP1204), PDE10A (CHP1455), PDE2A (CHP1403), PDE3B 
(CHP1194), PDE1B (CHP1222), PDE1C (CHP1220) and PDE9A-expressing (CHP1218) 
strains. Similarly, a slight effect was observed on PDE8A-expressing strain by compound 
BC8-28 but it promoted growth of PDE1B, PDE1C, PDE10, and PDE11-expressing 
strains (Figure 5.5).   
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Figure 5.3 Rolipram promotes the growth of PDE4A, PDE4B and PDE4D-
expressing strains 
Dose response profiling with rolipram against yeast strains that express different PDEs 
promotes only the growth of PDE4A (CHP1262), PDE4B (CHP1268), and PDE4D 
(CHP1186) expressing strains. The strains shown are CHP1222 (PDE1B), CHP1220 
(PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), CHP1194 (PDE3B), CHP1262 
(PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), CHP1223 (PDE5A), CHP1189 
(PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), DDP40 (PDE8Acat), CHP1218 
(PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), and CHP1224 (PDE11A). 
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Figure 5.3 Rolipram promotes the growth of PDE4A, PDE4B and PDE4D-
expressing strains 
 
 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
0 10 20 30 40 50 60 70 80
O
p
ti
ca
l 
D
e
n
si
ty
[Compound] (µM)
PDE1B
PDE1C
PDE2A
PDE3A
PDE3B
PDE4A
PDE4B
PDE4D
PDE5A
PDE7A
PDE7B
PDE8A
PDE8Acat
PDE9A
PDE10A
PDE11A
178 
 
Figure 5.4 Compounds that promote the 5FOA growth of most PDE-expressing 
strains 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-J) Compounds BC8-2, BC8-6, BC8-12, BC8-13, BC8-14, 
BC8-18, BC8-19, BC8-20, BC8-21, BC8-26. 
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Figure 5.4 Compounds that promote the 5FOA growth of most PDE-expressing 
strains 
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Figure 5.5 Compounds that promote the 5FOA growth of several strains 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-C) Compounds BC8-3, BC8-4, BC8-28. 
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5.2.3 BC8-5 Promotes the 5FOA Growth of Strains Expressing cAMP-Specific 
PDEs 
Dose response curves against different PDE-expressing strains identified an interesting 
profile by compound BC8-5, which only promoted the growth of PDE8A (CHP1204), 
PDE8Acat (DDP40), PDE7A (CHP1189), PDE7B (CHP1209), PDE4A (CHP1262) and 
PDE4B-expressing (CHP1268) strains. These are the members of the PDE superfamily 
that specifically hydrolyze cAMP (Figure 5.6). This compound also failed to promote the 
growth of PDE4D-expressing strain (CHP1186). 
5.2.4 Compounds That Promote the 5FOA Growth of Strains That Express 
Enzymes from PDE8 and PDE7 Families 
Two compounds, BC8-9 and BC8-16, mainly promoted the growth of PDE8A, 
PDE8Acat, PDE7A, and PDE7B-expressing strains. In addition, BC8-9 slightly affected 
PDE4A, PDE4B, and PDE10A-expressing strains. BC8-16 also promoted the growth of 
PDE10A-expressing strain and it affected PDE11A-expressing strain at high 
concentrations (Figure 5.7).  
5.2.5 Compounds That Promote the 5FOA Growth of Strains That Express 
Enzymes from PDE8 and PDE4 Families 
Compound BC8-15 increased the growth of strains that express PDE8A, PDE8Acat, 
PDE4A and PDE4B-expressing strains. At the highest test concentration, it seems to 
affect PDE1C, PDE10A and PDE11A-expressing strains slightly.  
188 
 
Figure 5.6 BC8-5 promotes the 5FOA growth of strains expressing cAMP-specific 
PDEs 
Compound BC8-5 promoted the 5FOA growth of strains CHP1262, CHP1268, 
CHP1189, CHP1209, CHP1204, and DDP40; expressing PDE4A, PDE4B, PDE7A, 
PDE7B, PDE8A, PDE8Acat, respectively.  
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Figure 5.6 BC8-5 promotes the 5FOA growth of strains expressing cAMP-specific 
PDEs 
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Figure 5.7 Compounds that promote the 5FOA growth of strains that express 
enzymes from PDE8 and PDE7 families 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A) Compound BC8-9 (B) Compound BC8-16. 
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Figure 5.8 Compounds that promote the 5FOA growth of strains that express 
enzymes from PDE8 and PDE4 families 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A) Compound BC8-15 (B) Compound BC69. 
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A similar profile was observed with the compound BC69 such that it only affects the 
strains that express enzymes from PDE4 and PDE8 families. Unlike BC8-15, BC69 also 
promoted the growth of PDE4D-expressing strain CHP1186 (Figure 5.8). 
5.2.6 Compounds That Promote the Growth of Only Strains That Express the 
Full-Length or Catalytic Domain of PDE8A 
 Two compounds, BC8-1 and BC8-8 mainly promote the growth of strains CHP1204 and 
DDP40 that express full length and catalytic domain of PDE8A, respectively (Figure 
5.9).  
5.2.7 Compounds That Promote the Growth of Only Full-Length PDE8A-
Expressing Strain 
Dose response profiling assays against strains expressing different PDEs identified 
several compounds that promote the 5FOA growth of only full-length PDE8A-expressing 
strain CHP1204. These compounds are BC8-10, BC8-11, BC8-17, BC8-22, BC8-23, and 
BC8-24 (Figure 5.10). It should be noted that none of these compounds elevated the 
growth of DDP40 strain that expresses the catalytic domain of PDE8A. Also, although an 
effect was seen with BC8-24 against CHP1204, it did not promote growth in an earlier 
assay, indicating possible solubility problems. 
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Figure 5.9 Compounds that promote the growth of only strains that express the full 
length or catalytic domain of PDE8A 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A) BC8-1, (B) BC8-8. 
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Figure 5.10 Compounds that promote the growth of only full-length PDE8A-
expressing strain 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-F) Compounds BC8-10, BC8-11, BC8-17, BC8-22, BC8-
23, BC8-24.  
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5.2.8 Compounds That Do Not Stimulate 5FOA Growth in Yeast Strains 
In contrast to the class of compounds that were described above, some compounds did 
not show any effect in the 5FOA growth of yeast strains that express different PDEs. 
Compounds BC8-7, BC8-25 and BC8-27 fail to promote growth of all of the yeast strains 
similar to its failure to reproduce the stimulatory effect on the PDE8A-expressing strain 
described in the previous section (Figure 5.11). 
5.3   IN VITRO ENZYME ASSAYS 
The compounds shown in Table 5.2 were tested against recombinant human full length 
PDE8A enzyme by means of in vitro enzyme assays. The changes in the cyclic AMP 
hydrolytic activity of the PDE8A enzyme were evaluated in the presence of 10 µM of test 
compounds. Compounds BC8-1, BC8-2, BC8-5, BC8-7, BC8-8, BC8-9, BC8-15, BC8-
16, BC8-21, BC8-22, BC8-23, BC8-28, BC8-1F, and BC8-1H were confirmed to have 
inhibitory activity on PDE8A enzyme. This corresponds to approximately a 50 % 
confirmation rate. The results of a set of representative in vitro assays are given as 
percent inhibition by the compounds was calculated in comparison to the no-compound 
control along with the ED50 values of the compounds for the 5FOA growth of the 
PDE8A-expressing strain (Table 5.2). ED50 values are calculated by normalizing the data 
using the OD values of negative control and positive control conditions and estimating 
the concentration that leads to half-maximal optical density through non-linear regression 
analysis. The structures of the compounds that inhibit or fail to inhibit PDE8A in the in 
vitro assays are given in Tables 5.3 and 5.4, respectively. 
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Figure 5.11 Compounds that do not stimulate 5FOA growth in yeast strains 
Compounds BC8-7, BC8-25 and BC8-27 failed to promote growth of yeast strains that 
express different PDEs. The 5FOA growth responses are shown in the presence of 
individual compounds in separate graphs. The strains shown are CHP1222 (PDE1B), 
CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), CHP1194 (PDE3B), 
CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), CHP1223 (PDE5A), 
CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), DDP40 (PDE8Acat), 
CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), and CHP1224 
(PDE11A). (A-C) Compounds BC8-7, BC8-25, BC8-27. 
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Table 5.2 Percent inhibition of PDE8A enzyme in comparison to yeast growth assay 
(Compounds that inhibited the PDE8A enzyme more than 10% are shown in red; BC8-1 
and BC8-8 had higher inhibition levels in other repetitions of the assay) 
Compound 
name 
ED50 value for 
5FOA growth in 
yeast 
Percent inhibition of PDE8A 
at 10 µM compound 
concentration 
BC8-1 50 46 
BC8-2 28 12 
BC8-3 >100 -10 
BC8-4 31 -9 
BC8-5 11 72 
BC8-6 27 -3 
BC8-7 >100 51 
BC8-8 4 46 
BC8-9 24 87 
BC8-10 51 -7 
BC8-11 55 -9 
BC8-12 12 -12 
BC8-13 21 -6 
BC8-14 21 -5 
BC8-15 66 86 
BC8-16 12 60 
BC8-17 6 8 
BC8-18 32 -2 
BC8-19 53 2 
BC8-20 2 3 
BC8-21 35 12 
BC8-22 35 40 
BC8-23 74 54 
BC8-24 83 -5 
BC8-25 >100 -2 
BC8-26 22 -3 
BC8-27 >100 -7 
BC8-28 >100 18 
BC8-1F 16 67 
BC8-1H 12 50 
   BC69 9 37 
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Table 5.3 Structures of compounds that inhibit PDE8A in vitro 
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Table 5.4 Structure of compounds that fail to inhibit PDE8A in vitro 
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When these results are compared to the yeast growth profiles, it can be seen that the 
compounds that made most yeast strains grow do not inhibit PDE8A in vitro. Among this 
group of compounds only BC8-2 and BC8-21 inhibit PDE8A in vitro. This reinforces the 
notion that most compounds in this group are acting through a non-PDE target. PDE-
independent 5FOA resistant growth can be achieved in several ways. Activating a 
component in the pathway that is downstream of cAMP generation such as activation of 
PKA will promote growth in 5FOA. Alternatively, a compound that inhibits orotidine-5'-
phosphate (OMP) decarboxylase or orotate phosphoribosyltransferase would prevent the 
conversion of 5FOA into the toxic product leading to 5FOA resistant growth. Although 
these compounds lead to the growth of many strains that express different PDEs in the 
5FOA medium, not all strains were affected the same way.  
Secondly, among the group of compounds that did not promote growth of any of the 
yeast strains (i.e. BC8-7, BC8-25, and B8-27), only BC8-7 inhibited the PDE8A enzyme 
in vitro. The other group of compounds that fails to inhibit PDE8 in vitro consists of 
compounds that promote the growth of only the full-length PDE8A expressing strain 
CHP1204. It should be noted that the enzyme used in the in vitro assays is human 
recombinant enzyme while the one expressed in the yeast is murine PDE8A. Species-
dependent differences might be one of the causes of this discrepancy since mouse and 
human PDE8A share only 85% sequence identity within the catalytic domain (Soderling 
et al. 1998b).  
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Also, a lack of inhibition in vitro while observing growth only for the full-length PDE8A-
expressing strain might suggest an effect of the compound through the regulatory 
domains of the enzyme. It should also be kept in mind that the in vitro enzyme assay 
measures the remaining substrate concentration after the reaction. Since the counts are 
very large numbers, the assay is not extremely sensitive to detect small effects on the 
enzyme activity.  
The cyclic AMP hydrolysis rate of the human PDE8A enzyme was analyzed as shown in 
Figure 5.12. The data fit to Michaelis-Menten curve yields a Vmax value of 34.6 + 2.9 
picomols/min.µg and a Km of 111.8+20.6 nM (n=5). The enzyme activities were also 
measured in the presence of changing concentrations of PDE8 inhibitors at a given 
condition in order to determine the half maximal inhibitory concentration (IC50). The IC50 
values of several compounds against PDE8A, PDE4A or PDE7A enzymes are given in 
Table 5.5. Compound BC8-15 with the Ki value of 275 nM (determined by nonlinear 
regression of the Michaelis-Menten curve in the absence and presence of the compound) 
is the most potent PDE8 inhibitor in vitro.  
Finally, the compounds were also tested against human PDE8B enzyme using in vitro 
enzyme assays. The compounds that showed inhibition on recombinant PDE8A enzyme 
also inhibited PDE8B (Figure 5.13).  
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Figure 5.12 Michaelis-Menten kinetics of PDE8A 
The cAMP hydrolysis rate of human PDE8A enzyme under changing substrate 
concentrations is shown (n= 5).  
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Figure 5.12 Michaelis-Menten Kinetics of PDE8A 
 
 
Table 5.5 IC50 values of selected PDE inhibitors 
IC50 values of the indicated compounds were tested against PDE8A, PDE4A10 or 
PDE7A enzymes. The substrate concentrations for PDE8A enzyme are either 50 nM (for 
BC8-1, BC8-5 and BC8-1H) or 10 nM (for BC8-8, BC8-15, BC8-22 and BC8-23). IC50 
values for PDE4A are tested either at 2 µM (for BC8-5, BC8-8, BC8-15) or at 50 nM (for 
BC8-1 and BC8-23) substrate concentration. PDE7A was tested at either 35 nM (for 
BC8-5, BC8-8, BC8-15) or at 10 nM (BC8-1, BC8-23). The values are given in µM. 
IC50 PDE8A PDE4A PDE7A 
BC8-1 4.7 51.9 8.4 
BC8-5 2.9 2.0 1.1 
BC8-8 9.4 75.4 72.0 
BC8-15 0.6 0.3 16.2 
BC8-22 13.2 N/A N/A 
BC8-23 4.3 274.6 18.8 
BC8-1H 9.7 N/A N/A 
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Figure 5.13 PDE8A inhibitors also inhibit PDE8B 
The percent inhibition values of compounds BC8-1, BC8-5, BC8-8, BC8-9, BC8-15, 
BC8-16, BC8-22, BC8-23, BC69 and dipyridamole are shown in the graph. Compounds 
were tested at 1 or 10 µM against PDE8A and PDE8B enzymes. The substrate 
concentration is 50 nM for PDE8A and 1 µM for PDE8B. 
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Figure 5.13 PDE8A inhibitors also inhibit PDE8B 
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5.4  ANALYSIS OF STRUCTURALLY RELATED COMPOUNDS 
Compounds structurally related to BC69, BC8-1, BC8-5, BC8-8, BC8-15 and BC8-23 are 
evaluated via yeast growth assays or in vitro enzyme assays in an attempt to understand 
the pharmacophore of each molecule and to determine important parts of the molecule 
that influence the selectivity or potency of the test compounds.  
5.4.1 BC69 Series 
Six compounds that are structurally related to BC69 were tested for their ability to 
promote growth of yeast strains expressing different phosphodiesterases (Table 5.6, 
Figure 5.14). As mentioned earlier, BC69 inhibits PDE8A and promotes the growth of 
yeast strains that express PDE4 and PDE8 enzymes including PDE4D. Compound BC69-
1 has a carbonitrile group the acetonitrile group found in the parent molecule. This 
change abolished the ability of the compound to promote growth of the yeast strains, 
indicating that the acetonitrile group could be important in terms of inhibitory activity. 
On the other hand, changing the acetonitrile group to carbaldehyde oxime in compound 
BC69-2 and BC69-3 changes the yeast inhibition profile such that these compounds 
promote growth of only the PDE4D-expressing strain. These compounds differ only in 
one of the phenyl groups, which was changed to a thiophene in BC69-3. Both of these 
compounds show a slight effect on the PDE4A-expressing strain. When tested with in 
vitro assays, BC69, BC69-2 and BC69-3 have IC50 values between 10-13 µM for PDE4A 
(at 500 nM substrate concentration) and 210-460 nM for PDE4D (at 200 nM substrate 
concentration). 
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Table 5.6 Structures of BC69 derivatives 
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Figure 5.14 5FOA growth response of compounds structurally related to BC69 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-F) Compounds BC69-1, BC69-2, BC69-3, BC69-4, BC69-
5, BC69-6. BC69-6 was tested against only PDE3A, PDE4A-B-D, PDE7A-B, PDE8A-
8Acat expressing strains.  
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Figure 5.14 5FOA growth response of compounds structurally related to BC69 
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 For BC69-4, when the acetonitrile group is changed to propionic acid, all PDE-inhibitory 
activity appears to be lost. On the other hand, when this group is replaced with a bulky 
moiety the compound starts to promote the growth of PDE4A, PDE4D, PDE7A, PDE7B 
and PDE8Acat-expressing strains and show a slight effect on PDE1C, PDE1B, PDE2A, 
PDE9A, PDE10A, PDE11A-expressing strains. This effect of BC69-5, along with those 
of BC69-1 and BC69-4, suggests that the acetonitrile group is important for the inhibitory 
potential of this compound. Finally, as seen with BC69-6, when one of the phenyl groups 
is changed with chlorophenyl, the compound promotes the growth of PDE4D, PDE8A 
and PDE8Acat-expressing strains, which shows that the effect on PDE4A and PDE4B-
expressing strains is abolished.  
5.4.2 BC8-1 Series 
Eight compounds that are structurally related to BC8-1 (Table 5.7) were tested against 
different strains in a dose response 5FOA yeast growth assay (Figure 5.15). Two of these 
compounds are BC8-1F and BC8-1H, which were identified from the primary screen and 
confirmed with in vitro assays. As described previously, BC8-1 promotes the growth of 
only PDE8A and PDE8Acat expressing strains in the 5FOA growth assay. Compound 
BC8-1A differs from BC8-1 only in the location of the methyl group on the phenyl ring. 
This causes the compound to lose its ability to promote growth of PDE8-expressing 
strains. Similarly, BC8-1D, which has a chlorine group in the phenyl ring instead of a 
methyl group at the same position where methyl group is located in BC8-1A, lacks 
activity in the yeast growth.  
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Table 5.7 Structures of BC8-1 derivatives 
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Figure 5.15 5FOA growth response of compounds structurally related to BC8-1 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-H) Compounds BC8-1A – BC8-1H. 
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Figure 5.15 5FOA growth response of compounds structurally related to BC8-1 
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In addition, the modifications that are made on the methylpropylamino group also cause 
the compounds to become ineffective in the yeast growth assays as seen with BC8-1B, 
BC8-1E, and BC8-1G. These inefficacies could be due to loss of the inhibitory activity of 
the compounds on the PDE8 enzyme or due to changes in compounds’ solubility, 
stability or entrance into the cells. One compound that retained its ability to promote the 
growth of the PDE8A strains despite having a change in the methylpropylamino group is 
BC8-1C. Although it has lower efficacy (i.e. lower OD values at a given compound 
concentration compared to BC8-1) in the yeast growth assays, it has a similar selectivity 
profile as BC8-1. On the other hand, compounds BC8-1F and BC8-1H have different 
selectivity profiles than BC8-1 according to the yeast growth assays. In addition to their 
effect on PDE8A-expressing strains, BC8-1F also stimulates the growth of the PDE4D-
expressing strain and BC8-1H promotes the growth of PDE4A, PDE4B and PDE4D-
expressing strains. Structurally, BC8-1F and BC8-1H differ from BC8-1 and BC8-1C -
respectively- by the lack of the methyl group from the phenyl ring. This suggests that the 
removal of the methyl group from the phenyl ring decreases the selectivity. Both BC8-1F 
and BC8-1H inhibit PDE8A enzyme in the in vitro assays.  
5.4.3 BC8-5 Series 
Three compounds that are structurally related to BC8-5 (Table 5.8) were tested for their 
ability to promote the 5FOA growth of yeast strains that express different PDEs (Figure 
5.16). As shown previously, BC8-5 promotes the 5FOA growth of strains that express 
cAMP PDEs PDE8A, PDE8Acat, PDE4A, PDE4B, PDE7A, and PDE7B. When a methyl 
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group is introduced to the phenyl ring as in BC8-5A, the compound promotes the growth 
of only PDE7A and PDE7B-expressing strains. If the methyl group is located at another 
position (i.e. 4 methylphenyl instead of 2 methylphenyl; BC8-5B), the compound can no 
longer promote the growth of PDE7 strains but slightly increases the growth of full-
length PDE8A-expressing strain. On the contrary, introduction of a methoxy group 
instead of a methyl group in the same position blocks the PDE inhibition as judged by 
both the yeast-based and in vitro assays. The yeast growth phenotypes are consistent with 
in vitro assays with the exception of PDE4 data (Figure 5.16, Table 5.9) in that the 
compounds BC8-5A and BC8-5B retain significant activity against PDE4A, yet lose 
activity in the yeast based assay. 
5.4.4 BC8-8 Series 
Two compounds that are structurally related to BC8-8 were tested by in vitro enzyme 
assays against PDE4A and PDE8A enzymes. The terminal methylbenzene group is 
changed to fluorobenzene for BC8-8A and to cholorobenzene for BC8-8B.  Both of these 
compounds can still inhibit PDE8A (BC8-8A has lower efficacy) but they also become 
better PDE4A inhibitors (Table 5.10).  
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Table 5.8 Structures of BC8-5 derivatives 
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Figure 5.16 5FOA growth response of compounds structurally related to BC8-5 
The 5FOA growth responses of yeast strains that express different phosphodiesterases are 
shown in the presence of individual compounds in separate graphs. The strains shown are 
CHP1222 (PDE1B), CHP1220 (PDE1C), CHP1403 (PDE2A), CHP1249 (PDE3A), 
CHP1194 (PDE3B), CHP1262 (PDE4A), CHP1268 (PDE4B), CHP1186 (PDE4D), 
CHP1223 (PDE5A), CHP1189 (PDE7A), CHP1209 (PDE7B), CHP1204 (PDE8A), 
DDP40 (PDE8Acat), CHP1218 (PDE9A), CHP1224 (PDE11A), CHP1445 (PDE10A), 
and CHP1224 (PDE11A). (A-C) Compounds BC8-5A – BC8-5C. 
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Figure 5.16 5FOA growth response of compounds structurally related to BC8-5 
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Table 5.9 In vitro enzyme assays with BC8-5 derivatives 
IC50 values (given in µM) are determined at following substrate concentrations: 10 nM 
for PDE8A, 35 nM for PDE7A, 1 µM for PDE4A.  
PDE8A PDE4A PDE7A 
BC8-5 1.9 2.5 1.6 
BC8-5A 5.5 0.7 0.2 
BC8-5B 3.8 4.9 15.9 
BC8-5C 100.2 25.7 3213.7 
 
 
 
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
0 20 40 60 80
O
p
ti
ca
l 
D
e
n
si
ty
[Compound] (µM)
BC8-5C PDE1B
PDE1C
PDE2A
PDE3A
PDE3B
PDE4A
PDE4B
PDE4D
PDE5A
PDE7A
PDE7B
PDE8A
PDE8Acat
PDE9A
PDE10A
PDE11A
232 
 
Table 5.10 Structures of BC8-8 derivatives and their effect on PDE4A/PDE8A 
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Percent inhibition at 10 µM Percent inhibition at 1 µM 
PDE8A PDE4A PDE8A PDE4A 
BC8-8 61 12 17 0 
BC8-8A 27 46 3 10 
BC8-8B 57 72 8 17 
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5.4.5 BC8-15 Series   
Sixteen compounds that are structurally related to BC8-15 were tested by in vitro enzyme 
assays against PDE4A -catalytic domain of PDE4A10-  and PDE8A –full-length 
PDE8A1 (Table.5.11, 5.12). BC8-15 inhibits PDE4A and PDE8A with an IC50 of 260 
and 610 nM, respectively. As it can be seen with compounds BC8-15A and BC8-15B, the 
presence of a methyl group instead of an ethyl group on the triazole ring or changing the 
position of carboxyl group on the phenyl ring slightly decreases the inhibitory activity. 
Furthermore, the presence of the carboxyl group on the phenyl ring (i.e. a benzoic acid) 
seems very important in terms of the ability of the compound to inhibit PDE8A. When 
the carboxyl group is removed (i.e. benzoic acid is changed to a phenyl ring) as in BC8-
15D or changed to a hydroxyl group as in BC8-15E or the benzoic acid group is change 
to a ethylbenzoate as in BC8-15F; the inhibition on PDE8A diminishes almost by half 
compared to BC8-15 while all of these compounds are still able to inhibit PDE4A 
effectively. Changing the original benzoic acid group to dimethoxyphenyl also 
diminishes inhibition on PDE8A and slightly decreases the effect on PDE4A. Also, 
changing the benzoic acid group to chlorobenzene almost totally abolishes the inhibition 
on PDE8A but the compound can still inhibit PDE4A. The addition of a six-membered 
aromatic ring to the phenyl ring instead of a carboxyl group as shown for BC8-15L 
decreases the inhibition potential of the compound for both PDE4 and PDE8. On the 
other hand, addition of a five-membered aromatic ring instead of the carboxyl group 
(BC8-15J) abolishes inhibition on PDE8 while the compound can still inhibit PDE4A. 
Additional modifications on the benzoic acid group as seen in compound BC8-15I, BC8-
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15K, BC8-15M, BC8-15N, BC8-15O, and BC8-15P make the compounds lose the 
inhibitory potential for both enzymes. 
5.4.6 BC8-23 Series 
Five compounds that are structurally related to BC8-23 were tested by in vitro enzyme 
assays against PDE8A and PDE4A (Table 5.13, 5.14). BC8-23 inhibits PDE8A but not 
PDE4A. Compound BC8-23A has a methyl group in the terminal phenyl group instead of 
an ethyl group and BC8-23B has lacks one carbon in the backbone compared to BC8-23. 
Both of these compounds still do not inhibit PDE4A and can inhibit PDE8A with slightly 
lower efficacy than BC8-23. On the other hand, the modifications in the terminal benzene 
(changing to chlorobenzene as in BC8-23D or dimethoxybenzene as in BC8-23E) 
decrease the efficacy toward PDE8A approximately by half. Finally having oxygen 
bound to the sulfur atom totally abolishes the inhibition.  
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Table 5.11 Structures of BC8-15 derivatives  
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Table 5.12 The effect of BC8-15 derivatives on PDE4A and PDE8A 
Enzyme assays are performed at 1µM cAMP for PDE4A and 10 nM cAMP for PDE8A. 
Percent inhibition at 10 µM Percent inhibition at 1 µM 
PDE8A PDE4A PDE8A PDE4A 
BC8-15 84 92 70 92 
BC8-15A 85 77 49 35 
BC8-15B 79 86 41 45 
BC8-15C 40 93 4 78 
BC8-15D 44 100 7 93 
BC8-15E 60 94 12 80 
BC8-15F 44 94 7 62 
BC8-15G 45 79 9 31 
BC8-15H 13 94 5 83 
 
Percent inhibition at 10 µM 
PDE8A PDE4A 
BC8-15 95 100 
BC8-15I 20 14 
BC8-15J 10 78 
BC8-15K 13 38 
BC8-15L 65 67 
BC8-15M 29 18 
BC8-15N 28 5 
BC8-15O 38 22 
BC8-15P 34 34 
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Table 5.13 Structures of BC8-23 derivatives 
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Table 5.14 The effect of BC8-23 derivatives on PDE4A and PDE4B 
 
Percent inhibition at 10 µM 
PDE8A PDE4A 
BC8-23 69 7 
BC8-23A 47 7 
BC8-23B 52 8 
BC8-23C 4 0 
BC8-23D 35 5 
BC8-23E 32 15 
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5.5  EFFECT OF PDE8 INHIBITORS ON MAMMALIAN SYSTEMS 
One of the demonstrated functions of PDE8A is its regulatory role in steroidogenesis in 
the Leydig cells, which are the interstitial cells located adjacent to the seminiferous 
tubules in the testes. Lutenizing hormone (LH) stimulates testosterone synthesis in the 
Leydig cells through binding the receptor on the cell membrane and inducing cAMP 
synthesis (Haider. 2007). Activation of PKA is needed for the transport of cholesterol 
from the cytoplasmic pool to mitochondria. This is the rate limiting step of 
steroidogenesis and it is initiated by steroidogenic acute regulatory protein (StAR) (Hauet 
et al. 2002). It has been previously shown by the Beavo lab that the Leydig cells from 
PDE8A knock-out mice are more sensitive to LH for testosterone production. The 
sensitivity to LH seen by the ablation of PDE8A function is much more pronounced than 
the slight effect that was observed by PDE inhibitor IBMX (which does not inhibit 
PDE8). Furthermore, additional sensitivity to LH response is potentiated when Leydig 
cells from PDE8A knock-out mice are treated with IBMX, suggesting the role of another 
phosphodiesterase in this process (Vasta et al. 2006).  
I tested the effect of our candidate PDE8 inhibitors in the steroidogenesis response from 
Leydig cells. Leydig tumor cell line MA-10 was used to monitor the changes in the 
progesterone production upon compound treatment. These cells express very low or 
undetectable amounts of P450c17, which is the enzyme with 17 alpha-hydroxylase and 
17,20 lyase activities in the synthesis of steroid hormones. Thus, progesterone is 
considered as the major steroid output in this cell line. Upon treatment for 4 hours, 
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compounds BC8-1, BC8-5, BC8-8 and BC8-15 elevated in the progesterone production. 
BC8-15 had a more pronounced effect than other compounds. Also, the compounds were 
more effective at 40 µM. During the same assay, some wells were treated with LH for 
two hours following two hours of compound treatment. Increased progesterone release 
was also observed for compounds BC8-5, BC8-8 and BC8-15 after LH stimulation 
(Figure 5.17). The highest amount of steroid production was attained by compound BC8-
15 and followed by BC8-5. The effect that was seen with compound BC8-15 was dose 
dependent and reproducible. Figure 5.18 shows the dose dependent increase in 
progesterone release as BC8-15 concentration increases. It should be noted that BC8-15 
is a PDE4/PDE7 dual specificity inhibitor and BC8-5 inhibits PDE4/7/8. This is 
consistent with the observations where IBMX (i.e. inhibition of other PDEs) in a PDE8 
null background has synergistic effect in steroid production. Also, according to in vitro 
enzyme assays BC8-15 has the lowest IC50 value against PDE8A among the compounds 
that are identified from HTS. This may be relevant to the increased potency of this 
compound compared to other test compounds in the mammalian assays.  
We also tested the effect of these compounds on primary Leydig cells that were isolated 
from testes of wild type and PDE8A/8B knock-out adult mice. Following isolation and 
incubation to allow cell attachment, cells were treated with compounds at two 
concentrations (10 and 40 µM) for three hours.  
  
242 
 
Figure 5.17 Effect of PDE8 inhibitors on progesterone levels from MA-10 cells 
The effect of compounds BC8-1, BC8-5, BC8-8, BC8-15, BC8-22 and BC8-23 alone and 
in the presence of IBMX are shown. (A) Progesterone release from MA-10 cells after 4 
hours of compound treatment (B) Progesterone release after 2 hours of LH stimulation. 
Cells were treated with the compounds 2 hours prior to hormone stimulation. 
 
 
 
 
 
 
 
 
 
 
 
  
243 
 
Figure 5.17 Effect of PDE8 inhibitors on progesterone levels from MA-10 cells 
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Figure 5.18 BC8-15 elevates progesterone levels in a dose dependent way  
The increase in the progesterone release in response to different concentrations of BC8-
15 treatment is shown.  
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Figure 5.18 BC8-15 elevates progesterone levels in a dose dependent way  
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As expected, compared to the wild type Leydig cells, cells from the knock-out animal 
showed a higher basal level of testosterone production. Cell preparations had similar 3β-
hydroxysteroid dehydrogenase activities, which is a marker enzyme of Leydig cells. Its 
activity is monitored by reduction of nitroblue tetrazolium (cell suspensions displayed 
OD570 values of 0.17 and 0.18) to ensure the number of isolated Leydig cells are 
comparable. Consistent with the notion that the cAMP pool in the Leydig cells is 
governed by mainly PDE8 but secondarily by other PDE(s), IBMX or rolipram did not 
cause any change in testosterone production in the wild type background while they 
elevate testosterone levels for cells from the PDE8 knock-out animal. No change was 
detected with compounds BC8-1 or BC8-8. A slight increase with BC8-5 is observed. 
The response stimulated by BC8-15 is consistent with its PDE inhibition profile. It 
elevates the testosterone production of the wild type cells at 10 µM and the effect at 40 
µM is much greater. On the other hand, PDE8 knock-out cells did not display great levels 
of elevation in testosterone levels. The amount of testosterone released in the presence of 
BC8-15 is similar to the amount released when cells are treated with the PDE4 inhibitor 
rolipram. The lack of a further increase in testosterone levels suggests that the effect 
observed by BC8-15 in wild type cells is due to inhibition of PDE4 and PDE8 enzymes 
and the compound seems to not have an immediate target to affect testosterone levels at 
short incubation periods (Figure 5.19).  
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Figure 5.19 Effect of BC8-15 on primary Leydig cells is consistent with its PDE 
inhibition profile 
The effect of compounds on the testosterone release from primary Leydig cells from wild 
type and PDE8A /PDE8B knock-out mice is shown.  
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Figure 5.19 Effect of BC8-15 on primary Leydig cells is consistent with its PDE 
inhibition profile 
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Figure 5.20 Correlation between progesterone response and PDE8 inhibitory 
activity in BC8-15 derivatives  
The effect of BC8-15 derivatives on progesterone release is shown. BC8-15H and BC8-
15J do not have PDE8 inhibitory activity and they behave as a PDE4 inhibitor.  
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Figure 5.20 Correlation between progesterone response and PDE8 inhibitory 
activity in BC8-15 derivatives  
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Finally, the effect of BC8-15 on the progesterone release from MA-10 cells was retested 
using structural derivatives of BC8-15. As described in the previous section, BC8-15A, 
and BC8-15B are PDE4/8 inhibitors with slightly lower efficacy than BC8-according to 
the in vitro enzyme assays. BC8-15L also has a similar profile but much lower efficacy. 
Compared to BC8-15, BC8-15C and BC8-15D has lower efficacy toward PDE8A but 
retain their ability to inhibit PDE4A. Finally, BC8-15J and BC8-15H almost completely 
lose their inhibition on PDE8A while they can inhibit PDE4A. When the progesterone 
release was measured in response to these compounds, a correlation was seen with regard 
to PDE8A, but not PDE4A inhibition as measured by in vitro enzyme assays (Figure 
5.20).  
5.6  CONCLUSION 
Thirty compounds identified from HTS were characterized by their ability to affect the 
5FOA growth of yeast strains that express different phosphodiesterases and by their 
behavior in in vitro enzyme assays.  Dose response profiling of compounds against 16 
different strains expressing various PDEs identified compounds of different patterns of 
inhibition. Most of the compounds that do not promote growth of all of the yeast strains 
confirmed to inhibit human PDE8A in vitro. Similarly, these compounds also inhibit 
human PDE8B enzyme. In conclusion, eleven structurally distinct PDE8 inhibitors were 
identified. The most potent compound identified by the in vitro enzyme assays is the 
PDE4/8 dual specificity inhibitor BC8-15. Progesterone release assays from MA-10 cells 
indicate that BC8-15 elevates steroid production in these cells as a function of its PDE8 
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inhibition. Furthermore, BC8-15 causes elevated testosterone production from wild type 
primary Leydig cells but -consistently with its PDE inhibition profile- its effect does not 
exceed the effect of PDE4 inhibitor rolipram in PDE8A/B knock out mouse. Thus, I have 
successfully identified PDE8 inhibitors that are biologically active even prior to efforts to 
enhance pharmacokinetic properties via medicinal chemistry.  
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CHAPTER SIX 
6 SUMMARY AND FUTURE DIRECTIONS 
From unicellular organisms to humans, cyclic AMP dependent signal transduction 
pathways mediate a diverse range of cellular responses. One of the important components 
of the cyclic nucleotide signaling pathways is phosphodiesterases. Through hydrolysis of 
cyclic AMP/GMP, they serve as the major enzymes to control the amplitude and duration 
of the signal. Twenty one genes in the PDE superfamily along with various splice 
variants have distinct roles controlling specific physiological conditions and disease 
states. Recently, the PDE8 family has been found to be important in steroid production 
from the adrenal gland and testis. The unavailability of PDE8 inhibitors has limited the 
functional studies of PDE8 enzymes that may also be important therapeutic targets. The 
aim of this thesis is to develop a screenable platform for inhibitors of PDE8 and to find 
and characterize novel PDE8 inhibitors.  
6.1   DEVELOPMENT OF A SCREENING PLATFORM FOR PDE8 
INHIBITORS 
The mouse PDE8A gene was successfully cloned into the yeast chromosome. Initial 
attempts to optimize the full-length PDE8A expressing strain were not successful due to 
the absence of a clean 5FOA sensitivity phenotype when tested in a 384-well microtiter 
dish format leading to high background values. I successfully employed an adenylyl 
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cyclase deletion strategy to create a strain that expresses full-length PDE8A (CHP1204).  
Adenylyl cyclase deleted strains require exogenous addition of cAMP to repress fbp1 
transcription and their PDE activity is judged by the increased levels of exogenous cAMP 
needed to confer 5FOA resistant growth. I optimized the pre-growth conditions and 
cAMP concentration in the 5FOA medium that produces a distinct growth response when 
comparing a PDE-lacking strain to a PDE8A-expressing strain.  This allowed me to test 
the effects of candidate PDE inhibitors on the 5FOA growth of the PDE8A strain.  
6.2  LOW-THROUGHPUT SCREENING 
I tested fifty-six compounds identified from high-throughput screens against PDE4 and 
PDE7 families for their ability to promote growth of the PDE8A-expressing strain 
CHP1204. Several compounds promoted growth of CHP1204 in 5FOA. When I tested 
these compounds against a strain that lacks PDE activity, some of them (BC21, BC42, 
BC51, BC55) shifted the cAMP titration curve to the left, suggesting that these 
compounds promote growth via a PDE-independent route. In contrast, several 
compounds such as BC24, BC60, BC63, BC69 and BC76 not only shifted the cAMP 
titration curve of only the PDE8A-expressing strain (in comparison to the strain that lacks 
PDE activity) but also inhibited PDE8A in in vitro enzyme assays. I demonstrated that 
the PDE4 inhibitor compound BC69 was the most effective compound in promoting the 
growth of PDE8A-expressing strain, and identified it as an effective PDE8 inhibitor both 
in yeast growth and in vitro enzyme assays.   
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These findings successfully demonstrate that it is possible to use the glucose sensing 
pathway of the fission yeast to study mammalian phosphodiesteases for strains in which 
the PDE activity is insufficient to confer 5FOA sensitivity even in strains carrying 
mutations to reduce adenylyl cyclase activation. In addition, since strains lacking the 
adenylyl cyclase gene respond to either exogenous cAMP or cGMP to activate PKA, the 
use of adenylyl cyclase deletion strains extended our ability for utilization of this fission 
yeast based screening platform to detect the inhibitors of phosphodiesterases that 
hydrolyze cGMP or are dual specific. As a proof of this concept, I identified BC76 as an 
inhibitor of the cGMP specific phosphodiesterase PDE5A with an IC50 of 232 nM 
(Demirbas et al. 2010). 
Finally, I also cloned the catalytic domain of PDE8A under nmt promoters (nmt1 and 
nmt41) and identified the strain with the most suitable genetic background that confers 
5FOA sensitivity. Since the catalytic domain of PDE8A shows high phosphodiesterase 
activity when expressed under nmt1 promoter, the strain with an intact git pathway 
(DDP40) showed 5FOA sensitivity and was optimized to respond to compound BC69.  
6.3  HIGH-THROUGHPUT SCREENING AGAINST PDE8A 
I optimized the full-length PDE8A expressing strain CHP1204 for high-throughput 
screening using compound BC69 as the positive control. Z factor tests for optimized 
screening conditions yield values between 0.6-0.9 in different experiments. This indicates 
the robustness of the screening conditions. I screened 241,691 compounds from known 
bioactives, natural products, and commercial libraries; and identified 2447 total hits. The 
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positive hits are mostly from commercial libraries and no strong hits were obtained form 
the natural product libraries. Secondary cherrypick assays with 367 selected compounds 
confirmed the effect of approximately 70% of these compounds on the 5FOA growth of 
strain CHP1204. We believe that some of these compounds fail to promote the growth in 
5FOA medium due to inefficient compound transfer from stock plate to assay plates by 
the pocket tips. Although the provided amount of cherrypick compounds is only 1 µL, the 
remaining compounds from the unconfirmed wells can be diluted and retested using 
micropipets to transfer compounds into wells. This could increase the confirmation ratio 
of the compounds in the secondary assays. 
One aspect of the cherrypick assays was to test the compounds against strains that 
express other phosphodiesterases to identify non-selective compounds. I used PDE4A 
and PDE7A or PDE7B-expressing strains CHP1262, CHP1189, CHP1209, respectively. 
These enzymes are also cAMP specific phosphodiesterases, so some compounds that 
inhibit PDE8A may also be able to inhibit PDE4 or PDE7 enzymes. Although PDE4A 
and PDE7-expressing strains helped eliminate some of the compounds as non-selective 
inhibitors, several compounds that were not very effective at promoting the growth of 
these strains in the cherrypick assays stimulated growth in the follow-up assays.  
6.4  CHARACTERIZATION OF IDENTIFIED COMPOUNDS 
Thirty compounds were selected by their effect on primary screening and on cherrypick 
assays, including the compounds that seem to have hightest potency and/or selectivity. 
After confirming their ability to promote growth of PDE8A-expressing strain CHP1204, I 
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tested these compounds against other strains that express various PDEs. Ten compounds 
out of thirty (BC8-2, BC8-6, BC8-12, BC8-13, BC8-14, BC8-18, BC8-19, BC8-20, BC8-
21, and BC8-26) promoted the growth of most of the yeast strains that express different 
PDEs. Furthermore, eight of them (all except BC8-2 and BC8-21) failed to inhibit 
PDE8A in in vitro enzyme assays. This suggests that these compounds act through a non-
PDE target to promote growth of yeast strains. These targets could act downstream of 
cAMP generation by activating PKA or inhibiting enzymes that convert 5FOA into the 
toxic product. Since this group constitutes the major source of false positive results, it 
should be addressed in the future HTS practices. As seen from the dose response profiles, 
PDE4 and PDE7 strains do not always grow in 5FOA in the presence of these compounds 
that act through non-PDE targets. These strains have a very clean 5FOA sensitivity 
phenotype without being adenylyl cyclase deficient. Due to the differences in the genetic 
background, they may not be as sensitive to non-selective compounds that promote 
growth of many yeast strains as the adenylyl cyclase deletion strains. This suggests that 
utilization of an adenylyl cyclase deletion strain during the cherrypick assays could have 
been helpful in eliminating these false positives.  
At the time of this project, no prior data related to 5FOA growth of yeast strains was 
available. Although the data from the high throughput screens against PDE4 and PDE7 
enzymes performed at the Broad Institute had some overlapping compound libraries, they 
constituted the small fraction of the screened compounds. Recently, Hoffman Lab 
member Ozge Ceyhan completed an HTS using a PDE11 strain. The comparison of hits 
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from that screen shows that ten of the identified compounds (BC8-3, BC8-6, BC8-12, 
BC8-13, BC8-14, BC8-16, BC8-20, BC8-22, BC8-25, and BC8-27) were also annotated 
as hits in the PDE11 screen (Ozge Ceyhan, unpublished data). Eight of these compounds 
did not confirm PDE8 inhibition in the in vitro assays, while BC8-16 and BC8-22 inhibits 
PDE8.   
6.5 RE-EVALUATION OF THE SCREENING DATA 
I examined the compounds that were selected for cherrypicking from PDE8A screen with 
respect to their response in the PDE11 screen (Ozge Ceyhan, unpublished data). 362 of 
the cherrypicked compounds were screened against PDE11. 263 of these compounds 
were not annotated as hits for PDE11. Seventy of these compounds had composite Z 
scores above 35 for PDE8A screen, twelve of which are already in the ‘in house’ 
collection (BC69, BC8-1, BC8-11, BC8-15, BC8-17, BC8-18, BC8-1F, BC8-1H, BC8-
23, BC8-28, BC8-5, BC8-7) that were characterized during this thesis project. Among the 
remaining 58 compounds, 35 were confirmed in cherrypick assays for promoting growth 
of PDE8A. I eliminated eleven compounds from this group due to their high Z score 
values against PDE7-expressing strains. The primary and secondary assay responses of 
the remaining 24 compounds are given in Table 6.1 and the structural description of these 
compounds as SMILES (simplified molecular input line entry specification) are given in 
Table 6.2. Five of these compounds (1589 K14, 1598 O16, 1490 B16, 1722 D08, and 
1598 I16) are structurally similar to BC8-1. Similarly, two compounds (1626 O16 and  
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Table 6.1 PDE8 hits 
a 
Compounds structurally related to BC8-1, 
b 
compounds structurally related to BC8-23. 
Primary Screen Cherrypick assays (Absorbance) 
Plate/well ID 
Average 
Absorbance 
Composite 
Z Score 
PDE8A PDE8Acat PDE4A 
PDE7A or 
PDE7B  
1722  D08
a
 0.75 50.8 0.488 0.16 0.10 0.05 
1772  M19 0.74 39.4 0.501 0.63 0.10 0.06 
1643  K05 0.71 66.2 0.309 0.14 0.11 0.04 
1626  O10
 b
 0.70 64.6 0.693 0.74 0.10 0.04 
1778  I10 0.68 35.3 0.573 0.76 0.11 0.04 
1598  I16
 a
 0.64 53.4 0.583 0.20 0.10 0.05 
1581  G07 0.61 50.1 0.417 0.15 0.12 0.03 
1577  E20 0.60 38.3 0.446 0.11 0.09 0.03 
1696  L14 0.59 38.6 0.317 0.11 0.09 0.04 
1640  B10 0.58 51.5 0.362 0.32 0.10 0.05 
1589  K14
 a
 0.57 46.3 0.49 0.68 0.10 0.05 
1504  N14 0.55 56.3 0.494 0.17 0.13 0.22 
1591  I14 0.52 41.5 0.386 0.13 0.11 0.05 
1598  O16
 a
 0.52 41.0 0.569 0.13 0.10 0.07 
1490  B16
 a
 0.51 50.3 0.573 0.74 0.12 0.22 
1507  B17 0.50 49.2 0.437 0.12 0.14 0.25 
1504  M14 0.48 47.1 0.466 0.11 0.11 0.18 
1598  O11 0.47 36.5 0.309 0.47 0.09 0.05 
1582  F07 0.47 36.3 0.34 0.08 0.10 0.04 
1630  B11 0.43 36.0 0.368 0.13 0.11 0.05 
1642  G02 0.43 35.3 0.329 0.13 0.10 0.05 
527  J07 0.39 66.6 0.523 0.08 0.14 0.12 
1837  E05 0.36 37.8 0.48 0.12 0.14 0.16 
1915  D02
 b
 0.33 53.0 0.576 0.84 0.13 0.27 
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Table 6.2 SMILES table 
Plate Well Compound SMILES 
1722 D08 N#Cc1nc(oc1NCC1CCCO1)c1ccccc1 
1772 M19 N#CCOC(=O)c1c(C)nn(Cc2ccccc2)c1Cl 
1643 K05 CCOC(=O)c1noc2ncnc(N3CCc4cc(OC)c(OC)cc4C3C)c12 
1626 O10 CCc1ccc(cc1)c1oc(C)c(CSCC(=O)NCc2ccco2)n1 
1778 I10 N#CCn1c(CSc2ccc3OCCOc3c2)nc2ccccc2c1=O 
1598 I16 N#Cc1nc(Cc2ccccc2)oc1NCCc1ccccc1 
1581 G07 NC(=O)N/N=C(/C=C\c1ccccc1)\C(C)(C)O 
1577 E20 CC(=O)OC(C)(C)C(=O)/C=C\c1ccccc1 
1696 L14 CCn1c(=O)c2ccccc2n(Cc2cccc(Cl)c2)c1=O 
1640 B10 CCOC(=O)c1c(C)oc2ncnc(N(C)Cc3ccccc3)c12 
1589 K14 C=CCNc1oc(nc1C#N)c1cccs1 
1504 N14 c1ccc2nc(NC3CC3)c3nnnn3c2c1 
1591 I14 Cc1ccc(o1)c1nn(cc1CN(Cc1ccccc1)C(=O)c1ccco1)c1ccccc1 
1598 O16 CCOc1ccc(cc1)Nc1oc(Cc2ccccc2)nc1C#N 
1490 B16 CCOc1ccc(cc1)c1oc(NCC(C)C)c(C#N)n1 
1507 B17 CCCN(c1ccc(Cl)c(Cl)c1)C(=O)c1ccc2c(c1)nc1CCCCn1c2=O 
1504 M14 CCc1n[nH]c(=O)c2cc3oc(C)cc3n12 
1598 O11 CCC(C)Oc1c(Cl)cc(C#N)cc1OC 
1582 F07 O/N=C\C(=N\O)/C12CC3CC(CC(C3)C2)C1 
1630 B11 Cc1ccc(C)c(c1)N1CCN(CC1)C(=O)c1ccc2nc(sc2c1)N1CCOCC1 
1642 G02 O=C(N1CCCC1)c1ccc(s1)N1CCCc2ccccc12 
527 J07 C(CCN(S(c1ccc(CCC)cc1)(=O)=O)[H])CCC 
1837 E05 S(=O)(=O)(c1ccc(cc1)C)c2cnc(c3c2Nc(cc4)ccc4OCC)ccc(OC)c3 
1915 D02 n1c(CSCC(NCCc2ccccc2)=O)c(oc1c3ccc(cc3)OCC)C 
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1915 D02) are structurally related to BC8-23. In future studies, other hits from this 
collection can also be characterized. 
6.6  EVALUATION OF STRUCTURALLY RELATED COMPOUNDS 
The compounds that are structurally related to BC69, BC8-1, BC8-5, BC8-8, BC8-15 and 
BC8-23 were tested either in yeast growth assays or through in vitro enzyme assays. As 
described in Chapter 5, minor changes in the parent molecule can alter the selectivity or 
potency of the compounds. For example, the removal of the carboxylic acid moiety from 
the phenyl ring of BC8-15 decreases the efficacy of the compound for PDE8A while it 
can still inhibit PDE4A. The preliminary docking analysis of BC8-15 into PDE4A and 
PDE8A enzyme structures demonstrates the possible binding orientation of the 
compound. This shows that carboxylic acid group interacts with PDE8A through the 
unique tyrosine 748 residue while this interaction is not involved in its binding to PDE4A 
(Figure 6.1).  
The preliminary data on the structurally related compounds can help to guide medicinal 
chemistry efforts to increase the potency and selectivity of the identified PDE8 inhibitors. 
Also, improvements in the pharmacokinetic properties such as solubility, bioavailability 
etc. can also be implemented via medicinal chemistry approaches. These steps would 
greatly enhance the utility of these compounds in both cell culture and whole animal 
studies.  
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6.7  EFFECTS OF IDENTIFIED COMPOUNDS IN MAMMALIAN ASSAYS 
The selected compounds were tested in mammalian systems to evaluate their effect in 
steroid production. Compound BC8-15 increased the progesterone release from MA-10 
cells in a dose dependent manner. Also, a correlation between progesterone response and 
PDE8 inhibitory activity was observed with BC8-15 derivatives. These promising results 
on the effect of BC8-15 on steroid production from MA-10 cells and primary Leydig 
cells suggest that these compounds can be further developed and could be used in 
physiological conditions and diseases related to testosterone deficiency or adrenal steroid 
production. For example, low testosterone levels are observed in hypogonadism and 
aging (Harman et al. 2001; Matsumoto. 2002). It is associated with andropause, 
idiopathic male infertility, metabolic syndrome and cardiovascular disease (Makhsida et 
al. 2005; Ochsenkuhn and de Kretser. 2003); (Traish et al. 2009). Also, low serum 
testosterone levels and abnormalities in adrenal function are common in HIV patients 
(Dube et al. 2007; Lo and Grinspoon. 2010). Thus, effective PDE8 inhibitors can be 
therapeutically used in aging, hypogonadism and andropause; they can also be used for 
reducing the loss of muscle and bone mass in AIDS patients. 
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Figure 6.1 Docking simulation of BC8-15 on PDE8A and PDE4A structures 
The docking simulation of a BC8-15 for PDE8A and PDE4A enzymes was carried out 
using the AutoDock4 software through the AutoDockTools GUI. 
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Figure 6.1. Docking simulation of BC8-15 on PDE8A and PDE4A structures 
 
PDE8A 
 
PDE4A 
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APPENDIX 
PART I: DEVELOPMENT OF A CHEMICAL SCREEN FOR ACTIVATORS OF 
PDE8A 
A1.1 INTRODUCTION 
PDE8A is a high affinity, cAMP-specific phosphodiesterase which is mostly expressed in 
the testis, eye, liver, skeletal muscle, heart, kidney, ovary and brain (Soderling et al. 
1998). PDE8 is unique among PDE families in containing a PAS (Per-Arnt-Sim) domain 
along with a putative REC domain (signal receiver domain) in its N terminus. PDE8A is 
important for the regulation of steroidogenesis in Leydig cells and in adrenal gland (Tsai 
et al. 2010; Vasta et al. 2006). A PDE8A activator would -in theory- decrease local 
production of testosterone in the Leydig cells and can be used as a male contraceptive 
drug. The possibility of reducing testosterone pharmacologically might also provide 
advantages for the treatment of prostate cancer (Vasta et al. 2006).  
A1.2 BASIS OF SCREENING 
A screen for an activator is based on the ability of yeast strains to grow in a medium 
lacking uracil when fbp1-ura4 expression is derepressed in a cAMP dependent manner.  
The starting strain for an activator strain should have high enough cAMP levels to repress 
the fbp1 promoter and thus should not be able to grow in the absence of uracil. In the 
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presence of an activator of the PDE in question, PDE8A in this case, cAMP levels would 
be lower than that of the starting strain and fbp1-ura4 would be expressed and cells 
would be able to grow in a medium lacking uracil in the presence of an activator (Figure 
A1). 
A1.3 DETERMINATION OF THE SUITABLE STRAIN FOR THE SCREENING 
In order to select the right strain to be utilized in the activator screen, PDE8A strains 
containing different levels of defects in the cAMP producing pathway were grown in SC-
Ura, EMM-Ura and 5FOA media. Figure A2 shows the growth pattern of those strains in 
EMM-Ura, SC-Ura and 5FOA with various initial cell densities. It was suggested by 
these data that CHP1149 strain, which has a wild type git pathway, is more suitable for 
screening since it showed very low optical density after 48h in EMM-Ura and SC-Ura. 
The data also suggest that SC-Ura is a more restrictive medium than EMM-Ura. Thus, 
EMM-Ura medium was selected to be used in screening experiments in that it might 
permit growth more readily in the presence of an activator.  
As a control for the screening, a strain which has S. pombe phosphodiesterase instead of 
mammalian PDEs was planned to be used in order to monitor and eliminate potential hits 
that might arise by affecting a component of the cAMP pathway other than PDE.  
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Figure A1: Basis of activator screen 
In PDE8A-expressing strains, cAMP levels are high and fbp1-ura4 expression is 
repressed. The cells cannot grow in medium lacking uracil. In the presence of a PDE8A 
activator, cAMP levels will be lower to allow fbp1-ura4 expression, which makes cells 
able to grow in a medium lacking uracil.  
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Figure A1: Basis of activator screen 
 
Cells are not able to grow in medium lacking uracil 
 
 
 
Cells can grow in medium lacking uracil 
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Figure A2: Growth of PDE8A-expressing candidate strains in different media 
Optical density values of strains CHP1139, CHP1140, CHP1148 and CHP1149 in 5FOA, 
EMM-Ura and SC-Ura media after 48 h are shown.   
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For optimization purposes two strains, one with a wild type git pathway and one with a 
git11 deletion were used. Both strains showed an inability to grow in the absence of 
uracil (Figure A3).  
A1.4 EVALUATION OF SCREENING STRAINS WITH DMSO PINNING 
Prior to DMSO pinning, CHP1149 (pap1∆ cgs2::PDE8A) and CHP1187 (pap1∆ cgs2-s1) 
were tested and their coefficient of variation were calculated (Table A1). Accordingly, 
CHP1149 at 5x10
4
 cells/mL initial cell density seems to be suitable for screening, 
however since there is no positive control for this experiment; it is not known if the 
culture will pass the threshold and reach a visible amount of growth after 48 h incubation. 
Thus, I tested 0.75x10
5
 and 1x10
5
 cells/mL initial cell densities for DMSO pinning 
experiments. The experiments were done in a 384 well plate as 2 sets from two 
independent cultures and performed on two separate days. The CV values for Day 1 and 
Day 2 was shown in Table A2. Although the obtained CV values are higher than 15 % 
threshold employed by the Broad Institute, CHP1149 (PDE8A) strain was approved by 
the high throughput assay supervisor due to the small OD values. However, CHP1187 
(cgs2 strain) did not pass the test due to its high mean value.  
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Figure A3: Growth of Cgs2-expressing candidate strains in different media 
Optical density values of strains CHP1187 and CHP1188 in 5FOA, EMM-Ura and SC-
Ura media after 48 h are shown. 
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Figure A3: Growth of Cgs2-expressing candidate strains in different media 
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Table A1: Coefficient of variation values for CHP1149 and CHP1187 
 
Strain Cell density Average StDev CV CV (%) 
CHP1149 5x10
4
 0.041 0.007 0.16 16 
CHP1149 1x10
5
 0.051 0.014 0.28 28 
CHP1149 2x10
5
 0.073 0.015 0.21 21 
CHP1187 5x10
4
 0.060 0.012 0.20 20 
CHP1187 1x10
5
 0.134 0.012 0.09 9 
CHP1187 2x10
5
 0.438 0.040 0.09 9 
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Table A2: Coefficient of variation values of CHP1149 and CHP1187 after DMSO 
pinning 
DMSO PINNING- DAY1  
Strain Experiment Cell density Mean StDev CV % 
CHP1149 Set1 0.75x10
5
 0.047 0.011 23 
CHP1149 Set2 0.75x10
5
 0.042 0.009 21 
CHP1149 Set1 1x10
5
 0.052 0.010 20 
CHP1149 Set2 1x10
5
 0.049 0.010 21 
CHP1187 Set1 0.75x10
5
 0.121 0.022 18 
CHP1187 Set2 0.75x10
5
 0.126 0.032 25 
CHP1187 Set1 1x10
5
 0.200 0.040 20 
CHP1187 Set2 1x10
5
 0.194 0.047 24 
 
DMSO PINNING- DAY2 
Strain Experiment Cell density Mean StDev CV % 
CHP1149 Set1 0.75x10
5
 0.047 0.012 26 
CHP1149 Set2 0.75x10
5
 0.049 0.017 35 
CHP1149 Set1 1x10
5
 0.049 0.008 16 
CHP1149 Set2 1x10
5
 0.052 0.016 30 
CHP1187 Set1 0.75x10
5
 0.261 0.027 10 
CHP1187 Set2 0.75x10
5
 0.130 0.014 11 
CHP1187 Set1 1x10
5
 0.410 0.026 6 
CHP1187 Set2 1x10
5
 0.213 0.019 9 
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A1.5 SCREENING RESULTS 
High throughput screening was performed at the Broad Institute using CHP1149 (pap1∆ 
cgs2::PDE8A) as the screening strain with 0.75x10
5
 cells/mL as the initial cell density in 
EMM-Ura medium in 384-well plates. The optical density at 600 nm was measured at the 
end of 48 h. 18 compound plates from the Bioactives library, 26 compound plates from 
the PKO4 library, 8 compound plates from Analyticon, 7 compound plates from Forma, 5 
compound plates from natural extracts and 46 compound plates from commercial 
chemical libraries were screened. For each compound plate, the assay was performed in 
duplicate. After the readings were completed, the data were analyzed by the Data 
Analysis department of the Broad Institute and expressed as Z scores which express the 
divergence of the experimental result from the mean result as a number of standard 
deviations. In high throughput analyses, compounds with composite Z scores higher than 
8.53 is generally considered as a ‘hit’. 
The Bioactive compound library was screened and among 5802 compounds, four had a 
composite Z score higher than 8.53. When the data were examined carefully, only two of 
these compounds had reproducible raw data in the duplicate plates (Figure A4). At the 
end of high throughput screening, a total 38,327 compounds were screened from 5 
different compound libraries. Results are given in Figure A5.  
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Figure A4: Screen with known bioactives collection 
The scatter plot of Z score of plate A is plotted against Z score of plate B. Two positive 
hits are indicated as Compound A and Compound B.   
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Figure A4: Screen with known bioactives collection 
 
 
Plate Well RawValueA ZScoreA RawValueB ZScoreB CompositeZ Reproducibility 
2099 C20 0.446 16.14 0.203 5.19 15.1 0.890 
XW-DalcDM1 I14 0.426 15.44 0.161 3.71 13.5 0.853 
XW-DalcDM1 P20 0.456 16.66 0.04 -0.39 11.5 0.690 
2105 B07 0.383 13.61 0.045 -0.06 9.6 0.704 
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Figure A5: Screening Results 
Screening results are shown. (A) Scatter plot of Z score A against Z score B for 38,327 
compounds is shown. (B) Compounds with composite Z score above 8.5 are shown. (C) 
Compounds with composite Z score aboce 8.5 and reproducibility above 0.9 are 
demonstrated, DMSO well is shown with arrow. (D) Top six compounds are shown. (E) 
The structure of BC18 is given.  
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Figure A5: Screening Results 
A. 38,327 compounds 
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B. Compounds with composite Z score above 8.5 
  
C. Compounds with compozite Z above 8.5 and reproducibility above 0.9 : 43 
compounds, 1 DMSO 
 
 
DMSO 
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D.  
Plate Well RawValueA RawValueB CompositeZ 
2019 E17 0.349 0.57 63.3 
2002 D08 0.142 0.161 27.4 
2023 P18 0.184 0.262 27.1 
2018 H11 0.231 0.189 24.8 
2024 H06 0.197 0.193 22.8 
2050 F06 0.134 0.116 21.7 
 
E. 2019 E17 is Compound BC18 
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A1.6 EVALUATION OF THE SCREEN 
The activator screen data contained many false positives revealed as data points with high 
Z score along only one axis when Z score A vs Z score B plot is examined. For an 
authentic hit, a plot of the Z score A vs the Z score B plot should give a data point located 
along the diagonal, which is a sign of reproducibility. One should also expect that plots of 
DMSO wells, which are the negative controls, should gather around the origin. This type 
of trend has not been observed in the current activator screen data.  
When the data is filtered by composite Z score higher than 8.5 and reproducibility 0.9; 43 
compounds were detected. Among them, 1 was found to be arising from a DMSO well 
which indicates that those hits might have arisen as chance events. The top 6 compounds 
are shown in Figure A5. The most promising compound (BC18) did not increase the 
activity of PDE8A enzyme in the follow-up experiments (data not shown); suggesting 
that all compounds identified might be false positives.  
The general problem with the activator screen was that some data points were not 
reproducible in plate A and plate B. For example, for the same compound plate the OD600 
was found to be 0.316 for plate A and 0.045 for plate B. This problem raises the 
possibility that plate A represents a false positive or plate B represents a false negative. If 
the problem is the presence of a false positive then it might have arisen due to mutations, 
contamination or cell delivery problems such as clumping. Some possible reasons for the 
presence of false negatives would be problems due to vortexing or clumping in the well, 
which might prevent the homogenous optical density reading of the well in question. 
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Since no such problem had been observed in a similar screen for PDE inhibitors where 
5FOA medium was used instead of EMM-Ura, the possibility of presence of mutations 
was investigated. Cells were struck from potential false positive compound wells and 
their growth in solid medium lacking uracil was checked. It was found that cells arising 
from a potential false positive well were able to grow on medium lacking uracil while the 
starting screening strain CHP1149 could not (Figure A6). This suggests that the presence 
of the false positive data points is due to random mutations.  
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Figure A6: Growth of CHP1149 and false positive hits on EMM-Ura 
Cells taken from the false positive wells (candidates #1-6) are struck on EMM-Ura 
medium. Their growth is compared to the growth phenotype of CHP1149.  
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Figure A6: Growth of CHP1149 and false positive hits on EMM-Ura 
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PART II: STRATEGIES TO UNCOVER PDE8 ACTIVATORS BY DATA 
MINING 
PDE8 activators were sought by using the inhibitor screen data. As mentioned before, in 
the inhibitor screen cells are grown in 5FOA medium. The initial screening conditions do 
not allow cells to grow and the ability of the test compounds to promote the growth of 
PDE8A-expressing cells was evaluated to identify PDE8 inhibitors. The compounds that 
lower the optical density in 5FOA medium below the background levels are usually toxic 
compounds. We wanted to test the hypothesis that potential activators might also lower 
the optical density in 5FOA medium.  Since there is no available PDE activator to be 
used as a positive control, the degree of change in the growth phenotype in the presence 
of PDE activators is unknown.  
We did data mining in the inhibitor data set by comparing the PDE8A inhibitor screen 
data with data from PDE11A inhibitor screen (Ceyhan, O; unpublished data). 
Compounds that lower the optical density in both data sets were considered as toxic 
whereas the compounds that decrease the growth in PDE8A-expressing strain while still 
allowing growth of PDE11A-expressing strain were considered as potential PDE8 
activators. Figure A9 shows the scatter plot of PDE8A vs PDE11A data. Nine of the 
selected compounds were tested by yeast growth assays and in vitro enzyme assays. 
Figure A8 shows the effect of these compounds in cyclic nucleotide titration curves. 
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Figure A7: Comparison of data from PDE8 and PDE11 screens 
(A) Scatter plot of average absorbance values of PDE8A-expressing strain against 
PDE11A-expressing strain. (B) Compounds that have lower OD values for PDE8A-
expressing strain, while did not decrease the OD values of PDE11A-expressing strain are 
filtered.  
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Figure A7: Comparison of data from PDE8 and PDE11 screens 
A. 
 
B. 
 
290 
 
Table A3: Primary screen data of selected PDE8A activator candidates 
PDE8A Absorbance 1 Absorbance 2 Average Abs Z score 1 Z score 2 Composite Z 
BC8-A1 0.032 0.029 0.031 -6.18 -6.40 -8.89 
BC8-A2 0.061 0.058 0.060 -4.08 -4.30 -5.92 
BC8-A3 0.06 0.075 0.068 -4.15 -3.06 -5.10 
BC8-A4 0.066 0.064 0.065 -3.72 -3.86 -5.36 
BC8-A5 0.035 0.036 0.036 -5.96 -5.89 -8.38 
BC8-A6 0.072 0.067 0.070 -3.28 -3.64 -4.90 
BC8-A7 0.026 0.026 0.026 -6.30 -6.30 -8.91 
BC8-A8 0.032 0.028 0.030 -5.43 -6.01 -8.09 
BC8-A9 0.072 0.075 0.074 -5.79 -5.62 -8.07 
PDE11A Absorbance 1 Absorbance 2 Average Abs Z score 1 Z score 2 Composite Z 
BC8-A1 0.114 0.084 0.099 8.48 2.07 7.46 
BC8-A2 0.095 0.126 0.111 4.42 11.05 10.94 
BC8-A3 0.156 0.205 0.181 17.46 27.93 32.10 
BC8-A4 0.101 0.102 0.102 5.70 5.92 8.22 
BC8-A5 0.107 0.103 0.105 6.99 6.13 9.28 
BC8-A6 0.33 0.325 0.328 54.64 53.58 76.52 
BC8-A7 0.067 0.066 0.067 0.21 0.01 0.16 
BC8-A8 0.086 0.09 0.088 4.03 4.83 6.27 
BC8-A9 0.075 0.086 0.081 1.82 4.03 4.13 
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Since PDE8A is a cAMP specific enzyme, the presence of a PDE8 activator will decrease 
the internal cAMP levels and more cAMP will be required to promote growth in 5FOA 
medium, leading to a right-ward shift compared to the no compound conditions. On the 
other hand, a candidate PDE8 activator should not affect the cGMP levels and thus the 
cGMP titration curve. Figure A8 shows both cyclic nucleotide titration curves in the 
presence of candidate PDE8 activators. Compound BC8-A2 seems to shift the curve of 
strain CHP1204 to the right in the presence of cAMP while no shift is observed with 
cGMP. However, the data was not reproducible and no significant increase was observed 
in the activity of PDE8 enzyme in the in vitro enzyme assays.  
CONCLUSION 
Although, the data mining approach did not yield any activators of PDE8A, it clearly 
shows that the compounds that are not activators (i.e. decrease OD values in 5FOA 
medium possibly by exerting toxic effects) lower the OD values in both cAMP and 
cGMP containing 5FOA media. This suggests that the use of increased levels of cyclic 
nucleotides to promote a higher level of growth in 5FOA medium could be used in HTSs 
to detect PDE activators. 
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Figure A8: Growth curve of CHP1204 in the presence of candidate PDE8A activator 
compounds in 5FOA medium in response to varying cyclic nucleotide 
concentrations 
The cyclic nucleotide titration growth curve of CHP1204 in the presence of candidate 
activator compounds is shown. The growth curve is expected to shift to the right 
compared to the no compound curve in the presence of an activator molecule. (A) cAMP 
titration (B) cGMP titration.  
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Figure A8: Growth curve of CHP1204 in the presence of candidate PDE8A activator 
compounds in 5FOA medium in response to varying cyclic nucleotide 
concentrations 
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